JP6959274B2 - IL-11R binding protein and its use - Google Patents

Description

Related Application Data This application is filed on February 7, 2013, entitled "IL-11R-Binding Protein and Its Use", Australian Patent Application No. 2013900389 and February 14, 2013.
US Patent Application No. 6 entitled "IL-11R Binding Protein and Its Use" filed in Japan
Claim the priority of 1 / 746,756. All of these applications are incorporated herein by reference.

Sequence Listing This application is accompanied by a sequence listing submitted in electronic form. The entire contents of the sequence listing are incorporated herein by reference.

Technical Fields The present disclosure relates to proteins containing the antigen binding site of an antibody that binds to the interleukin-11 (IL-11) receptor α (IL-11Rα) and, for example, its use in therapeutic methods.

IL-11 is a member of the IL-6 cytokine family, including, among other things, IL-27, IL-31, leukemia inhibitory factor (LIF), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF). The IL-6 family of cytokines induce signal transduction via the common signaling receptor β subunit gp130 and the specific receptor α subunit. In the case of IL-11, its specific receptor α subunit IL-11R
Binding of this cytokine to α induces homodimerization of gp130. Dimerization of gp130 activates the JAK / STAT signaling pathway, resulting in activation of signaling substances and transcriptional activators (STAT) 3 (STAT3), to a lesser extent STAT.
Brings 1 activation.

IL-11 signaling is known to play a role in hematopoiesis, immune response, inflammation, lipogenesis, osteoclast formation, neurogenesis, megakaryocyte maturation and platelet production. IL-11 can be associated with a variety of conditions, such as chemotherapy-induced thrombocytopenia and arthritis, inflammatory bowel disease.
It is used clinically or in development to treat a variety of inflammatory disorders, including radiation-induced lung damage, sepsis and psoriasis. However, clinical use of IL-11 has been restricted due to the reporting of serious adverse events, including edema. In addition, IL-11 has been shown to have detrimental effects in a variety of conditions.

For example, IL-11 has been found to act as an inhibitor of bone formation.
It is essential for osteoclast formation and activity and bone resorption. Therefore, blocking the activity of IL-11 prevents bone resorption / prevents bone resorption as a treatment for osteoporosis and in other conditions such as metastatic bone cancer, myeloma, Paget's disease of bone and fracture and bone healing. Proposed to promote.

IL-11 signaling has been implicated in having a pathogenic role during the early stages of tuberculosis. Blocking IL-11 with an anti-IL-11 antibody has been shown to reduce histopathology of lung tissue and neutrophil infiltration in M. tuberculosis-infected mice.

The antagonism of IL-11 has also been proposed as a method of treating Th2-mediated disorders including asthma, chronic obstructive pulmonary disease (COPD), rhinitis, allergic and atopic dermatitis. In this regard, IL-11 using a mutant form of IL-11 that does not induce signal transduction.
Blocking signal transduction has been shown to be therapeutically beneficial in a mouse model of asthma.

IL-11 and / or IL-11Rα are overexpressed in liver cancer, pancreatic cancer, gastric cancer, osteosarcoma, endometrial cancer and ovarian cancer. Further, as discussed above, IL-11 induced gp
Dimerization of 130 results in activation of STAT3, which is angioplasty (eg, VEG).
F), cell cycle progression (eg, cyclin D1) and cell survival (eg, B)
Induces the expression of genes related to cl-XL (survival). Persistent STAT3 activity appears to be associated with hematological malignancies and tumors of epithelial origin. Excessive STAT3 activation promotes gastric cell proliferation and survival in mice and is associated with increased gastric angiogenesis, resulting in gastric tumorigenesis. However, gastric inflammation, thickening and tumorigenesis are suppressed in IL-11 non-responsive mice or mice treated with non-signal transduction variants of IL-11.

IL-11 also, for example, inhibits fat production, induces cachexia (eg, cancer cachexia), induces exothermic reactions, regulates extracellular matrix metabolism, stimulates acute phase reactants and implants embryos. It is also involved in other biological processes.

It will be clear to skilled professionals from the above that reagents that neutralize IL-11 signaling are desirable because of their potential to provide therapeutic benefits in any of a number of diverse conditions. Reagents that bind IL-11Rα also bind soluble IL-11 throughout the subject and
It is desirable because it has the advantage of being able to specifically target cells in vivo as opposed to the need for neutralization.

Despite this desirability, numerous reagents that bind to IL-11Rα (eg, antibodies) do not neutralize IL-11 signaling. For example, Blanc et al. (Journal)
of Immunological Methods, 241: 43-59, 2000
) Described a panel of 14 mouse monoclonal antibodies prepared against human IL-11Rα, all of which were IL-11-induced BaF3 / gpl30 / IL-11R.
The inability to inhibit cell proliferation indicates that the antibody does not neutralize IL-11 signaling. Commercially available anti-IL-11Rα antibody, eg S
4D12 available from anta Cruz Biotechnology is also IL-1
Does not neutralize the signal transduction of 1.

In producing the present invention, we have bound to IL-11Rα and IL-1.
An attempt was made to create a reagent that neutralizes the signal transduction of 1 (eg, an antibody and a protein containing its antigen-binding domain). We have produced a series of antibodies with such activity, some of which strongly neutralize IL-11 signaling, eg IL-11.
Prevents the proliferation of dependent BaF3 cells. These antibodies are human IL-11Rα (hIL-1)
The fact that they have been shown to be cross-reactive with 1Rα) and cynomolgus monkey IL-11Rα (cynoIL-11Rα) means that they can be used in primate models of human disease. The antibody was also found to bind to overlapping epitopes. We then affinity-maturate one of these antibodies to additional desirable properties, such as neutralization and / or improved affinity for IL-11 signaling and / or human germline. A series of additional antibodies with similar sequences (eg, less likely to induce an immune response when administered to humans) were created.

Based on the above, the present inventors have created a protein containing an antigen-binding domain of an antibody, which is capable of binding to or specifically binding to IL-11Rα, and is capable of binding to IL-11. It will be clear to skilled experts that it is possible to neutralize signal transduction.

In one example, the disclosure provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, which binds or specifically binds to IL-11Rα and IL-1.
Neutralizes signal transduction of 1, where the antigen-binding domain is hIL-11Rα and cin
It is possible to bind to oIL-11Rα.

In one example, the IL-11Rα binding protein neutralizes signaling in human IL-11 (hIL-11) and / or cynomolgus monkey IL-11 (cynoIL-11).

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The protein is 10 μg / ml or less of IC _{5
At 0} , it inhibits IL-11 (eg, hIL-11 or cynoIL-11) -mediated proliferation of BaF3 cells expressing IL-11Rα and gp130. In one example, the IC ₅₀ is 5 μg / ml or less. For example, the IC ₅₀ is 4 μg / ml or less or 3.
It is 5 μg / ml or less. In one example, the IC ₅₀ is 3 μg / ml or less or 2 μg / ml.
It is as follows. For example, the IC ₅₀ is 1 μg / ml or less. For example, the IC ₅₀ is 0.
It is 9 μg / ml or less, 0.8 μg / ml or less, or 0.7 μg / ml or less. In one example, the IC ₅₀ is 0.7 μg / ml or less. In one example, in connection with each of the above examples, the IC ₅₀ is greater than or equal to 10 pg / ml or greater than or equal to 10 ng / ml.

In one embodiment, the IC ₅₀ is 10 nM or less. For example, the IC ₅₀ is 8 nM or less or 7 nM or less. In one embodiment, the IC ₅₀ is 6 nM or less or 6.5 nM or less. For example, the IC ₅₀ is 5 nM or less. For example, the IC ₅₀ is 4.5 nM or less. For example, the IC ₅₀ is 4 nM or less. In one embodiment, in connection with each of the above examples,
The IC ₅₀ can be 10 pM or higher.

In one example, the IL-11Rα binding protein is at least about 1.5 times larger than antibody 8E2, which includes a heavy chain containing the sequence set forth in SEQ ID NO: 83 and a light chain containing the sequence set forth in SEQ ID NO: 84. BaF3 expressing IL-11Rα and gp130 at IC ₅₀
Inhibits cell IL-11 (eg, hIL-11 or cynoIL-11) -mediated proliferation. In one example, the IC ₅₀ is at least about 2 times larger, or at least about 2.5 times larger, or at least about 3 times larger than antibody 8E2.

In one example, the IL-11Rα binding protein is at least about 1.5 times larger than the antagonistic hIL-11 mutant protein (including, for example, the sequence set forth in SEQ ID NO: 110) (ie, the IC50 value is about 1). .5 times smaller), or at least 2 times larger, or 3
I of BaF3 cells expressing IL-11Rα and gp130 at twice as large IC ₅₀
L-11 (e.g., hIL-11) inhibits proliferation mediated case, _{IC 50} is nM
Measured at. In one embodiment, _{IC 50} at least about than mutein 3.5
Double or at least about four times larger.

In one example, the IC ₅₀ is about 0.3 ng / ml hIL-11-1 to about 5 ng / ml h.
In the presence of IL-11 (eg, about 0.3 ng / ml hIL-11 or about 0.5 ng / ml
BaF3 cells expressing IL-11Rα and gp130 in the presence of ml hIL-11 or approximately 5 ng / ml hIL-11 (eg, IL-11Rα and / or gp1).
Genetically engineered to express 30) (e.g., about 1x10 ⁴ cells) of about 48-5
Measured by culturing for 0 hours, or about 48 hours or about 50 hours. In one example, cells are cultured in the presence of the proteins of the present disclosure prior to the addition of IL-11 (eg, for about 30 minutes). In one example, proliferation is determined by measuring the uptake of 3H-thymidine into DNA in the last 6 hours of culture. In the assay performed to measure the neutralization of cynoIL-11, about 0.5 ng / ml cynoIL-11-1 to about 5n
In the presence of g / ml cynoIL-11 (eg, about 0.5 ng / ml cynoIL)
Cells can be cultured in the presence of -11 or about 5 ng / ml cynoIL-11).

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. IL-11R to the polypeptide of SEQ ID NO: 86
The level of binding of the sigma binding protein is IL- to the polypeptide of SEQ ID NO: 3 and / or 85.
Below the level of binding of the 11Rα binding protein.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. IL-11R to the polypeptide of SEQ ID NO: 89
The level of binding of the sigma binding protein is IL- to the polypeptide of SEQ ID NO: 3 and / or 85.
Below the level of binding of the 11Rα binding protein.

In one example, the level of binding is determined by Western blot of cells expressing the polypeptide and / or by fluorescence activated cell selection (FACS).

In one example, the level of binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 86 or 89 is at least compared to the binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 3 and / or 85. It decreases by about 10 times, 20 times, 50 times, 100 times, 150 times, or 200 times.

In one example, the IL-11Rα binding protein does not detectably bind to the polypeptide of SEQ ID NO: 86 or 89.

In one example, the IL-11Rα binding protein binds to the polypeptide of SEQ ID NO: 87 or 88. For example, the level of binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 87 or 88 is similar to or approximately the same as the level of binding of SEQ ID NO: 3 and / or 85 to the polypeptide (eg, about 20). % Or 15% or 10% or 5%).

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The antigen-binding domain binds to an epitope containing a residue in the first fibronectin III domain of IL-11Rα.

In one example, the epitope comprises residues within the immunoglobulin-like domain of IL-11Rα and within the first fibronectin III domain.

In one example, the epitope comprises a residue between amino acids 111-215 of SEQ ID NO: 1.

In one example, the epitope comprises a residue between amino acids 1-215 of SEQ ID NO: 1.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. neutralized, hIL-11 of the protein (including a _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in SEQ ID NO: 37) antibodies 8E2
Competitively inhibits the binding of Rα and / or SEQ ID NOs: 3 and / or 85 to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. neutralized, hIL-1 of the protein (including a _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 73 comprises the sequence given in SEQ ID NO: 74) antibodies 8E4
1 Rα and / or SEQ ID NO: 3 and / or 85 competitively inhibit binding to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. to neutralize, the protein (including a _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 75 comprises the sequence given in SEQ ID NO: 76) antibodies 8D10 of hIL-
It competitively inhibits the binding of 11Rα and / or SEQ ID NOs: 3 and / or 85 to the polypeptide.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. neutralized, light chain and a human comprising a V _L comprising the sequence represented by the constant region and SEQ ID NO: 5 of the heavy chain and human IgG4 comprising a V _H containing a sequence the protein represented by the antibody 8E2 (SEQ ID NO: 37 Competitively inhibits the binding of hIL-11Rα and / or SEQ ID NOs: 3 and / or 85 (including the light chain constant region) to the polypeptide.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. neutralized, light chain and a human comprising a V _L comprising the sequence represented by the constant region and SEQ ID NO: 73 the heavy chain and human IgG4 comprising a V _H containing a sequence the protein represented by the antibody 8E4 (SEQ ID NO: 74 Competitively inhibits the binding of hIL-11Rα and / or SEQ ID NOs: 3 and / or 85 (including the light chain constant region) to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. neutralized, light chain and a human comprising a V _L comprising the sequence represented by the constant region and SEQ ID NO: 75 the heavy chain and human IgG4 comprising a V _H containing a sequence the protein represented by antibody 8D10 (SEQ ID NO: 76 HIL-11Rα and / of (including light chain constant region)
Alternatively, it competitively inhibits the binding of SEQ ID NOs: 3 and / or 85 to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The protein contains hIL-1 of antibody 8E2, which includes a heavy chain containing the sequence set forth in SEQ ID NO: 83 and a light chain containing the sequence set forth in SEQ ID NO: 84.
1 Rα and / or SEQ ID NO: 3 and / or 85 competitively inhibit binding to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The protein contains hIL-1 of antibody 8E4, which includes a heavy chain containing the sequence set forth in SEQ ID NO: 92 and a light chain containing the sequence set forth in SEQ ID NO: 91.
1 Rα and / or SEQ ID NO: 3 and / or 85 competitively inhibit binding to the polypeptide.

The disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The protein contains hIL- of antibody 8D10, which includes a heavy chain containing the sequence set forth in SEQ ID NO: 94 and a light chain containing the sequence set forth in SEQ ID NO: 93.
It competitively inhibits the binding of 11Rα and / or SEQ ID NOs: 3 and / or 85 to the polypeptide.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. Neutralized, IL-11Rα binding protein SEQ ID NO: 95
The level of binding to the polypeptide of IL-11Rα binding protein is lower than the level of binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 85.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. Neutralized, IL-11Rα binding protein SEQ ID NO: 96
The level of binding to the polypeptide of IL-11Rα binding protein is lower than the level of binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 85.

In one example, the level of binding of the IL-11Rα binding protein to the polypeptide containing the substitution is reduced by at least about 1.5-fold or 2-fold.

In one example, the level of binding of the IL-11Rα binding protein to the polypeptide containing the substitution is reduced by at least about 3-fold, 4-fold, 5-fold, or 10-fold.

In one example, the IL-11Rα binding protein does not detectably bind to the polypeptide containing the substitution.

In one example, the level of binding is assessed using a biosensor, eg, by surface plasmon resonance. For example, the IL-11Rα binding protein is immobilized and the level of binding to the polypeptide of SEQ ID NO: 85, 95 or 96 is measured. As illustrated herein, affinity can be determined by assessing the level of binding at several concentrations.

In another example, the level of binding is assessed using FACS. For example, SEQ ID NO: 8
Binding of IL-11Rα binding protein to cells expressing 5, 95 or 96 polypeptides, or to the form of IL-11Rα comprising the substitutions described herein.

In one example, the IL-11Rα binding protein binds preferentially to the polypeptide of SEQ ID NO: 85 relative to its ability to bind to the polypeptide of SEQ ID NO: 95 or 96.

In one example, the IL-11Rα binding protein binds preferentially to the polypeptide of SEQ ID NO: 85 relative to its ability to bind to the polypeptide of SEQ ID NO: 95.

In one embodiment, IL-11Ra binding proteins (including _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in SEQ ID NO: 37) antibodies 8E2 and / or 8E4 (
_VH containing the sequence set forth in SEQ ID NO: 74 and _VL containing the sequence set forth in SEQ ID NO: 73 _{) and / or 8D10 (VH} containing the sequence set forth in SEQ ID NO: 76 and the sequence set forth in SEQ ID NO: 75 Competitively inhibits the binding of SEQ ID NO: 3 and / or 85 (including _{VL) to the polypeptide.}

In one example, the antigen binding domain cross-reacts with (i) the polypeptide of SEQ ID NO: 97 and / or (ii) the polypeptide of SEQ ID NO: 98 and / or (iii) the polypeptide of SEQ ID NO: 99.

In one example, the IL-11Rα binding protein is mouse IL-11Rα (SEQ ID NO: 8).
2 or 102) and / or does not detectably bind to the polypeptide of SEQ ID NO: 90.

In one example, the IL-11Rα binding protein is mouse IL-11Rα (SEQ ID NO: 8).
2 or 102) and / or cross-react with the polypeptide of SEQ ID NO: 90.

In one embodiment, IL-11Ra binding protein is human IL-11Ra and / or SEQ ID NO: 3 and / or the 85 polypeptide from about 9 × ^{10 -9} M or less the affinity constant _{(K D}
). For example, _{K D} is less than or equal to about 8 × ^{10 -9} M or less, or about 7 × ^{10 -9} M or less, or about 6 × ^{10 -9} M or less, or about 5 × ^{10 -9} M. In one embodiment, _{K D} of about 4.8 ×
^{It is 10-9} M or less.

In another example, the IL-11Rα binding protein has an affinity constant (K ^{) of about 2 × 10-9} M or less for the human IL-11Rα and / or the polypeptide of SEQ ID NO: 3 and / or 85.
_D ). For example, _{K D} is less about 1 × ^{10 -9} M or less, or about 9 × ^{10 -10} M or less, or about 8 × ^{10 -10} M or less, or about 7 × ^{10 -10} M. In one embodiment, _{K D} is less than about 5 × ^{10 -10} M. In one embodiment, _{K D} is less than about 4 × ^{10 -10} M. In one embodiment, _{K D} is less than about 3 × ^{10 -10} M. In one embodiment, _{K D} is about 2 × 10 ^{-
It is 10} M or less. In one embodiment, _{K D} is less than about 1.5 × ^{10 -10} M.

In one embodiment, _{K D} is 0.1 × ^{10 -12} M or more in relation to each of the foregoing examples or 1
It can be × ^10-12 M or more.

In one embodiment, K _D by using a biosensor, for example, it is evaluated by surface plasmon resonance. For example, the IL-11Rα binding protein is immobilized and the level of binding to the polypeptide of SEQ ID NO: 85 is measured.

In one example, the IL-11Rα binding protein has a midpoint (Tm) of temperature transition above about 60 ° C.
Have. For example, Tm is about 61 ° C. or higher, for example, about 6 ° C. or higher, such as about 63 ° C. or higher.
It is 2 ° C or higher. For example, Tm is about 65 ° C. or higher. For example, Tm is about 69 ° C. or higher. For example, Tm is about 70 ° C. or higher. Proteins with higher Tm are considered to be more stable, thereby providing better storage and / or reduced effects due to aggregation, for example during administration.

The present disclosure further or instead provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and signals IL-11. The antigen-binding domain is (i) at least about 40 relative to the sequence shown between amino acids 31-35 of SEQ ID NO: 37.
% Identical (or 50% identical or 60% identical or 70% identical or 8
0% identical or 90% identical or 95% identical or 98% identical or 9
Complementarity determining regions (CDR) 1 containing sequences that are 9% identical or 100% identical and at least about 76% identical to the sequence shown between amino acids 50-66 of SEQ ID NO: 37 ( Or CDR2 containing sequences that are 80% identical or 90% identical or 95% identical or 98% identical or 99% identical or 100% identical) and amino acids 99- of SEQ ID NO: 37. At least about 55% identical (or 60% identical or 70% identical or 80% identical or 90% identical or 95% identical or 98) to the sequences shown between 107. _VH containing CDR3 containing sequences (% identical, 99% identical, or 100% identical);
(Ii) At least about 95% or 96% or 97% with respect to the sequence represented by SEQ ID NO: 37.
_{Or VH} containing sequences that are 98% or 99% identical;
(Iii) At least about 4 with respect to the sequence shown between amino acids 24-34 of SEQ ID NO: 5.
5% identical (or 50% identical or 55% identical or 60% identical or 70% identical or 80% identical or 90% identical or 95% identical or 98 CDR1 containing the sequence (% identical, 99% identical, or 100% identical), CDR2 containing the sequence shown between amino acids 50-56 of SEQ ID NO: 5, and amino acids 89-97 of SEQ ID NO: 5. At least about 44% identical (or 5) to the sequences shown between
6% identical or 60% identical or 70% identical or 80% identical or 9
0% identical or 95% identical or 98% identical or 99% identical or 1
_VL containing CDR3 containing a sequence (which is 00% identical);
(Iv) At least about 94% identical (or 95%) to the sequence set forth in SEQ ID NO: 5.
Identical or 96% identical or 97% identical or 98% identical or 99%
_VL containing (identical) sequences;
(V) CDR1 containing the sequence shown between amino acids 31-35 of SEQ ID NO: 74, CDR2 containing the sequence shown between amino acids 50-66 of SEQ ID NO: 74, and amino acids 99-115 of SEQ ID NO: 74. _VH containing CDR3 containing the sequences shown between;
_{(Vi) VH} containing the sequence set forth in SEQ ID NO: 74;
(Vii) CDR1 containing the sequence shown between amino acids 23-36 of SEQ ID NO: 73, CDR2 containing the sequence shown between amino acids 52-58 of SEQ ID NO: 73, and amino acids 91-101 of SEQ ID NO: 73. _VL containing CDR3 containing the sequences shown between;
_{(Viii) VL} containing the sequence represented by SEQ ID NO: 73;
(Ix) CDR1 containing the sequence shown between amino acids 31 to 35 of SEQ ID NO: 76, CDR2 containing the sequence shown between amino acids 50 to 66 of SEQ ID NO: 76, and amino acids 99 to 107 of SEQ ID NO: 76. _VH containing CDR3 containing the sequences shown between;
_{(X) VH} containing the sequence shown in SEQ ID NO: 76;
(Xi) CDR1 containing the sequence shown between amino acids 24-34 of SEQ ID NO: 75, CDR2 containing the sequence shown between amino acids 50-57 of SEQ ID NO: 75, and amino acids 89-97 of SEQ ID NO: 75. _VL containing CDR3 containing the sequences shown between;
_{(Xii) VL} containing the sequence represented by SEQ ID NO: 75;
_{(Xiii) V H represented} by (i) and _{VL represented} by (iii);
_{(Xiv) V H} indicated by (i) and _{V L} indicated by (iv);
_{(Xv) V H represented} by (ii) and _{VL represented} by (iii);
_{(Xvi) V H} indicated by (ii) and _{V L} indicated by (iv);
_{(Xvii) V H represented} by (v) and _{VL represented} by (vii);
_{(Xviii) V H represented} by (v) and _{VL represented} by (viii);
_{V H represented} by (xix) (vi) and _{VL represented} by (vi);
_{V H represented} by (xx) (vi) and _{VL represented} by (viii);
_{(Xxi) V H represented} by (ix) and _{V L represented} by (xi);
_{(Xxi) V H represented} by (ix) and _{VL represented} by (xii);
_{(Xxiii) V H} indicated by (x) and _{V L} indicated by (xi); or (xxx) V _{H indicated by (x) and V L} indicated by (xii);
Includes at least one of.

In one example, the antigen binding domain is (i) at least about about CDR1 containing the sequence shown between amino acids 31-35 of SEQ ID NO: 37 and the sequence shown between amino acids 50-66 of SEQ ID NO: 37. CDR2 containing sequences that are 80% identical (or 90% identical, 95% identical, 98% identical, 99% identical, or 100% identical) and amino acids 99- of SEQ ID NO: 37. 10
At least about 55% identical (or 60% identical or 70% identical or 80% identical or 90% identical or 95% identical or 98) to the sequences shown between 7 CDR3 containing sequences (% identical, 99% identical, or 100% identical)
_{V H} and a CDR1 comprising the sequence shown between amino acids 24-34 of SEQ ID NO: 5, a CDR2 comprising the sequence shown between amino acids 50-56 of SEQ ID NO: 5, SEQ ID NO: 5 amino acids 89 comprising bets _VL or SEQ ID NO: 5 containing CDR3 containing the sequences shown between ~ 97
_VL containing the sequence indicated by
(Ii) CDR1 containing the sequence shown between amino acids 31-35 of SEQ ID NO: 37 is at least about 80% identical (or 90%) to the sequence shown between amino acids 50-66 of SEQ ID NO: 37. CDR2 containing a sequence (identical, 95% identical, 98% identical, 99% identical, or 100% identical) and amino acids 99-1 of SEQ ID NO: 37.
_VH containing CDR3 containing the sequence shown between 07 and amino acids 24-3 of SEQ ID NO: 5.
CDR1 containing the sequence shown between 4 and CDR2 containing the sequence shown between amino acids 50-56 of SEQ ID NO: 5 and C containing the sequence shown between amino acids 89-97 of SEQ ID NO: 5.
_VL containing DR3 _{or VL} containing the sequence shown by SEQ ID NO: 5; or (iii) CDR1 containing the sequence shown between amino acids 31 to 35 of SEQ ID NO: 37, and amino acids 50 to 66 of SEQ ID NO: 37. CDR2 containing the sequence shown between and at least about 55% identical (or 60% identical or 70% identical or 80) to the sequence shown between amino acids 99-107 of SEQ ID NO: 37. % Identical or 90% identical or 95% identical or 98% identical or 99% identical or 100% identical)
_VH containing the sequence-containing CDR3 and CDR1 containing the sequence shown between amino acids 24-34 of SEQ ID NO: 5 and CDR containing the sequence shown between amino acids 50-56 of SEQ ID NO: 5
_{V L} containing 2, and a CDR3 comprising the sequence shown between amino acids 89-97 of SEQ ID NO: 5
_{Alternatively, VL} ; including the sequence represented by SEQ ID NO: 5 is included.

In one example, the antigen binding domain
(I) CDR1 containing the sequence shown between amino acids 31 to 35 of SEQ ID NO: 37, CDR2 containing the sequence shown between amino acids 50 to 66 of SEQ ID NO: 37, and amino acids 99 to 107 of SEQ ID NO: 37. is at least about 54% identical to the sequence given between the amino acids 24-34 of the V _H and SEQ ID NO: 5 comprising the sequence set forth in V _H or SEQ ID NO: 37 includes a CDR3 comprising the sequence shown between ( Or 60% identical or 70% identical or 80
% Identical or 90% identical or 95% identical or 98% identical or 99
CDR1 containing the sequence (% identical or 100% identical) and amino acid 5 of SEQ ID NO: 5.
CDR2 containing the sequence shown between 0 and 56 is at least about 66% identical (or 70% identical or 80% identical) to the sequence shown between amino acids 89-97 of SEQ ID NO: 5.
Identical or 90% identical or 95% identical or 98% identical or 99%
_VL containing CDR3 containing sequences (identical or 100% identical);
(Ii) CDR1 containing the sequence shown between amino acids 31 to 35 of SEQ ID NO: 37, CDR2 containing the sequence shown between amino acids 50 to 66 of SEQ ID NO: 37, and amino acids 99 to 107 of SEQ ID NO: 37. CDR3 containing the sequence shown between and _VH or SEQ ID NO: 37 containing
It is at least about 54% identical (or 60% identical or 70% identical or 8) to the sequence shown between amino acids 24-34 of _VH and SEQ ID NO: 5, including the sequence shown in.
0% identical or 90% identical or 95% identical or 98% identical or 9
It is shown between CDR1 containing the sequence (which is 9% identical or 100% identical), CDR2 containing the sequence shown between amino acids 50-56 of SEQ ID NO: 5, and amino acids 89-97 of SEQ ID NO: 5. _VL containing the sequence-containing CDR3; or (iii) CDR1 containing the sequence shown between amino acids 31-35 of SEQ ID NO: 37 and CDR2 containing the sequence shown between amino acids 50-66 of SEQ ID NO: 37. _{And VH} or SEQ ID NO: 3 containing CDR3 containing the sequence shown between amino acids 99 to 107 of SEQ ID NO: 37.
_{CDR1 containing the sequence shown between VH} containing the sequence shown in 7 and amino acids 24 to 34 of SEQ ID NO: 5, CDR2 containing the sequence shown between amino acids 50 to 56 of SEQ ID NO: 5, and SEQ ID NO: At least about 66% identical (or 70% identical or 80% identical or 90% identical or 95% identical or 98% identical to the sequence shown between amino acids 89-97 of 5. _{Includes VL} ; including CDR3 containing sequences (identical, 99% identical, or 100% identical).

In one embodiment, the protein comprises a _{V H} comprising CDR1 and CDR2 of the _{V H} of _{V L} and antibody 8E2 including CDR1 and CDR2 and CDR3 of _{V L} antibody 8E2.

In one embodiment, the protein comprises a _{V H} comprising CDR1 and CDR3 of the _{V L} and CDR1 and _{V H} antibody 8E2 including CDR1 and CDR2 and CDR3 of _{V L} antibody 8E2.

In one embodiment, the protein comprises a _{V H} containing the CDR2 and CDR3 of _{V H} of _{V L} and antibody 8E2 including CDR1 and CDR2 and CDR3 of _{V L} antibody 8E2.

In one embodiment, the protein comprises a _{V H} comprising CDR1 and CDR2 and CDR3 of _{V H} of _{V L} and antibody 8E2 comprising CDR1 and CDR3 of the _{V L} of antibody 8E2.

In one example, the antigen binding domain is (i) V _H comprising the sequence set forth in SEQ ID NO: 71 and V containing the sequence set forth in SEQ ID NO: 35.
_L; or _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 36 comprises the sequence represented by (ii) SEQ ID NO: 72; including.

Such IL-11Rα binding proteins are at the level of binding of any one or more of the functional activities described herein, eg, the polypeptide of SEQ ID NO: 3 containing substitutions as described above. In comparison, it can show preferential binding to the polypeptide of SEQ ID NO: 3.

In one example, the difference between the cited sequence and the IL-11Rα binding protein is a substitution.

A skilled expert can determine, for example, within the framework region of a variable region containing protein, the site of mutation to the IL-11Rα binding protein of the present disclosure. Furthermore, it maintains a large number of sites, and the activity of IL-11Ra binding proteins of the present disclosure in CDR1 and / or CDR3 of CDR1, CDR2 and / or CDR3 and _{V L V H,} which can be mutated We have identified a number of mutations that do or improve. For example, mutations, such as substitutions, are HCDR1 and / or HCD of antibody 8E2.
In one or more of R2 (eg, 2 or 3 or 4) and / or one or more of the six N-terminal residues of HCDR3 or six C-terminal residues (eg, 2 or 3 or 4 or 5 or 6) be. For example, a mutation, eg, a substitution, is at least one of the six C-terminal amino acids of antibody 8E2 (eg, 2 or 3 or 4 or 5 or 6) and / or at least one of the five C-terminals of LCDR3 (eg, 2 or 3 or 4 or 5 or 6). , 2 or 3 or 4 or 5).

In one example, the IL-11Rα binding proteins of the present disclosure are sequenced QASQDX ₁ X ₂ X ₃
Contains light chain CDR1 containing X ₄ X ₅ X ₆ (SEQ ID NO: 77), where X ₁ = I or V; X
₂ = N or D or G or S or A or H; X ₃ = N or Y or I or K or M or Q or G or H; X ₄ = Y or W; X ₅ = L or V or I or M And X ₆ = N or E.

In one example, the IL-11Rα binding proteins of the present disclosure are sequenced X ₁ QX ₂ X ₃ X ₄ X ₅
Contains light chain CDR3 containing X ₆ PX ₇ (SEQ ID NO: 78), where X ₁ = Q or E or S
Or T; X ₂ = Y or H or F or N or S or W; X ₃ = D or E; X ₄ = N, D, F
, S, E or T; X ₅ = L or Q; X ₆ = S or A or W or T or M or Q and X ₇ =
T or E or F or A or L or F or N or Q.

In one embodiment, X ₁ is Q and X ₂ is Y.

In one embodiment, X ₆ is S and X ₇ is T.

In one example, the IL-11Rα binding protein of the present disclosure comprises a heavy chain CDR1 comprising the _{sequence X 1} X ₂ SX ₃ X _{4 , where X 1} = W or R; X ₂ = Y or W or F; X ₄ = M or I or V or T or L and X ₅ = T or A.

In one example, the IL-11Rα binding proteins of the present disclosure are sequence SIVPX ₁ X ₂ X ₃ X.
₄ Includes heavy chain CDR2 containing TQYADSVKG, in which case X ₁ = S or W or Y or H
X ₂ = G or A; X ₃ = G or D or T and X ₄ = H or Y or L or I or F.

In one example, the IL-11Rα binding proteins of the present disclosure are sequenced X ₁ X ₂ X ₃ WGX ₄ F.
Includes heavy chain CDR3 containing X ₅ X _{6 where X 1} = G or P; X ₂ = P or E or V or L or N or H; X ₃ = G or D; X ₄ = S or M Or R or L; X ₅ = D or A or W and X ₆ = L or V or F or Q or E or Y or T.

In one embodiment, X ₁ is G, X ₂ is P, and X ₃ is G.

In one embodiment, X ₅ is D and X ₆ is L.

In one example, the IL-11Rα binding protein CDs one of the aforementioned consensus sequences.
Included as R, the remaining CDR is derived from antibody 8E2.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
_{Neutralizes the signal transduction of, and the antigen-binding domain is any of VH} and / or SEQ ID NOs: 5-34, 73 or 75 containing the sequence set forth in any one of SEQ ID NOs: 37-70, 74 or 76. _{Includes a VL} containing the sequence represented by one.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Signaling and neutralization of the antigen binding domains (including amino acids N-terminal to the CDR1 optionally) containing CDR1,2 and 3 of the sequence shown in (i) SEQ ID NO: 37 _{V H} and SEQ ID NO: _V L containing CDR1,2 and 3 of the sequence shown in 5;
_{(Ii) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 38 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_{(Iv) V H} containing the sequence represented by SEQ ID NO: 38 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 39 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 _VL ;
_{(Vi) V H} containing the sequence set forth in SEQ ID NO: 39 and V containing the sequence set forth in SEQ ID NO: 5.
_L ;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 40 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 40 L;
(Ix) (including also the N-terminal amino acids relative optionally CDRl) comprising CDR1, 2 and 3 of the sequence shown in SEQ ID NO: 41 _{V H} and the sequence indicated in SEQ ID NO: 5 CDR1, 2 and 3
_VL ;
V comprises the sequence represented by V _H and SEQ ID NO: 5 comprising the sequence represented by (x) SEQ ID NO: 41 _L
;
(Xi) (including also the N-terminal amino acids relative optionally CDRl) comprising CDR1, 2 and 3 of the sequence shown in SEQ ID NO: 42 _{V H} and the sequence indicated in SEQ ID NO: 5 CDR1, 2 and 3
_VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xii) SEQ ID NO: 42 L;
(Xiii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 43 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xiv) SEQ ID NO: 43 L;
(Xv) including CDR1, 2 and 3 of the sequence shown in SEQ ID NO: 44 (including the N-terminal amino acid for any in CDRl) _{V H} and the sequence indicated in SEQ ID NO: 5 CDR1, 2 and 3
_VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xvi) SEQ ID NO: 44 L;
(Xvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 45 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xviii) SEQ ID NO: 45 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xix) SEQ ID NO: 46 _VL ;
_{(Xx) V H} containing the sequence represented by SEQ ID NO: 46 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxi) SEQ ID NO: 47 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxii) SEQ ID NO: 47 L;
(Xxiii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 48 (optionally CDRs.
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxiv) SEQ ID NO: 48 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxv) SEQ ID NO: 49 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxvi) SEQ ID NO: 49 L;
(Xxxvii) Contains CDRs 1, 2 and 3 of the sequence represented by SEQ ID NO: 50 (optionally CDRs.
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xxviii) SEQ ID NO: 50 L;
(Xxix) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 51 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxx) SEQ ID NO: 51 L;
(Xxxx) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 52 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxii) SEQ ID NO: 52 L;
(Xxxxii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 53 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 5 (including the N-terminal amino acid with respect to R1),
_VL including 2 and 3;
_{(Xxxx) V H} containing the sequence represented by SEQ ID NO: 53 and _VL containing the sequence represented by SEQ ID NO: 5.
(Xxxxv) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 54 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xxxvi) SEQ ID NO: 54 L;
(Xxxxvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 55 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 5 (including the N-terminal amino acid with respect to R1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxviii) SEQ ID NO: 55 L;
(Xxxx) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 56 (optionally CDR
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_{(Xl) V H} containing the sequence represented by SEQ ID NO: 56 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xli) SEQ ID NO: 57 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlii) SEQ ID NO: 57 L;
(Xliii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 58 (optionally CDRs.
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xliv) SEQ ID NO: 58 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xlv) SEQ ID NO: 59 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlvi) SEQ ID NO: 59 L;
(Xlvii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 60 (optionally CDRs.
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlviii) SEQ ID NO: 60 L;
(Xlix) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 61 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
V comprises the sequence represented by V _H and SEQ ID NO: 5 comprising the sequence represented by (l) SEQ ID NO: 61 _L
;
(Li) including CDR1, 2 and 3 of the sequence shown in SEQ ID NO: 62 (including the N-terminal amino acid for any in CDRl) _{V H} and the sequence indicated in SEQ ID NO: 5 CDR1, 2 and 3
_VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lii) SEQ ID NO: 62 L;
(Liii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 63 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (liv) SEQ ID NO: 63 L;
(Lv) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1, 2 and 3 comprising the sequence shown in ID NO: 64 _{V H} and the sequence indicated in SEQ ID NO: 5 CDR1, 2 and 3
_VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lvi) SEQ ID NO: 64 L;
(Lvii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 65 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lviii) SEQ ID NO: 65 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lix) SEQ ID NO: 66 _VL ;
_{(Lx) V H} containing the sequence represented by SEQ ID NO: 66 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lxi) SEQ ID NO: 67 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXII) SEQ ID NO: 67 L;
(Lxiii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 68 (optionally CDRs.
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXIV) SEQ ID NO: 68 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (LXV) SEQ ID NO: 69 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXVI) SEQ ID NO: 69 L;
(Lxvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 70 (optionally CDR
CDR1, 2 of the sequence shown by _VH and SEQ ID NO: 5 (including the amino acid at the N-terminal with respect to 1)
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXVIII) SEQ ID NO: 37 L;
(Lxix) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 70 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 5 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lxx) SEQ ID NO: 70 L;
(Lxxi) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 6 against;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 6 comprising the sequence represented by (LXXII) SEQ ID NO: 37 L;
(Lxxiii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 7 (including the N-terminal amino acid with respect to R1),
_VL including 2 and 3;
_{(Lxxiv) V H} containing the sequence set forth in SEQ ID NO: 37 and _VL containing the sequence set forth in SEQ ID NO: 7.
(Lxxv) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
_V L containing CDR1,2 and 3 of the sequence shown in N including terminal amino acid) _{V H} and SEQ ID NO: 8 with respect to;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 8 comprising the sequence given in (LXXVI) SEQ ID NO: 37 L;
(Lxxvii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 9 (including the N-terminal amino acid with respect to R1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 9 comprises a sequence represented by (LXXVIII) SEQ ID NO: 37 L;
(Lxxix) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 10 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 10 comprises the sequence represented by (LXXX) SEQ ID NO: 37 L;
(Lxxxi) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 11 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 11 comprises the sequence given in (LXXXII) SEQ ID NO: 37 L;
(Lxxxxiii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally C).
_{CDR of the sequence shown by VH} and SEQ ID NO: 12 (including the N-terminal amino acid with respect to DR1)
_VL including 1, 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 12 comprises the sequence represented by (LXXXIV) SEQ ID NO: 37 L;
(Lxxxx) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 13 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 13 comprises the sequence represented by (lxxxvi) SEQ ID NO: 37 L;
(Lxxxxvii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally C).
_{CDR of the sequence shown by VH} and SEQ ID NO: 14 (including the N-terminal amino acid with respect to DR1)
_VL including 1, 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 14 comprises the sequence given in (LXXXVIII) SEQ ID NO: 37 L;
(Lxxxx) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 15 (including the N-terminal amino acid with respect to R1)
_VL including 2, 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence represented by (xc) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 16 including CDR1,2 and 3 of the sequence shown in (xci) SEQ ID NO: 37 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xcii) SEQ ID NO: 37 L;
(Xciii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 17 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 17 comprises the sequence given in (XCIV) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 18 CDR1,2 and 3 comprising the sequence represented by (xcv) SEQ ID NO: 37 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence represented by (XCVI) SEQ ID NO: 37 L;
(Xcvii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 19 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 19 comprises the sequence represented by (XCVIII) SEQ ID NO: 37 L;
(Xcix) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CDR1).
The N-terminal amino acid is also included) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 20.
_VL including 3 and 3;
_{(C) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 20.
_L ;
(Ci) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 21 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 21 comprises the sequence represented by (cii) SEQ ID NO: 37 L;
(Cii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) V _H and CDR1, 2 of the sequence shown by SEQ ID NO: 22
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 22 comprises the sequence represented by (civ) SEQ ID NO: 37 L;
(Cv) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 23 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 23 comprises the sequence represented by (cvi) SEQ ID NO: 37 L;
(Cvii) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 24.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 24 comprises the sequence represented by (cviii) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 25 including CDR1,2 and 3 of the sequence shown in (cix) SEQ ID NO: 37 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 25 comprises the sequence represented by (cx) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 26 CDR1,2 and 3 comprising the sequence represented by (cxi) SEQ ID NO: 37 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 26 comprises the sequence given in (CXII) SEQ ID NO: 37 L;
(Cxiii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 27 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_{(Cxiv) V H} containing the sequence set forth in SEQ ID NO: 37 and _VL containing the sequence set forth in SEQ ID NO: 27;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 28 CDR1,2 and 3 comprising the sequence represented by (CXV) SEQ ID NO: 37 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 28 comprises the sequence given in (CXVI) SEQ ID NO: 37 L;
(Cxvii) Contains CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDRs.
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 29 (including the N-terminal amino acid with respect to 1),
_VL including 2 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence represented by (cxviii) SEQ ID NO: 37 L;
(Cxix) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 30.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 30 comprises the sequence given in (cxx) SEQ ID NO: 37 L;
(Cxxx) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 31.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 31 comprises the sequence represented by (CXXII) SEQ ID NO: 37 L;
(Cxxxii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 32 (including the N-terminal amino acid with respect to R1)
_VL including 2, 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 32 comprises the sequence represented by (CXXIV) SEQ ID NO: 37 L;
(Cxxxv) Contains CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 33.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 33 comprises the sequence represented by (CXXVI) SEQ ID NO: 37 L;
(Cxxxvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CD).
_{CDR1 of the sequence shown by VH} and SEQ ID NO: 34 (including the amino acid at the N-terminal to R1)
, _{V L} containing 2 and 3; including; _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 34 comprises the sequence given in or (CXXVIII) SEQ ID NO: 37.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Signaling and neutralization of the antigen binding domains (including N-terminal amino acid for any in CDRl) comprising CDR1,2 and 3 of the sequence shown in (i) SEQ ID NO: 49 _{V H} and SEQ ID NO: _V L containing CDR1,2 and 3 of the sequence shown in 5;
_{(Ii) V H} containing the sequence represented by SEQ ID NO: 49 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 53 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_{(Iv) V H} containing the sequence represented by SEQ ID NO: 53 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 57 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 _VL ;
_{(Vi) V H} containing the sequence represented by SEQ ID NO: 57 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 58 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 58 L;
(Ix) sequence (including amino acids N-terminal to the CDR1 optionally) comprising CDR1, 2 and 3 of the sequence shown in ID NO: 37 _V the sequence indicated in _H and SEQ ID NO: 8 CDR1, 2 and 3
_VL ;
V comprises the sequence represented by V _H and SEQ ID NO: 8 comprising the sequence represented by (x) SEQ ID NO: 37 _L
;
(Xi) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 15 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence given in (xii) SEQ ID NO: 37 L;
(Xiii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 16.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xiv) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (xv) SEQ ID NO: 37 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 18 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence given in (xvi) SEQ ID NO: 37 L;
(Xvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 29.
And _{V L} containing 3; including; _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence given in or (xviii) SEQ ID NO: 37.

In one embodiment, the CDRs are:
(I) Heavy chain CDR1: Amino acids 31-35 of the cited sequence;
(Ii) Heavy Chain CDR2: Amino Acids 50-66 in the Cited Sequence (optionally, any one or more of the five C-terminal amino acids are replaced with another naturally occurring amino acid);
(Iii) Heavy Chain CDR3: Amino Acids 99-107 in the Cited Sequence;
(Iv) Light chain CDR1: Amino acids 24-34 of the cited sequence;
(V) Light chain CDR2: Amino acids 50-56 in the cited sequence; and (vi) Light chain CDR3: Amino acids 89-97 in the cited sequence.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 49.
_{V L} containing CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 including 1, 2 and 3
including.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes signal transduction, and the antigen-binding domain contains the sequence set forth in SEQ ID NO: 49.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 53.
Containing 1, 2 and 3 comprises a _{V L} containing CDR1,2 and 3 (optionally including N-terminal amino acid with respect CDRl) sequence shown in _{V H} and SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes signal transduction, and the antigen-binding domain contains the sequence set forth in SEQ ID NO: 53.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 57.
Containing 1, 2 and 3 comprises a _{V L} containing CDR1,2 and 3 (optionally including N-terminal amino acid with respect CDRl) sequence shown in _{V H} and SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 57.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 58.
Containing 1, 2 and 3 comprises a _{V L} containing CDR1,2 and 3 (optionally including N-terminal amino acid with respect CDRl) sequence shown in _{V H} and SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes signal transduction, and the antigen-binding domain contains the sequence set forth in SEQ ID NO: 58.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 5.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 37.
Containing _{V L} containing CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 8 including 1, 2 and 3.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 8.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 37.
Containing 1, 2 and 3 comprises a _{V L} containing CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 15.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 15.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 37.
Containing _{V L} containing CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 16 containing 1, 2, and 3.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 16.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 37.
Containing _{V L} containing CDR1,2 and 3 of the sequence shown in 1, 2 and 3 containing (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 18.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 18.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
The antigen-binding domain is the CDR of the sequence set forth in SEQ ID NO: 37.
Containing _{V L} containing CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 29 containing 1, 2, and 3.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
_{Includes VL containing H} and the sequence set forth in SEQ ID NO: 29.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 37.
Including _H. In one embodiment, _{V L} comprises CDR1,2 and 3 of the sequence shown in SEQ ID NO: 18.

The present disclosure also provides an IL-11Rα-binding protein comprising an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα and IL-11.
Neutralizes the signal transduction of the antigen-binding domain, which comprises the sequence set forth in SEQ ID NO: 18.
Including _L. In one embodiment, V _H comprises CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37.

In one embodiment, the CDRs are:
(I) Heavy chain CDR1: Amino acids 31-35 of the cited sequence;
(Ii) Heavy Chain CDR2: Amino Acids 50-66 in the Cited Sequence (optionally, any one or more of the five C-terminal amino acids are replaced with another naturally occurring amino acid);
(Iii) Heavy Chain CDR3: Amino Acids 99-107 in the Cited Sequence;
(Iv) Light chain CDR1: Amino acids 24-34 of the cited sequence;
(V) Light chain CDR2: Amino acids 50-56 in the cited sequence; and (vi) Light chain CDR3: Amino acids 89-97 in the cited sequence.

In one example, the IL-11Rα binding proteins described herein are at least _VH.
And _VL , the V _H and _VL combine to form an Fv containing an antigen-binding domain. A skilled expert will understand that the antigen binding domain contains the binding site of the antibody.

In one example, V _H and _VL are in a single polypeptide chain. For example, the protein is (i) a single chain Fv fragment (scFv);
(Ii) Dimer scFv (di-scFv);
(Iii) Constant region of antibody, Fc or heavy chain constant domain ( _CH ) 2 and / or _CH 3
One of (i) or (ii) linked to, or (i) or (ii) linked to a protein that binds to (iv) immune effector cells.
);

In one example, V _H and _VL are in separate polypeptide chains.

For example, proteins are (i) bispecific antibodies;
(Ii) Trispecific antibody;
(Iii) Quadruspecific antibody;
(Iv) Fab;
(V) F (ab') ₂ ;
(Vi) Fv
(Vii) Constant region of antibody, Fc or heavy chain constant domain ( _CH ) 2 and / or _CH 3
One of (i) to (vi) linked to;
(Viii) Linked to proteins that bind to immune effector cells (i)-(vi)
One of;

The aforementioned proteins (listed in the previous two lists) can also be referred to as the antigen-binding domain of an antibody.

In one example, the protein is an antibody, eg, a monoclonal antibody. In one example, the antibody is a naked antibody.

In one example, the protein (or antibody) is chimeric, deimmunized, humanized, human, or primated.

In one example, the protein or antibody is human.

The present disclosure further or instead provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling.
(I) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 49 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 _VL ;
_{(Ii) V H} containing the sequence represented by SEQ ID NO: 49 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 53 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_{(Iv) V H} containing the sequence represented by SEQ ID NO: 53 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 57 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 _VL ;
_{(Vi) V H} containing the sequence represented by SEQ ID NO: 57 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 58 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 58 L;
(Ix) sequence (including amino acids N-terminal to the CDR1 optionally) comprising CDR1, 2 and 3 of the sequence shown in ID NO: 37 _V the sequence indicated in _H and SEQ ID NO: 8 CDR1, 2 and 3
_VL ;
V comprises the sequence represented by V _H and SEQ ID NO: 8 comprising the sequence represented by (x) SEQ ID NO: 37 _L
;
(Xi) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 15 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence given in (xii) SEQ ID NO: 37 L;
(Xiii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 16.
_VL including 3 and 3;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xiv) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (xv) SEQ ID NO: 37 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 18 _VL ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence given in (xvi) SEQ ID NO: 37 L;
(Xvii) Contains CDR1, 2 and 3 of the sequence represented by SEQ ID NO: 37 (optionally CDR1).
(Including N-terminal amino acid) _VH and CDR1, 2 of the sequence shown by SEQ ID NO: 29.
And _{V L} containing 3; including; _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence given in or (xviii) SEQ ID NO: 37.

The present disclosure also provides antibodies that neutralize binding to and signaling IL-11 to IL-11Ra, the antibody comprises a V _H containing the sequence shown in SEQ ID NO: 37. In one embodiment, V
_L comprises CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 18.
(Xix) The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising a _VL containing the sequence set forth in SEQ ID NO: 18. In one embodiment, V _H comprises CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 37.

In one embodiment, the CDRs are:
(I) Heavy chain CDR1: Amino acids 31-35 of the cited sequence;
(Ii) Heavy Chain CDR2: Amino Acids 50-66 in the Cited Sequence (optionally, any one or more of the five C-terminal amino acids are replaced with another naturally occurring amino acid);
(Iii) Heavy Chain CDR3: Amino Acids 99-107 in the Cited Sequence;
(Iv) Light chain CDR1: Amino acids 24-34 of the cited sequence;
(V) Light chain CDR2: Amino acids 50-56 in the cited sequence; and (vi) Light chain CDR3: Amino acids 89-97 in the cited sequence.

An example _{sequence of V H} and _VL is shown in Table 1.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 49 (optionally CDR1). (Including N-terminal amino acid) V _H and CDR of the sequence shown by SEQ ID NO: 5
_{Includes VL} including 1, 2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 49 and the sequence set forth in SEQ ID NO: 5. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 53 (optionally CDR1). (Including N-terminal amino acid) V _H and CDR of the sequence shown by SEQ ID NO: 5
_{Includes VL} including 1, 2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH containing the sequence set forth in SEQ ID NO: 53 and the sequence set forth in SEQ ID NO: 5. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 57 (optionally CDR1). (Including N-terminal amino acid) V _H and CDR of the sequence shown by SEQ ID NO: 5
_{Includes VL} including 1, 2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 57 and the sequence set forth in SEQ ID NO: 5. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDRs 1, 2 and 3 of the sequence set forth in SEQ ID NO: 58 (optionally CDR1). (Including N-terminal amino acid) V _H and CDR of the sequence shown by SEQ ID NO: 5
_{Includes VL} including 1, 2 and 3.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH containing the sequence set forth in SEQ ID NO: 58 and the sequence set forth in SEQ ID NO: 5. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1). (Including N-terminal amino acid) V _H and CDR of the sequence shown by SEQ ID NO: 8
_{Includes VL} including 1, 2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 37 and the sequence set forth in SEQ ID NO: 8. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1). (Including N-terminal amino acid) V _H and CD of the sequence shown by SEQ ID NO: 15.
Including the _{V L,} including a R1,2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 37 and the sequence set forth in SEQ ID NO: 15. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1). (Including N-terminal amino acid) V _H and CD of the sequence shown by SEQ ID NO: 16
Including the _{V L,} including a R1,2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 37 and the sequence set forth in SEQ ID NO: 16. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1). (Including N-terminal amino acid) V _H and CD of the sequence shown by SEQ ID NO: 18.
Including the _{V L,} including a R1,2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 37 and the sequence set forth in SEQ ID NO: 18. Includes _VL including.

The disclosure also provides an antibody that binds to IL-11Rα and neutralizes the signaling of IL-11, the antibody comprising CDR1, 2 and 3 of the sequence set forth in SEQ ID NO: 37 (optionally CDR1). (Including N-terminal amino acid) V _H and CD of the sequence shown by SEQ ID NO: 29
Including the _{V L,} including a R1,2 and 3.

The present disclosure also provides an antibody that binds to IL-11Rα and neutralizes IL-11 signaling, the antibody being _VH comprising the sequence set forth in SEQ ID NO: 37 and the sequence set forth in SEQ ID NO: 29. Includes _VL including.

In one embodiment, the CDRs are:
(I) Heavy chain CDR1: Amino acids 31-35 of the cited sequence;
(Ii) Heavy Chain CDR2: Amino Acids 50-66 in the Cited Sequence (optionally, any one or more of the five C-terminal amino acids are replaced with another naturally occurring amino acid);
(Iii) Heavy Chain CDR3: Amino Acids 99-107 in the Cited Sequence;
(Iv) Light chain CDR1: Amino acids 24-34 of the cited sequence;
(V) Light chain CDR2: Amino acids 50-56 in the cited sequence; and (vi) Light chain CDR3: Amino acids 89-97 in the cited sequence.

References herein to a protein or antibody that "binds" to IL-11Rα "specifically" to a protein or antibody that "specifically binds" to IL-11R or "specifically binds" to IL-11R. Provides literal support.

The disclosure also provides the antigen-binding domain or antigen-binding fragment of the aforementioned antibody.

In one example, the protein or antibody described herein comprises a human constant region, eg, an IgG constant region of IgG1, IgG2, IgG3 or IgG4. V _H and _VL
In the case of a protein or antibody comprising, V _H can be linked to the heavy chain constant region and _VL can be linked to the light chain constant region.

All antibodies of the disclosure (or IL-11Ra binding protein comprising a constant region or _{C H} 3)
The C-terminal lysine of the heavy chain constant region of is removed, for example, during the production or purification of the antibody or protein or by recombinant manipulation of the nucleic acid encoding the heavy chain of the antibody. Thus, all antibodies (or IL-11Rα-binding proteins) are associated with a population in which all C-terminal lysine residues have been removed, a population in which C-terminal lysine residues have not been removed, and / or a C-terminal lysine residue. It may include a population having a mixture of proteins with or without. In some examples
The population may further contain a protein from which the C-terminal lysine residue is removed while in the heavy chain constant region. Similarly, the composition of all antibodies may comprise the same or similar mixture of antibody populations with or without a C-terminal lysine residue.

In one example, the protein or antibody described herein comprises a constant region of an IgG4 antibody or a stabilized constant region of an IgG4 antibody. In one example, the protein or antibody has proline at position 241 (Kabat et al., S.
equations of Proteins of Immunological In
terrace Washington DC United States Depar
moment of Health and Human Services, 1987
Includes a constant region of IgG4 (according to and / or 1991).

In one embodiment, the heavy chain constant region comprises the sequences from positions 119 to 445 of SEQ ID NO: 83. In one example, the protein or antibody described herein or the composition of the protein or antibody described herein is a complete or mixture of sequences with or without a C-terminal lysine residue. Includes a heavy chain constant region that includes a partially contained, stabilized heavy chain constant region.

In one example, the antibodies of the present disclosure include _VH disclosed herein linked or fused to an IgG4 constant region or a stabilized IgG4 constant region (eg, as described above). _VL is linked or fused to the κ light chain constant region.

The antibodies of the present disclosure will be applied mutatis mutandis by taking advantage of the functional characteristics of the IL-11Rα binding proteins of the present disclosure.

In one example, the IL-11Rα binding protein or antibody as described herein is isolated and / or recombinant.

In one example, the IL-11Rα binding protein or antibody of the present disclosure binds to another compound, such as a detectable label, or a compound that prolongs the half-life of a protein or antibody, such as, for example, polyethylene glycol or albumin binding protein. Will be done. Other suitable compounds are described herein.

The disclosure also provides nucleic acids encoding the IL-11Rα binding proteins or antibodies of the disclosure or polypeptides thereof.

In one embodiment, such nucleic acid is included in an expression construct in which the nucleic acid is operably linked to a promoter. Such an expression construct can be a vector, eg, a plasmid.

In the examples of the present disclosure for a single polypeptide chain IL-11Rα binding protein, the expression construct may comprise a promoter linked to a nucleic acid encoding that polypeptide chain.

In the embodiments of the present disclosure relating to multiple polypeptide chains forming an IL-11Rα binding protein, the expression construct is, for example, _{a nucleic acid encoding a polypeptide comprising VH} operably linked to a promoter and, for example, a promoter. Includes a nucleic acid encoding a polypeptide containing _VL operably linked to.

In another embodiment, the expression construct is composed of, for example, the following operably linked components in the order 5'to 3':
(I) With a promoter;
(Ii) With the nucleic acid encoding the first polypeptide;
(Iii) With internal ribosome invasion site;
(Iv) A bicistron expression construct comprising a nucleic acid encoding a second polypeptide.
At that time, the first polypeptide _{contains V H} , the second polypeptide _{contains VL} , and vice versa.

The present disclosure also includes separate expression constructs, one encoding a first polypeptide containing _{V H} and the other encoding a second polypeptide containing _VL. Plan. For example, this disclosure also
(I) A first expression construct comprising a nucleic acid encoding a polypeptide containing _VH operably linked to a promoter; and (ii) encoding a polypeptide containing _{VL operably linked to a promoter.} A composition comprising a second expression construct comprising a nucleic acid; is also provided.

The disclosure also provides isolated or recombinant cells expressing the IL-11Rα binding proteins of the disclosure.

In one embodiment, the cells, the expression construct of the present disclosure, or (i) a first expression construct comprising a nucleic acid encoding a polypeptide comprising the operably linked V _H to a promoter; and (ii) a promoter Contains a second expression construct comprising a nucleic acid encoding a polypeptide comprising an operably linked _VL;
At that time, the first and second polypeptides associate to form the IL-11Rα-binding protein of the present disclosure.

Examples of cells of the present disclosure include bacterial cells, yeast cells, insect cells or mammalian cells.

The present disclosure further provides a method of producing the IL-11Rα binding protein or antibody of the present disclosure. For example, such methods involve maintaining the expression constructs of the present disclosure under conditions sufficient to produce IL-11Rα binding proteins or antibodies.

In one example, the method of producing the IL-11Rα binding protein or antibody of the present disclosure is IL.
Includes culturing the cells of the present disclosure under conditions sufficient to produce and optionally secrete a -11Rα binding protein or antibody.

In one example, the method of producing the IL-11Rα binding protein or antibody of the present disclosure is to further isolate the protein or antibody and optionally formulate the IL-11Rα binding protein or antibody into a pharmaceutical composition. Including and.

The present disclosure further provides a composition comprising the IL-11Rα binding protein or antibody of the present disclosure and a pharmaceutically acceptable carrier.

In one example, the composition is (i) an antibody of the present disclosure comprising a C-terminal lysine residue derived from a heavy chain;
(Ii) Missing C-terminal lysine residue from heavy chain; and / or (iii) containing C-terminal lysine residue on one heavy chain and another (other) heavy chain Antibodies of the present disclosure lacking the C-terminal lysine residue above;
And optionally include pharmaceutically acceptable carriers.

The disclosure also provides a method of treating or preventing an IL-11-mediated disease in a subject, the method comprising administering the IL-11Rα binding protein, antibody or composition of the present disclosure. In this regard, IL-11Rα binding proteins, antibodies or compositions can be used to prevent recurrence of the disease, which is considered to prevent the disease.

In one example, the IL-11-mediated disease is an autoimmune disease, an inflammatory disease, a debilitating disease, a bone disease or cancer.

Examples of autoimmune diseases include arthritis, inflammatory bowel disease and psoriasis.

Examples of inflammatory diseases include infection-induced inflammation (eg, inflammation caused by tuberculosis), gastric inflammation (eg, associated with gastric cancer), and inflammatory airway disease (eg, asthma, chronic). Obstructive pulmonary disease (COPD), rhinitis or allergies), or inflammatory dermatitis (eg, atopic dermatitis).

An example of a debilitating disorder is cachexia (eg, cachexia due to cancer or renal failure).
Alternatively, sarcopenia can be mentioned.

Examples of bone disorders include osteoporosis (including postmenopausal osteoporosis), bone fractures, and cancer (metastatic bone cancer,).
Treatment of bone resorption / damage and cancer caused by myeloma or Paget's disease of bone (eg,)
Bone resorption / damage caused by chemotherapy, hormone removal or hormone inhibition).

Examples of cancers include hematologic cancers, epithelial cancers, liver cancers, pancreatic cancers, gastric cancers, osteosarcomas, endometrial cancers and ovarian cancers.

In one example, the cancer or bone disease is the metastasis of cancer to bone.

The disclosure also provides a method of inhibiting or neutralizing IL-11 in a subject, the method comprising administering the IL-11Rα binding protein, antibody or composition of the present disclosure. In one example, the subject suffers from an IL-11-mediated disease.

The disclosure also provides a method of preventing pregnancy in a subject, the method of which is IL-11R of the present disclosure.
Includes administration of α-binding proteins, antibodies or compositions.

In one example, the methods described herein are about 0.05 mg / kg to 30 mg / kg.
Includes administration of IL-11Rα binding protein or antibody between. For example, 0.1
IL-1 between mg / kg and 10 mg / kg or between about 0.2 mg / kg and 5 mg / kg
1 A method comprising administering an Rα-binding protein or antibody. In one embodiment, the method is about 0
.. It comprises administering 5 to 2 mg / kg of IL-11Rα binding protein or antibody.

The present disclosure is also IL-11 as described herein in any example in pharmaceuticals.
The use of Rα-binding proteins or antibodies is provided.

The disclosure also provides the use of IL-11Rα binding proteins or antibodies as described herein according to any example in the manufacture of a drug for treating an IL-11-mediated disease. Example diseases are described herein.

The present disclosure also provides methods for localizing and / or detecting and / or diagnosing and / or prognosing IL-11-mediated diseases associated with cells expressing IL-11Rα.
The method comprises detecting, if present, an IL-11Rα-binding protein or antibody as described herein that binds to cells expressing IL-11Rα, in vivo. The 11Rα binding protein or antibody is bound to a detectable tag.

In one example, the method further comprises administering to the subject an IL-11Rα binding protein.

The present disclosure also provides a method of detecting IL-11Rα or cells expressing IL-11Rα in a sample, the method herein according to any example such as complex formation. Contacting the sample with a protein or antibody as described involves detecting the complex, where detection of the complex is IL-11Rα or IL-1 in the sample.
Shows cells expressing 1Rα. In one embodiment, the method is performed in vitro or in vitro.

The present disclosure also provides a method for diagnosing or prognosing IL-11-mediated disease.
The method comprises performing a method as described herein according to any example of detecting IL-11Rα or detecting cells expressing IL-11Rα, in which IL
Detection of cells expressing -11Rα or IL-11Rα is a diagnosis of disease or prognosis. In one embodiment, the method is performed in vitro or in vitro. An example IL-11-mediated disease is described herein.

The disclosure also includes an IL-11Rα binding protein as described herein according to any example, optionally packaged with instructions for use in a manner as described herein or. Kits containing antibodies (eg, packaging or manufactured articles) are also provided.

Key to the Sequence Listing SEQ ID NO: 1: Amino acid sequence of human pre-IL-11Rα SEQ ID NO: 2: Amino acid sequence of crab quizalpre-IL-11Rα SEQ ID NO: 3: Amino acid sequence of a polypeptide containing amino acids 23 to 363 of SEQ ID NO: 1. 8
× Serine at the position corresponding to the 248th position of the HIS tag and SEQ ID NO: 1 (also referred to as “WT F / L”)
SEQ ID NO: 4: Human gpl30 amino acid sequence SEQ ID NO 5: amino acid sequence sequence of _{V L} chain of antibody 8E2 No. 6: antibody TS-303 of _{V L} chains of the amino acid sequence SEQ ID NO: 7: antibody TS-305 of _{V L} chains Amino acid SEQ ID NO: 8: Amino acid SEQ ID NO: 9 of _VL chain of antibody TS-306: Amino acid SEQ ID NO: 10 of _VL chain of antibody TS-307: Amino acid SEQ ID NO: 11 of _{VL chain of antibody TS-310} : Amino acid sequence number 12 of _VL chain of antibody TS-311: Amino acid sequence number 13 of _VL chain of antibody TS-312: Amino acid sequence number 14 of _{VL chain of antibody TS-313: Amino acid TS-322} the _{V L} chain of the amino acid sequence SEQ ID NO: 15: antibody TS-2 of the _{V L} chain of the amino acid sequence SEQ ID NO: 16: the _{V L} chain of antibody TS-4 amino acid sequence SEQ ID NO: 17: the _{V L} chain of antibody TS-6 Amino acid SEQ ID NO: 18: Amino acid sequence number of _VL chain of antibody TS-7 19: Amino acid sequence number 20 of _VL chain of antibody TS-9: Amino acid sequence number 21 of _{VL chain of antibody TS-13} : Amino acid sequence number 22 of _VL chain of antibody TS-14: Amino acid sequence number 23 of _VL chain of antibody TS-17: Amino acid sequence number 24 of _{VL chain of antibody TS-20: Amino acid TS-21} the _{V L} chain of the amino acid sequence SEQ ID NO: 25: antibody TS-22 of _{V L} chains of the amino acid sequence SEQ ID NO: 26: the _{V L} chain of antibody TS-29 amino acid sequence SEQ ID NO: 27: the _{V L} chain of antibody TS-32 Amino acid SEQ ID NO: 28: Amino acid sequence number 29 of the _VL chain of the antibody TS-49: Amino acid sequence number 30 of the _VL chain of the antibody TS-51: Amino acid sequence number 31 of the _{VL chain of the antibody TS-55} : Amino acid sequence number 32 of _VL chain of antibody TS-57: Amino acid sequence number 33 of _VL chain of antibody TS-58: Amino acid sequence number 34 of _{VL chain of antibody TS-63: Amino acid TS-64 VL} chain amino acid SEQ ID NO: 35: 8E2 antibody and derivative _VL chain consensus amino acid SEQ ID NO: 36: 8E2 antibody and selected derivative _VL chain consensus amino acid SEQ ID NO: 37: antibody 8E2 V _H- chain amino acid SEQ ID NO: 38: V of antibody TS-66 _H- chain amino acid SEQ ID NO: 39: V of antibody TS-69 _H- chain amino acid SEQ ID NO: 40: V of antibody TS-71 Amino acid sequence of _H-chain SEQ ID NO: 41: Amino acid sequence of _{VH chain of antibody TS-76} Column No. 42: Amino acid sequence No. 43 _{of V H} chain of antibody TS-79: Amino acid sequence No. 44 _{of V H} chain of antibody TS-82: Amino acid sequence No. 45 _{of V H chain of antibody TS-88: Antibody} TS-89 V _H chain amino acid SEQ ID NO: 46: V _H chain amino acid SEQ ID NO: 47 of _{antibody TS-91: V H} chain amino acid SEQ ID NO: 48 of antibody TS-92: V of antibody TS-97 _H Chain Amino Acid SEQ ID NO: 49: V _H Chain Amino Acid SEQ ID NO: 50: V _H Chain Amino Acid SEQ ID NO: 51: V _H Chain Amino Acid Sequence of Antibody TS-104 SEQ ID NO: 52: _{Amino acid sequence number of VH} chain of antibody TS-107 SEQ ID NO: 53: Amino acid sequence number 54 of _VH chain of antibody TS-108: Amino acid sequence number 55 of _{VH chain of antibody TS-115: Antibody} Amino acid sequence number 56 _{of V H} chain of TS-129: Amino acid sequence number 57 _{of V H chain of antibody TS-133: Amino acid sequence number 58 of V H} chain of antibody TS-134: V of antibody TS-135 _H- chain amino acid SEQ ID NO: 59: V of antibody TS-136 _H- chain amino acid SEQ ID NO: 60: V of antibody TS-140 _H- chain amino acid SEQ ID NO: 61: V of antibody TS-143 Amino acid sequence of _H-chain SEQ ID NO: 62: antibody TS-151 of the _{V H} chain of the amino acid sequence SEQ ID NO: 63: antibody TS-156 of the _{V H} chain of the amino acid sequence SEQ ID NO: 64: antibody TS-213 of the _{V H} chain amino acid sequence SEQ ID NO 65: antibody TS-214 V _H Chain Amino Acid SEQ ID NO: 66: V _H Chain Amino Acid SEQ ID NO: 67 of _{antibody TS-215: V H} Chain Amino Acid SEQ ID NO: 68 of antibody TS-218: V of antibody TS-221 _H Chain Amino Acid SEQ ID NO: 69: V _H Chain Amino Acid SEQ ID NO: 70: V _H Chain Amino Acid SEQ ID NO: 71: 8E2 of Antibody _{TS-224 V H} Chain Consensus of Antibodies and Derivatives Amino acid SEQ ID NO: 72: 8E2 _{Amino acid sequence of consensus of VH} chain of antibody and selected derivative Amino acid SEQ ID NO: 73: _{Amino acid sequence of VL} chain of antibody 8E4 SEQ ID NO: 74: Amino acid sequence of _{VH chain of antibody 8E4 75: V L} chain of the amino acid sequence SEQ ID NO: 76 antibody 8D10: antibody _{V H} chain of the amino acid sequence SEQ ID NO: 77 8D10: 8E2 antibody and derivatives of _{V L} chains of CDR1 consensus amino acid sequence SEQ ID NO 78: 8E2 antibody And derivatives of _{V L} chain of CDR3 consensus amino acid sequence SEQ ID NO 79: 8E2 antibodies and derivatives of the _{V H} chain of CDR1 consensus amino acid sequence SEQ ID NO 80: 8E2 antibody and the amino acid of CDR2 consensus _{V H} chain derivatives SEQ ID NO: 81: 8E2 _{Amino acid of consensus of VH} chain of antibody and derivative SEQ ID NO: 82: Amino acid of Hatsukanezumipre-IL-11Rα SEQ ID NO: 83: Amino acid of heavy chain of antibody 8E2 SEQ ID NO: 84: Antibody 8E2 Light Chain Amino Acid SEQ ID NO: 85: Amino acid sequence of a polypeptide containing amino acids 23-318 of human IL-11Rα (SEQ ID NO: 1), 8 × HIS tag and position corresponding to position 248 of SEQ ID NO: 1. Serin (also called "WT Dl / 2")
SEQ ID NO: 86: Amino acids 23 to 110 of human IL-11Rα (SEQ ID NO: 1) and amino acids 111 to 67 of Hatsukanezumi IL-11Rα (SEQ ID NO: 82) (there is serine at the position corresponding to position 206 of SEQ ID NO: 82) and Amino acid sequence of polypeptide containing 8 × HIS tag SEQ ID NO: 87: Amino acids 23-215 of human IL-11Rα (SEQ ID NO: 1) and amino acids 216-367 and 8 × HIS tag of Hatsukanezumi IL-11Rα (SEQ ID NO: 82) Amino acid SEQ ID NO: 88 of the polypeptide containing ) Amino acid 319 to 367 and amino acid of a polypeptide containing an 8 × HIS tag SEQ ID NO: 89: Amino acid 24 of Hatsukanezumi IL-11Rα (SEQ ID NO: 82) (there is serine at the position corresponding to position 206 of SEQ ID NO: 82). ~ 215 and Amino Acids of Human IL-11Rα (SEQ ID NO: 1) 216 to 363 and Amino Acids of Polypeptides Containing 8 × HIS Tags SEQ ID NO: 90: Amino Acids 24 to 367 of Hatsukanezumi IL-11Rα (SEQ ID NO: 82),
Amino acid sequence of a polypeptide containing serine at the position corresponding to position 206 of the 8 × HIS tag and SEQ ID NO: 82 SEQ ID NO: 91: Amino acid sequence of the light chain of antibody 8E4 SEQ ID NO: 92: Amino acid sequence of the heavy chain of antibody 8E4 No. 93: Amino acid sequence of the light chain of antibody 8D10 SEQ ID NO: 94: Amino acid sequence of the heavy chain of antibody 8D10 SEQ ID NO: 95: SEQ ID NO: 85 containing glutamate at a position corresponding to position 117 of SEQ ID NO: 1.
Amino acid SEQ ID NO: 96: Amino acid of SEQ ID NO: 85 containing arginine at the position corresponding to position 66 of SEQ ID NO: 1 Amino acid of SEQ ID NO: 85 containing serine at the position corresponding to position 65 of SEQ ID NO: 1. SEQ ID NO: 98: Amino acid of SEQ ID NO: 85 containing serine at the position corresponding to position 101 of SEQ ID NO: 1 Amino acid sequence of SEQ ID NO: 85 containing alanine at position corresponding to position 178 of SEQ ID NO: 1. No. 100: Amino acid sequence of mature human IL-11Rα SEQ ID NO: 101: Amino acid sequence of mature crab monkey IL-11Rα SEQ ID NO: 102: Amino acid sequence of mature honeybee IL-11Rα SEQ ID NO: 103: Amino acid sequence of consensus of 8E2L1 shown in FIG. No. 104: Amino acid sequence of the consensus of 8E2L3.1 shown in FIG. 1 Amino acid sequence No. 105: Amino acid sequence of the consensus of 8E2L3.2 shown in FIG. 8E2H2 Consensus Amino Acid SEQ ID NO: 108 shown in FIG. 2: 8E2H3.1 Consensus Amino Acid SEQ ID NO: 109 shown in FIG. 2: 8E2H3.2 Consensus Amino Acid SEQ ID NO: 110 shown in FIG. 2: Antagonistic IL- 11 Amino acid sequence of mutant protein

It is a graphic representation which shows the sequence of CDR of _VL of antibody 8E2 and the form of affinity maturation thereof. The listed consensus sequences (SEQ ID NOs: 103-105) represent the most commonly present amino acids at each position and were determined using MegAlign software. Other than the consensus sequence, the sequences are derived from the antibodies shown in Table 1. It is a diagrammatic representation illustrating the form of a sequence of CDR of the V _H of the antibody 8E2 and affinity maturation. The listed consensus sequences (SEQ ID NOs: 106-109) represent the most common amino acids at each position and were determined using MegAlign software. Other than the consensus sequence, the sequences are derived from the antibodies shown in Table 1. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. Figure 3A shows the consensus sequence of the _{V L} region of the 8E2 and sequences and 8E2 and antibody derivatives of the _{V L} region of the antibody derivative. The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. Figure 3A shows the consensus sequence of the _{V L} region of the 8E2 and sequences and 8E2 and antibody derivatives of the _{V L} region of the antibody derivative. The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. Figure 3B shows the consensus sequence of the _{V L} region of the sequences and 8E2 and selective antibody derivatives of _{V L} region of 8E2 and selective antibody derivatives. The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. FIG. 3C shows _{the sequence of the VH} region of 8E2 and its antibody derivative and the consensus sequence of the _{VH region of 8E2 and its antibody derivative.} The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. FIG. 3C shows _{the sequence of the VH} region of 8E2 and its antibody derivative and the consensus sequence of the _{VH region of 8E2 and its antibody derivative.} The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. 3A, B, C and D are graphical representations showing the sequences of the variable regions of the 8E2 antibody and derivative. FIG. 3D shows _{the sequence of the VH} region of 8E2 and the selected antibody derivative and the consensus sequence of the _{VH region of 8E2 and the selected antibody derivative.} The boxed area contains the CDRs (as shown) defined by the Kabat numbering scheme. IL-11 stimulates STAT-3 phosphorylation in human colon-rectal adenocarcinoma cell line DLD-1 and gastric adenocarcinoma cell line MKN-28, and the antibodies of the present disclosure inhibit this IL-11-mediated phosphorylation. It is a series of graph displays showing what can be done. Panels A and B show the levels of phosphorylation of STAT-3 in DLD-1 and MKN-28 cells following stimulation with increasing concentrations of hIL-11 for 15 minutes, respectively. Panels C and D show that increasing the concentration of 8E2 anti-IL-11R antibody (◯) inhibits IL-11-mediated phosphorylation of STAT-3 in DLD-1 and MKN-28 cells, respectively. .. In contrast, the BM4 isotype control antibody (Δ) had no effect on IL-11-mediated phosphorylation of STAT-3. (Antibodies were added to cells prior to stimulation with hIL-11 (50 ng / ml), showing mean and standard deviation.)

Summary Throughout the specification, a single step, composition, group of steps or reference to a group of compositions may be one and more (ie, unless specifically stated or as required by context).
It should be construed to include one or more of those steps, compositions, groups of steps or groups of compositions.

Those skilled in the art will appreciate that this disclosure is susceptible to changes and modifications other than those specifically described. It should be understood that this disclosure includes all such changes and modifications. The present disclosure also includes all of the steps, features, compositions and compounds referred to or indicated herein individually or collectively, and any or all of the steps or combinations of features or of the steps or features. Includes any of two or more.

The present disclosure should not be limited to the extent by the specific examples described herein that are intended for purposes of illustration only. Functionally equivalent products, compositions and methods are clearly within the scope of this disclosure.

Any other embodiment of the present disclosure herein should be construed as applying mutatis mutandis to any other embodiment of the present disclosure, unless otherwise stated.

Unless specifically defined, all terminology and scientific terms used herein are by those skilled in the art (eg, cell culture, molecular genetics, immunology, immunohistochemistry, protein chemistry and biochemistry). It should be interpreted to have the same meaning as generally understood.

Unless otherwise indicated, the techniques of recombinant proteins, cell culture and immunity utilized in this disclosure are standard procedures well known to those of skill in the art. Such techniques are described, for example, in J. et al. Perbal,
A Practical Guide to Molecular Cloning, J
oh Willy and Sons (1984), J. Mol. Sambrook et al., Mol
equilar Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory Press (1989), T.W.
A. Brown (editor), Essential Molecular Biology:
A Practical Approach, Vol.1 and 2, IRL Press (
1991), D.I. M. Grover and B. D. Hames (editor), DNA Clon
ing: A Practical Approach, Vol. 1-4, IRL Pre
ss (1995 and 1996), and F.I. M. Ausubel et al. (Editor), Curre
nt Protocols in Molecular Biology, Greene
Pub. Associates and Wiley-Interscience (
1988, including all updates to date), Ed Harlow and David Lan
e (Editor) Antibodies: A Laboratory Manual, Cold
Spring Harbor Laboratory, (1988), and J. Mol. E
.. Coligan et al. (Editor) Current Protocols in Immun
Described and described throughout the literature in sources such as orgy, John Wiley & Sons (including all updates to date).

The description and definition of variable regions and parts thereof, immunoglobulins, antibodies and fragments thereof herein are described in Kabat Sequences of Proteins of Immunol.
organic Institutes, National Institutes of H
earth, Bethesda, Md. , 1987 and 1991, Bork et al., J. Mo
l. Biol. 242,309-320, 1994, Chothia and Lesk, J. Mol.
Mol. Biol. 196: 901-917, 1987, Chothia et al., Nature
e, 342,877-883,1989 and / or Al-Lazikani et al., J. Mol. Mo
l. Biol. It can be further clarified by the considerations in 273, 927-948, 1997.

The term "and / or", eg, "X and / or Y", means either "X and Y" or "X or Y" and provides clear support for both or either meaning. Should be interpreted as.

Throughout the specification, variants such as the word "comprise" or, for example, "comprises" or "comprising" are referred to elements, integers or steps, or elements, integers or steps. Implying the inclusion of a group of
It will be understood not to imply the exclusion of any other element, integer or step, or group of elements, integers or steps.

As used herein, the term "derived from" is used to indicate that a specified integer can be obtained from a particular source, even though it does not necessarily come directly from that source. Should be interpreted as.

For example, references herein to the range of residues will be understood to be inclusive. For example, a reference to "a range containing amino acids 56-65" is understood in an inclusive manner, i.e., the range is 56, 57, 58, 59, 60, 61 in the specified sequence.
, 62, 63, 64 and 65 are numbered amino acid sequences.

Selected Definitions Human precursor IL-11Rα (pre-IL-11R) for naming purposes only, not limited
An example sequence of α) is presented in NCBI reference sequence: NP_0011362256.1.
And SEQ ID NO: 1). Mature human IL-11Rα is presented with SEQ ID NO: 100. In the case of the sequence represented by NP_001136226.1, the mature protein is amino acids 1 to 1.
Lacking 22. Amino acid positions are often referred to herein by reference to pre-IL-11Rα. The position in mature IL-11Rα is readily determined by explaining the signal sequence (amino acids 1-22 in the case of SEQ ID NO: 1). An example sequence of cynomolgus monkey pre-IL-11Rα is presented with SEQ ID NO: 2, and mature IL-11Rα is presented with SEQ ID NO: 101. An exemplary sequence of mouse pre-IL-11Rα is presented with SEQ ID NO: 82 and mature IL-11Rα is presented with SEQ ID NO: 102. Sequences of IL-11Rα from other species can be prepared using the sequences provided herein and / or using the sequences provided in publicly available databases and / or standard techniques. Can be determined using (eg, Ausubel et al., (Editor), Current Proto
cols in Molecular Biology, Greene Pub. As
associates and Wiley-Interscience (1988, including all updates to date) or Sambrook et al., Molecular Cloning
: A Laboratory Manual, Cold Spring Harbor
As described in Laboratory Press (1989)). Human IL-1
References to 1Rα may be abbreviated to hIL-11Rα, references to cynomolgus monkey IL-11Rα may be abbreviated to cynoIL-11Rα, and references to mouse IL-11Rα may be abbreviated to mIL-11Rα. .. A reference to soluble IL-11Rα is IL-11R
Refers to a polypeptide containing the extracellular region of α, for example, a polypeptide containing amino acids 23-363 or 23-318 of SEQ ID NO: 1. In this study, a soluble form of the receptor comprising amino acids 23-363 or 23-318 of SEQ ID NO: 1 with a serine substitution at position 248 was used (eg, SEQ ID NO: 3 or 85) and of SEQ ID NO: 82. The corresponding fragment of mIL-11Rα with serine substitution at position 206 (eg, SEQ ID NO: 90) was used for testing the receptor in mice. Mutations in these serins were introduced into soluble polypeptides to improve polypeptide expression and prevent aggregation. Various point mutations of the soluble receptors of SEQ ID NO: 3 and SEQ ID NO: 85 are also utilized (see, eg, SEQ ID NOs: 95-99). These soluble polypeptides are representative of hIL-1 as demonstrated by the ability of the IL-11Rα binding proteins of the present disclosure to bind to relevant receptors when expressed on the surface of cells.
It is 1Rα or mIL-11Rα. Therefore, tests using mutant polypeptides are hIL.
This is a model of a test using -11Rα and / or mIL-11Rα.

References to IL-11 herein refer to the native form of IL-11 and IL-11.
Included are mutant forms thereof that bind to Rα (eg, hIL-11Rα) and retain the ability to induce signal transduction.

References herein to a particular domain of hIL-11Rα are as follows:
-Immunoglobulin-like (IG-like) domain: Amino acids 23 to 110 of SEQ ID NO: 1;
First fibronectin III domain: amino acids 111-215 of SEQ ID NO: 1;
Second fibronectin III domain: amino acids 216-370 of SEQ ID NO: 1;
Transmembrane domain: amino acid 371-391 of SEQ ID NO: 1; and cytoplasmic domain: amino acid 392-422 of SEQ ID NO: 1;
Will be understood to mean.

As used herein, the term "hIL-11 mutant protein" refers to 58-6.
A mutant form of hIL-11 in which the wild-type residue (AMSAG) at position 2 is replaced by PAIDY and tryptophan at position 147 is replaced with alanine (W147A) is included. For example, the mutated protein comprises or consists of the sequence set forth in SEQ ID NO: 110. Other examples of hIL-11 mutant proteins are published in WO 2009/052588.
You can find it in the issue. Optionally, the mutated protein comprises an additional sequence, eg, a hexa-HIS tag.

The term "isolated protein" or "isolated polypeptide" is derived from the same source that does not associate with the naturally associated components associated with it in its native state because of its origin or origin. A protein or polypeptide that is substantially free of protein. Purification methods known in the art can be used to substantially eliminate the protein from naturally related components and to be substantially purified by isolation. By "substantially purified", the protein is substantially free of contaminants, eg, at least about 70% or 75% of the contaminants.
Or 80% or 85% or 90% or 95% or 96% or 97% or 98% or 99%
Means not included.

The term "recombination" should be understood to mean the product of artificial genetic modification. Thus, in the context of recombinant proteins that include the antigen-binding domain of an antibody, the term does not include naturally occurring antibodies in the subject's body that are the product of natural recombination that occurs during B cell maturation. However, if such an antibody is isolated, it should be considered an isolated protein containing the antigen-binding domain of the antibody. Similarly, if the nucleic acid encoding the protein is isolated and expressed using recombinant means, the resulting protein is a recombinant protein containing the antigen binding domain of the antibody. Recombinant proteins also include, for example, proteins expressed by artificial recombinant means when in the cell, tissue or subject in which they are expressed.

The term "protein" comprises a single polypeptide chain, i.e. a series of adjacent amino acids linked by peptide bonds or a series of polypeptide chains covalently or non-covalently linked to each other (ie, a polypeptide complex). Should be interpreted as. for example,
The series of polypeptide chains can be covalently bonded using suitable chemical or disulfide bonds. Examples of non-covalent bonds include hydrogen bonds, ionic bonds, van der Waals forces and hydrophobic interactions.

It will be understood from the preceding paragraph that the term "polypeptide" or "polypeptide chain" means a series of adjacent amino acids linked by peptide bonds.

As used herein, the term "antigen binding domain" is a region of an antibody capable of specifically binding to an antigen, i.e. Fv containing both _VH or _VL or _VH and _VL. Should be interpreted to mean. The antigen-binding domain need not be in the context of all antibodies, eg, it is isolated (eg, a domain antibody) or in another form, such as scFv, as described herein. obtain.

For the purposes of the present disclosure, the term "antibody" may be specifically bound to one or a few closely related antigens (eg, IL-11Rα) by the antigen binding domain contained within Fv. Contains possible proteins. The term includes four-stranded antibodies (eg, two light chains and two heavy chains), recombinant or modified antibodies (eg, chimeric antibodies, humanized antibodies, etc.).
Human antibodies, CDR-transplanted antibodies, primated antibodies, deimmunized antibodies, similar humanized (synthhama)
Nized) antibodies, semi-antibodies, bispecific antibodies) are included. Antibodies generally contain a constant domain, which can be composed of a constant region or constant fragment or a crystallizable fragment (Fc). An example form of an antibody comprises a four-stranded structure as its basic unit. Full-length antibodies include two covalently bound heavy chains (about 50-70 kDa) and two light chains (about 23 kDa each). Light chains generally contain variable regions (if present) and constant domains, and in mammals κ light chains or λ
It is one of the light chains. Heavy chains generally include one or two constant domains that are linked to additional constant domains by a variable region and a hinge region. Mammalian heavy chains have the following types: α, δ, ε, γ
Or one of μ. Each light chain is also covalently attached to one of the heavy chains. For example, two heavy chains and heavy and light chains are held together by interchain disulfide bonds and by non-covalent interactions. The number of interchain disulfide bonds can vary between different types of antibodies. Each chain has one or more constant domains at the _{N-terminal variable region (VH} or _VL, each about 110 amino acids in length) and the C-terminus. Constant domains of the light chain _{(C L} is a length of about 110 amino acids), and sequence _(C H 1 is the length from 330 to 440 amino acids) the first constant domain of the heavy chain, disulfide bonds. The light chain variable region is aligned with the heavy chain variable region. The heavy chain of the antibody is 2 or more additional _CHs
Domains _{(e.g., C H 2,} C H 3, etc.) can contain, can comprise a hinge region between the constant domain of _{C H} 1 and _{C H} 2. Antibodies can be of any type (eg IgG, Ig
E, IgM, IgD, IgA, and IgY), class (eg, IgG ₁ , IgG ₂ ,
It can be IgG ₃ , IgG ₄ , IgA ₁ and IgA ₂ ) or a subclass. In one example, the antibody is a murine (mouse or rat) antibody or a primate (eg, human) antibody. In one example, the antibody heavy chain has lost the C-terminal lysine residue. In one example, the antibody is humanized, similar humanized, chimeric, CDR transplanted, or deimmunized.

The terms "full-length antibody,""intactantibody," or "whole antibody" are used interchangeably to refer to an antibody in a substantially intact form as opposed to an antigen-binding fragment of an antibody. Specifically, all antibodies include those with heavy and light chains containing the Fc region. The constant region may be the constant domain of the wild-type sequence (eg, the constant domain of the human wild-type sequence) or a variant of its amino acid sequence.

As used herein, "variable regions" refers to the light and / or heavy chain portions of an antibody as defined herein that are capable of specifically binding to an antigen and are complementary. Determine regions (CD
R), ie, contains the amino acid sequences of CDR1, CDR2 and CDR3, and the framework region (FR). For example, the variable region comprises 3 or 4 FRs (eg, FR1, FR2, FR3 and optionally FR4) with 3 CDRs. V _H refers to the variable region of the heavy chain. _VL refers to the variable region of the light chain.

As used herein, the term "complementarity determining regions" (synonyms, CDRs, ie, C).
DR1, CDR2 and CDR3) refer to amino acid residues in the antibody variable region whose presence is a major contributor to specific antigen binding. Each variable domain domain ( _VH or _VL ) is a CDR
1. Usually has 3 CDRs identified as CDR2 and CDR3. In one embodiment
The positions of amino acids assigned to CDR and FR are Kabat Sequences o
f Proteins of Immunological Interest, Nat
ional Institutes of Health, Bethesda, Md. ，
It is defined according to 1987 and 1991 (also referred to herein as "Kabat's numbering scheme"). In another embodiment, the positions of amino acids assigned to CDRs and FRs are improved Chothia numbering schemes (http://www.bioinfo.o).
rg. uk / mdex. html). According to Kabat's numbering scheme, _{the FR and CDRs of VH} are as follows: residues 1-30 (FR1), 31-35 (CDR1).
, 36-49 (FR2), 50-65 (CDR2), 66-94 (FR3), 95-10
It is positioned as 2 (CDR3) and 103-113 (FR4). According to Kabat's numbering system, _{the FR and CDR of VL} are as follows: residues 1-23 (FR1), 24-3.
4 (CDR1), 35-49 (FR2), 50-56 (CDR2), 57-88 (FR3)
), 89-97 (CDR3) and 98-107 (FR4). The present disclosure is not limited to FR and CDR defined by Kabat's numbering scheme, and is Ch.
othia and Lesk, J. Mol. Mol. Biol. 196: 901-917, 1987;
Chothia et al., Nature, 342: 877-883,1989; and / or Al
Lazikani et al., J. Mol. Mol. Biol. 273: 927-948, 1997 canonical numbering schemes; Honneger and Plukthun, J. Mol. Mol. Biol. 30
9: 657-670, 2001 numbering scheme; or Giudicelli et al., Nucl
eic Acids Res. 25: 206-211 Includes all numbering schemes, including the IMGT scheme discussed in 1997. In one embodiment, CDRs are defined according to Kabat's numbering scheme. Optionally, the heavy chain CDR2 according to Kabat's numbering scheme does not contain the five C-terminal amino acids listed herein, or is another amino acid in which any one or more of these amino acids are naturally occurring. Will be replaced. In this regard, Padlan et al., FA
SEB J. , 9: 133-139, 1995 demonstrated that the five C-terminal amino acids of heavy chain CDR2 are generally not involved in antigen binding.

A "framework region" (FR) is a variable region residue other than a CDR residue.

As used herein, the term "Fv", whether composed of multiple polypeptides or a single polypeptide, _{is a complex in which VL} and _VH are associated and have an antigen-binding domain. It should be construed to mean any protein that forms the body, i.e., is capable of specifically binding to an antigen. V _L and V _H to form an antigen binding domain may be present in a single polypeptide chain, or different polypeptide chains. Furthermore, F of the present disclosure
v (and any protein of the present disclosure) may have multiple antigen-binding domains that may or may not bind the same antigen. The term should be understood to include fragments directly derived from the antibody as well as proteins corresponding to such fragments produced using recombinant means. In some examples, V _H is not linked to the heavy chain constant domain ( _CH ) 1 and / or _VL is not linked to the light chain constant domain ( _CL ). Examples of Fvs or proteins containing polypeptides include Fab fragments, Fab'fragments, F (ab') fragments, scFv, bispecific antibodies, trispecific antibodies, quadrispecific antibodies, or even higher. Included are the following complexes, or any of the above, eg, mini-antibodies linked to a constant region or constant domain thereof, eg, a _CH 2 or _{CH 3 domain.} "Fab Fragment"
Consists of a monovalent antigen-binding fragment of immunoglobulin, which can be produced by digestion of all antibodies with the enzyme papain to obtain a fragment consisting of intact light chain and heavy chain moieties, or produced by recombinant means. can do. "Fab 'fragment" of an antibody, obtained by treating whole antibody with pepsin, consists then it can be obtained by reducing a portion of the heavy chain and a single constant domain, comprising intact light chain and V _H molecules Is obtained. Two Fab'fragments are obtained per antibody treated in this way. Fab'fragments can also be produced by recombinant means. The F (ab') 2 fragment of an antibody consists of a dimer of two Fab'fragments held together by two disulfide bonds, obtained by treating the entire antibody molecule with the enzyme pepsin and then without reduction. .. Fab ₂ fragments, for example, a recombinant fragment comprising two Fab fragments linked by using leucine zippers or _{C H} 3 domain. "Single chain Fv" or "
"scFv" is a recombinant molecule containing a variable region fragment (Fv) of an antibody in which the variable region of the light chain and the variable region of the heavy chain are covalently linked by a suitable flexible polypeptide linker.

As used herein, the term "binding" associated with an interaction of an IL-11Rα-binding protein or its antigen-binding domain with an antibody means that the interaction is a specific structure on the antigen (eg, an antigenic determinant). Or it means that it depends on the presence of the epitope). For example, antibodies recognize and bind to the structure of a particular protein rather than the protein in general.
If the antibody binds to epitope "A", the presence of a molecule (or free unlabeled "A") containing epitope "A" in the labeled "A" and protein-containing reactants is present in the antibody. Will reduce the amount of labeled "A" to bind.

As used herein, the term "specificly b"
"inds)" or "binds specificly"
The IL-11Rα-binding protein of the present disclosure reacts or associates with a particular antigen or cells expressing a particular antigen more frequently, rapidly, for longer periods of time and / or with greater affinity than alternative antigens or cells. It should be interpreted to mean to do. For example, IL-11
Rα-binding proteins are antigens commonly recognized by other interleukin receptors or multi-reactive native antibodies (ie, naturally occurring antibodies known to bind various antigens found naturally in humans). With significantly greater affinity than (eg, 1.5-fold or 2-fold or 5-fold or 10-fold or 20-fold or 40-fold or 60-fold or 80-100-fold or 15-fold
0-fold or 200-fold) binds to IL-11Rα (eg, a polypeptide containing hIL-11Rα or a region thereof, eg, a polypeptide of SEQ ID NO: 3 or 85). In the examples of the present disclosure, at least one of the mutant forms of SEQ ID NO: 3 containing the sequence set forth in SEQ ID NO: 95.
.. 5x or 2x (eg 5x or 10x or 20x or 50x or 100x or 20x
Polypeptide containing hIL-11Rα or its region with a large affinity (eg, h)
An IL-11Rα-binding protein that "specifically binds" to one form of the polypeptide of the sequence set forth in (extracellular region of IL-11Rα) or SEQ ID NO: 3 or 85. In general, but not necessarily, it should be understood that a reference to a bond means a particular bond and that each term provides explicit support for other terms.

As used herein, the term "not detectable" refers to an IL-11Rα binding protein, eg, an antibody to a candidate antigen at a level above the background by 10% or 8% or 6% or less than 5%. It should be understood to mean joining. The background is the level of binding signal detected in the absence of the protein and / or in the presence of a negative control protein (eg, an isotype control antibody) and / or the level of binding detected in the presence of a negative control antigen. There can be. The level of binding is biosensor analysis (eg, Biacore) in which the IL-11Rα binding protein is immobilized and comes into contact with the antigen.
) Is detected.

As used herein, the term "not significantly bound" means that the level of binding of the IL-11Rα binding proteins of the present disclosure to a polypeptide is in the background, eg, IL-1.
1 Statistics from the level of binding signal detected in the absence of Rα-binding protein and / or in the presence of a negative control protein (eg, isotype control antibody) and / or the level of binding detected in the presence of a negative control polypeptide. It should be understood to mean that it is not significantly higher. The level of binding is such that the IL-11Rα binding protein is immobilized.
Detected using biosensor analysis (eg, Biacore) in contact with the antigen.

As used herein, the phrase referring to "lower binding" or "binding at a lower level" with respect to an antigen is that the IL-11Rα binding protein, eg, an antibody, is a control epitope or antigen (eg, sequence). Mutations containing the antigen (eg, the sequence set forth in SEQ ID NO: 95) with at least about 1.5-fold, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, or 200-fold lower affinity than number 3). It should be understood to mean binding to (variants of SEQ ID NO: 3) described herein, such as the body.

IL-11Ra binding protein or antibody, if binding of the polypeptide at a lower K _D than the dissociation constant of the protein or antibodies to another polypeptide (K _D), and "preferentially binds" to a polypeptide Can be considered. In one embodiment, IL-11Ra binding protein or antibody is at least about 1.5 times than the _{K D} protein or antibody to another polypeptide or double or 5 fold or 10-fold or 20-fold or 50-fold or 100-fold or 200-fold greater affinity (i.e., K _D) as long as binding of the polypeptide, are considered "preferentially binds" to the polypeptide.

As used herein, the terms "hIL-11Rα and cynoIL-11Rα"
"Able to bind to" will be understood to mean that the IL-11Rα binding protein cross-reacts with hIL-11Rα and cynoIL-11Rα, i.e. binds to either protein. ..

The purpose of clarity and on the basis of the subject matter illustrated herein as will be apparent to a skill skilled, see references to "affinity" as used herein to K _D protein or antibody Is.

As will be apparent to the skilled person of skill based on the description of the purposes and in the specification of clarity, the reference to "at least about affinity" affinity (or K _D) was quoted values That is (ie, the value cited as affinity is lower), i.e. the affinity of 2nM is 3
It will be understood to mean greater than the affinity of nM. In other words
The term can be "affinity below X" where X is the value cited herein.

"At least about IC ₅₀ " is less than or equal to the value cited by _{IC 50 (ie, I)}
The _{value quoted as C 50} is lower), i.e. IC _{50 at} 2 μg / ml is 1 μg / ml
It will be understood to mean greater than IC ₅₀ of ml. In other words, the term can be " _{IC 50} below X," where X is the value cited herein.

As used herein, the term "epitope" (synonymous with "antigen determinant") is understood to mean the region of IL-11Rα to which an IL-11Rα-binding protein, including the antigen-binding domain of an antibody, binds. It should be. The term is not necessarily limited to the particular residue or structure with which the IL-11Rα binding protein comes into contact. For example, the term IL-
A region spanning the amino acids with which the 11Rα-binding protein contacts and 5-10 outside this region
(Or more) or 2-5 or 1-3 amino acids are included. In some examples, the epitope comprises a series of discontinuous amino acids that are in close proximity to each other when the IL-11Rα binding protein is folded, i.e. a "three-dimensional epitope". Skilled experts will also notice that the term "epitope" is not limited to peptides or polypeptides. For example, the term "epitope" includes the grouping of chemically active surfaces of molecules such as, for example, sugar side chains, phosphoryl side chains or sulfonyl side chains, and in certain embodiments, certain tertiary. It may have original structural properties and / or specific charging properties.

The term "competitively inhibits" means that the IL-11Rα-binding protein of the present disclosure (or its antigen-binding domain) is the IL-11Rα of the antibody or IL-11Rα-binding protein cited.
, For example, should be understood to mean reducing or interfering with binding to hIL-11Rα. This is obtained by binding the IL-11Rα binding protein (or antigen binding domain) and antibody to the same or overlapping epitopes. The IL-11Rα binding protein does not have to completely inhibit antibody binding, but rather a statistically significant amount, eg, at least about 10% or 20% or 30% or 40% or 50% or 60% or 70. It will be clear from the above that it is sufficient to reduce the% or 80% or 90% or 95% binding. Preferably, the IL-11Rα binding protein binds the antibody at least about 30.
%, More preferably at least about 50%, even more preferably at least about 70%, even more preferably at least about 75%, even more preferably at least about 80% or 8
Reduce by 5%, and even more preferably by at least about 90%. Methods for measuring competitive inhibition of binding are known in the art and / or described herein. For example, the antibody is I
Exposure to IL-11Rα in the presence or absence of L-11Rα binding protein. IL
If fewer antibodies bind in the presence of IL-11Rα-binding protein than in the absence of -11Rα-binding protein, the protein is considered to competitively inhibit antibody binding. In one embodiment, competitive inhibition is not due to steric hindrance.

"Duplicate" in the context of two epitopes is IL-11Rα that binds to one epitope.
IL-11 to which a binding protein (or its antigen-binding domain) binds to the other epitope
It should be interpreted to mean that the two epitopes share a sufficient number of amino acid residues that allow competitive inhibition of the binding of the Rα-binding protein (or antigen-binding domain). For example, "overlapping" epitopes share at least 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 20 amino acids.

As used herein, the term "neutralizing" means that the protein is IL-11R in the cell.
It should be interpreted to mean that it is possible to block, reduce or interfere with α-mediated IL-11-mediated signal transduction. Methods of measuring neutralization are known in the art and / or described herein.

As used herein, the term "condition" refers to the disruption or disruption of normal function and may include disease or disorder, not limited to any particular disease.

As used herein, "IL-11-related disease" is excess IL-11 or I.
Refers to any disease caused by or associated with cells expressing L-11 or administration of IL-11. A skilled expert will be able to easily determine such a disease. Example diseases are described herein.

As used herein, the terms "prevent", "prevent" or "prevention"
Administration of the IL-11Rα binding protein of the present disclosure comprises stopping or preventing the onset of at least one symptom of the disease. The term also includes the treatment of subjects in remission to prevent or prevent recurrence.

As used herein, the terms "treating,""treating," or "treating."
Administration of the IL-11Rα binding proteins described herein comprises reducing or eliminating at least one symptom of a particular disease or disorder.

As used herein, the term "subject" should be construed to mean any animal, including humans, eg, mammals. Examples include, but are not limited to, humans and non-human primates. For example, the subject is a human.

Antibodies In one example, the IL-11Rα binding protein described herein according to any example is an antibody.

Methods of producing antibodies are known in the art and / or Harlow and Lane (
Editor), Antibodies: A Laboratory Manual, Cold
It is described in Spring Harbor Laboratory, (1988). Generally, in such methods, IL-11Rα (eg, hIL-11Rα) or a region thereof (eg, extracellular space) formulated with any suitable or desirable carrier, adjuvant or pharmaceutically acceptable excipient. Or non-human animals, such as mice, chickens, rats, rabbits, guinea pigs, dogs, horses, cows, Administer to goats or pigs. The immunogen can be administered intranasally, intramuscularly, subcutaneously, intravenously, intradermally, intraperitoneally or by other known routes.

After immunization, the production of polyclonal antibodies can be monitored by collecting blood from animals immunized at various time points. If necessary, one or more additional immunizations are performed to achieve the desired antibody titer. The process of booster immunization and titer measurement is repeated until a suitable titer is achieved. Once the desired level of immunogenicity is obtained, blood is drawn from the immunized animal, serum is isolated and stored and / or the animal is used to generate a monoclonal antibody (mAb).

Monoclonal antibodies are one of the exemplary forms of antibodies intended by the present disclosure. The term "monoclonal antibody" or "mAb" refers to a homogeneous antibody population capable of binding to the same antigen, eg, the same epitope within the antigen. The term is not intended to be limited with respect to the source of the antibody or the method by which it is made.

For the production of mAbs, one of many known techniques, such as US Pat. No. 4,
No. 196265 or Harlow and Line (1988) described above The procedures exemplified above can be used.

For example, immunogens are used to immunize suitable animals under conditions sufficient to stimulate antibody-producing cells. Rodents such as rabbits, mice and rats are exemplary animals. The antibodies of the present disclosure can also be produced using mice that express human antibodies and have been genetically engineered so as not to express mouse antibodies (eg, as described in WO 2002/06630). NS).

Following immunization, mA has the potential to produce antibody-producing somatic cells, especially B lymphocytes (B cells).
b Select for use in the generation protocol. These cells can be obtained from a biopsy of the spleen, tonsils, or lymph nodes or from a peripheral blood sample. The cells of immortal myeloma cells commonly derived from the same species as the animal immunized with the immunogen are then fused with the B cells derived from the immunized animal.

Hybrids are amplified by culture in tissue culture medium in selective medium containing agents that block nucleotide de novo synthesis. Examples of agents are aminopterin, methotrexate and azaserine.

Antibody specificity and / or antibody specificity, such as flow cytometry and / or immunohistochemistry and / or immunoassays (eg, radioimmunoassays, enzyme immunoassays, cytotoxicity assays, plaque assays, dot immunoassays, etc.) Provide an amplified hybrid for a functional selection of titers.

Alternatively, ABL-MYC technology (NeoClone, Madison WI 53713)
, USA) to produce cells that secrete mAbs (eg, Largaespada)
Et al., J. et al. Immunol. Methods. 197: 85-95, as described in 1996).

Antibodies can be produced or isolated by screening a display library, eg, a phage display library as described in US Pat. No. 6,300,400 and / or US Pat. No. 5,885,793. For example, we have completely isolated human antibodies from the phage display library.

IL-11, a portion of the present disclosure that binds hIL-11Rα, as described herein.
The Rα-binding protein cross-reacts with cynoIL-11Rα and / or hIL-11R
It binds to and / or does not bind to a polypeptide containing some mutant morphology of α or the region of mutated hIL-11Rα. These features can be used in the production of antibodies or IL-11Rα binding proteins.

For example, a phage display library is screened for a polypeptide containing SEQ ID NO: 3 to identify proteins that bind to it. Variant forms of the polypeptide that do not detectably bind the IL-11Rα binding protein (eg, valine at position corresponding to position 117 of SEQ ID NO: 1 is replaced with glutamate (eg, comprising the sequence of SEQ ID NO: 95). )) To remove the cross-reactive protein and / or the variant form of the polypeptide to which the IL-11Rα binding protein should bind (eg, SEQ ID NO: 97,
Proteins that cross-reactivity correctly are isolated using (containing 98 or 99 sequences). Screening methods for immunity of non-human mammals can also be devised based on the above.

In another example, a phage display library is screened or animals are c.
Extracellular domain of ynoIL-11Rα (or amino acids 23-215 or 1 of SEQ ID NO: 1)
IL-11Rα identified by immunization with a polypeptide containing (regions corresponding to 10-215)
Bound proteins and / or antibodies are screened to identify those that cross-react with hIL-11Rα or the polypeptide of SEQ ID NO: 3 and / or 85.

In a further embodiment, IL-11Rα or its extracellular space (optionally 8E2 or 8D1)
The variant form to which 0 or 8E4 binds) is contacted with one of the aforementioned antibodies. The phage display library is then contacted with IL-11Rα or region to select phage expressing a protein that can compete with the antibody for binding.

Moreover, in a further embodiment, a chimeric protein comprising mouse IL-11Rα, eg, where the subject epitope derived from hIL-11Rα is substituted for the corresponding mouse sequence. The chimeric protein is then used to immunize mice (which are unlikely to elicit an immune response against mouse proteins) and / or screen the phage display library. The resulting antibody / protein was then screened for hIL-11Rα.
Identify those that bind to (especially in the epitope of interest) but not to mouse IL-11Rα.

The antibodies of the present disclosure can be synthetic antibodies. For example, the antibody is a chimeric antibody, a humanized antibody, a human antibody, a similar humanized antibody, a primated antibody or a deimmunized antibody.

Deimmunized, chimeric, CDR-transplanted, humanized, similar humanized, primated, human and complex IL-11Rα-binding proteins The IL-11Rα-binding proteins of the present disclosure are derived from human antibodies. Contains or another type of antibody (eg, another type of human antibody) that contains a CDR of an antibody derived from a non-human species (eg, mouse or rat or non-human primate) transplanted or inserted into the FR. A CDR containing a CDR of an antibody derived from a type of antibody (a type of human antibody) transplanted or inserted into a FR derived from can be the transplanted protein. The term refers to a composite IL-11Rα comprising, for example, one or more CDR-implanted variable regions and one or more, for example, human variable regions, chimeric variable regions, similar humanized variable regions, or primated variable regions. Also includes binding proteins.

The IL-11Rα binding protein of the present disclosure can be a humanized protein.

The term "humanized protein" refers to a human-like variable region containing the CDR of an antibody derived from a non-human species (eg, mouse or rat or non-human primate) transplanted or inserted into a FR derived from a human antibody. It should be understood to refer to the protein that contains (this type of antibody is "
It falls within the category of "CDR transplanted antibody"). The humanized IL-11Rα binding protein also has one or more residues of the human protein modified by one or more amino acid substitutions and / or one or more FR residues of the human protein replaced by the corresponding non-human residues. Also includes proteins that are produced. Humanized proteins can also contain residues not found in human or non-human antibodies. Any additional region of the protein (eg, the Fc region) is generally human. Humanization can be performed using methods known in the art, such as US Pat. No. 5,225,539, US Pat. No. 6,052,297, US Pat. No. 7,566,771, or US Pat. No. 5,585,089. The term "humanized protein" is used, for example, in U.S. Pat. No. 7,732.
It also includes hyperhumanized proteins as described in No. 578. The term also includes, for example, one or more humanized variable regions and a complex protein comprising one or more, for example, human variable regions, chimeric variable regions, similar humanized variable regions, or primated variable regions.

The IL-11Rα-binding protein of the present disclosure can be a human IL-11Rα-binding protein. As used herein, the term "human protein" has a variable region and optionally a constant region of an antibody found in humans, eg, in human germline or somatic cells.
Or refers to a protein derived from a library created using such a region. A "human" protein is an amino acid residue that is not encoded by a human sequence, eg, a mutation introduced by random or site-specific mutagenesis in vitro, especially a small number of residues of the protein, eg, a protein. Mutations involving conservative substitutions or mutations at residues 1, 2, 3, 4, or 5) can be included. These "human proteins" do not necessarily have to be produced as a result of the human immune response, but rather they are
Using recombinant means (eg, screening a phage display library) and / or by transgenic animals (eg, mice) that contain nucleic acids encoding constant and / or variable regions of human antibodies, and / or Guide selection (for example
It can be produced using (as described in US Pat. No. 5,565,332). The term also includes the affinity matured form of such antibodies. For the purposes of the present disclosure, a human protein comprises an FR comprising a FR derived from a human antibody, or an FR comprising a sequence derived from a consensus sequence of a human FR, and one or more of the CDRs is U.S. Pat. No. 6,300,64 and /
Alternatively, it may also be considered to contain a protein that is random or semi-randomized as described in US Pat. No. 6,248,516.

An example human IL-11Rα binding protein is an antibody that contains the following pair of variable regions:
(I) _V comprising the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (ii) SEQ ID NO: 38 _L
;
_{(Iii) V H} containing the sequence represented by SEQ ID NO: 39 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_{(Iv) V H} containing the sequence represented by SEQ ID NO: 40 and _VL containing the sequence represented by SEQ ID NO: 5.
;
_{(V) V H} containing the sequence represented by SEQ ID NO: 41 and _VL containing the sequence represented by SEQ ID NO: 5;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (vi) SEQ ID NO: 42 _L
;
_{(Vii) V H} containing the sequence represented by SEQ ID NO: 43 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (viii) SEQ ID NO: 44 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (ix) SEQ ID NO: 45 _L
;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (x) SEQ ID NO: 46 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xi) SEQ ID NO: 47 _L
;
_{(Xii) V H} containing the sequence represented by SEQ ID NO: 48 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xiii) SEQ ID NO: 49 L;
_{(Xiv) V H} containing the sequence represented by SEQ ID NO: 50 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_{(Xv) V H} containing the sequence represented by SEQ ID NO: 51 and _VL containing the sequence represented by SEQ ID NO: 5.
;
_{(Xvi) V H} containing the sequence represented by SEQ ID NO: 52 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xvii) SEQ ID NO: 53 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xviii) SEQ ID NO: 54 L;
_{(Xix) V H} containing the sequence represented by SEQ ID NO: 55 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xx) SEQ ID NO: 56 _L
;
_{(Xxi) V H} containing the sequence represented by SEQ ID NO: 57 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxii) SEQ ID NO: 58 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxiii) SEQ ID NO: 59 L;
_{(Xxiv) V H} containing the sequence represented by SEQ ID NO: 60 and _VL containing the sequence represented by SEQ ID NO: 5.
_{(Xxv) V H} containing the sequence represented by SEQ ID NO: 61 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxvi) SEQ ID NO: 62 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxvii) SEQ ID NO: 63 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxviii) SEQ ID NO: 64 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxix) SEQ ID NO: 65 L;
_{(Xxxx) V H} containing the sequence represented by SEQ ID NO: 66 and V containing the sequence represented by SEQ ID NO: 5.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxi) SEQ ID NO: 67 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxii) SEQ ID NO: 68 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxiii) SEQ ID NO: 69 L;
_{(Xxxx) V H} containing the sequence represented by SEQ ID NO: 37 and _VL containing the sequence represented by SEQ ID NO: 5;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxv) SEQ ID NO: 70 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 6 comprising the sequence represented by (xxxvi) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 7 comprising the sequence set forth in (xxxvii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 8 comprising the sequence set forth in (xxxviii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 9 comprising the sequence set forth in (xxxix) SEQ ID NO: 37 L;
_{(Xl) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 10.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 11 comprising the sequence represented by (xli) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 12 comprising the sequence represented by (xlii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 13 comprising the sequence represented by (xliii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 14 comprising the sequence represented by (xliv) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprising the sequence represented by (xlv) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprising the sequence represented by (xlvi) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 17 comprising the sequence represented by (xlvii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprising the sequence represented by (xlviii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 19 comprising the sequence represented by (xlix) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 20 comprising the sequence set forth in (l) SEQ ID NO: 37 _L
;
_{(Li) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 21.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 22 comprising the sequence represented by (lii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 23 comprising the sequence represented by (liii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 24 comprising the sequence represented by (liv) SEQ ID NO: 37 L;
_{(Lv) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 25.
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 26 comprising the sequence represented by (lvi) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 27 comprising the sequence represented by (lvii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 28 comprising the sequence represented by (lviii) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 29 comprising the sequence represented by (lix) SEQ ID NO: 37 L;
_{(Lx) V H} containing the sequence represented by SEQ ID NO: 37 and V containing the sequence represented by SEQ ID NO: 30
_L ;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 31 comprising the sequence represented by (lxi) SEQ ID NO: 37 L;
_V comprises the sequence represented by _{V H} and SEQ ID NO: 32 comprising the sequence represented by (LXII) SEQ ID NO: 37 L;
Sequence represented by _{V H} and SEQ ID NO: 34 comprising the sequence set forth in or (LXIV) SEQ ID NO: 37; (LXIII) SEQ ID NO: _{V L} comprises the sequence given in _{V H} and SEQ ID NO: 33 comprising the sequence set forth in 37 _VL including.

Optionally, V _H is linked to a heavy chain constant region, eg, a heavy chain constant region of IgG4. In one example, the heavy chain constant region lacks a C-terminal lysine residue.

Optionally, the _VL is linked to the light chain constant region.

The IL-11Rα binding protein of the present disclosure can be a similar humanized protein. The term "similar humanized protein" refers to a protein prepared by the method described in WO 2007/01/9620. The similar humanized IL-11Rα binding protein comprises a variable region of the antibody, which is derived from the variable region of the New World primate antibody and the CDR derived from the variable region of the non-New World primate antibody. including. For example, similar humanized IL-11R
The sigma-binding protein comprises a variable region of the antibody, which comprises FR derived from the variable region of the New World primate antibody and CDR derived from the mouse or rat antibody. In one example, the similar humanized IL-11Rα binding protein is an IL-11Rα binding antibody in which one or both of the variable regions are humanized. The term refers to, for example, one or more similar humanized variable regions,
And also include complex proteins comprising one or more, eg, human or humanized variable regions or chimeric variable regions.

The IL-11Rα binding protein of the present disclosure can be a primated protein. A "primate protein" comprises a variable region derived from an antibody produced following immunization of a non-human primate (eg, cynomolgus monkey). Optionally, the variable region of the non-human primate antibody is linked to the human constant region to produce the primated antibody. An example method for producing a primated antibody is described in US Pat. No. 6,113898. The term also includes, for example, a complex protein comprising one or more primate variable regions and one or more, for example, human variable regions or humanized variable regions or chimeric variable regions.

In one example, the IL-11Rα binding protein of the present disclosure is a chimeric protein. The term "chimeric protein" is used when the antigen-binding domain is derived from a particular species (eg, rats such as mice or rats) or belongs to a particular antibody class or subclass, while the rest of the protein is another species (eg, a mouse or rat). For example, it refers to a protein derived from (human or non-human primates) or belonging to another class or subclass of antibody. _{In one example, the chimeric protein is a chimeric antibody comprising VH} and / or _VL derived from a non-human antibody (eg, a mouse antibody) and the remaining region of the antibody is derived from the human antibody. The production of such chimeric proteins is known in the art and is standard (eg, as described in U.S. Pat. No. 6,331,415; U.S. Pat. No. 5,807,715; U.S. Pat. No. 4,816,567 and U.S. Pat. No. 4,816,397). Can be achieved by the means of. The term also includes, for example, one or more chimeric variable regions and complex proteins comprising one or more, for example, human variable regions or humanized variable regions or chimeric variable regions.

The disclosure also includes, for example, WO 2000/34317 and WO 2004.
Deimmunized IL-11Rα binding proteins as described in / 108158 are also contemplated. Deimmunized antibodies and proteins eliminate (ie, mutate) one or more epitopes, such as B cell epitopes or T cell epitopes, thereby reducing the likelihood that the subject will elicit an immune response against the antibody or protein. .. For example, IL-1 of the present disclosure
1 Rα-binding proteins are analyzed to identify one or more B or T cell epitopes and mutate one or more amino acids within the epitope, thereby reducing the immunogenicity of IL-11Rα-binding proteins.

It will be apparent to skilled professionals from the above disclosure that a "complex" protein comprises _{one form of VH} (eg, human) and _{another form of VL (eg, humanization).} This disclosure is V
_It explicitly includes all combinations of H and _{VL forms.}

Proteins Containing Antibody Binding Domains Single Domain Antibodies In some embodiments, the proteins of the present disclosure are single domain antibodies (used interchangeably with the terms "domain antibody" or "dAb") or the same. including. A single domain antibody is a single polypeptide chain that contains all or part of the heavy chain variable region of an antibody. In certain embodiments, the monodomain antibody is a human monodomain antibody (Domantis, In).
c. , Waltham, MA; see, eg, US Pat. No. 6,248,516).

Bispecific Antibodies, Trispecific Antibodies, Quadrispecific Antibodies In some examples, the proteins of the present disclosure are described in WO 98/044001 and / or WO 94/007921. It is, or comprises, a bispecific antibody, a trispecific antibody, a quadruspecific antibody, or a higher-order protein complex, such as one.

For example, a bispecific antibody is a protein that comprises two associated polypeptide chains, each polypeptide chain comprising a structure V _L- X-V _H or V _H- X- _VL . _VL is the light chain variable region of the _{antibody, V H} is the heavy chain variable region of the antibody, and X is that V _H and _VL can be associated (or form Fv) in one polypeptide chain. A linker containing insufficient residues to be possible or absent, where the _VH of one polypeptide chain is the V of the other polypeptide chain
_It forms an antigen-binding domain that can bind to L and specifically bind one or more antigens, that is, it forms an Fv molecule. _VL and V _H can be the same in each polypeptide chain, or _VL and V _H are bispecific antibodies (ie, two Fs with different specificities).
Each polypeptide chain can be different to form (including v).

Single chain Fv (scFv)
Of skill skilled person, the scFv comprises the V _H region and the V _L region at a single polypeptide chain, and V _H and V to the desired structure for antigen binding makes it possible to form the scFv You will notice that it contains _{a polypeptide linker between Ls (ie, for the V H} and _VL of a single polypeptide chain that associates with each other to form an Fv). For example, the linker is 12
One of the more convenient linkers for scFv, which contains more amino acid residues than (Gl)
y ₄ Ser) ₃ .

The present disclosure also presents a disulfide-stabilized Fv (or diFv) in which a single cysteine residue is _{introduced into the FR of V H} or _{FR of VL and} the cysteine residue is linked by a disulfide bond to give a stable Fv. Or dsFv) is also intended.

Alternatively or in addition, the present disclosure is a dimeric scFv, a protein comprising two scFv molecules linked by non-covalent or covalent bonds, eg, by a leucine zipper domain (eg, from Fos or Jun). Including. Alternatively, for example, as described in US Pat. No. 20060263367, the two scFvs are linked by a peptide linker long enough to allow both scFvs to form and bind to the antigen.

Heavy Chain Antibodies Heavy chain antibodies, although they contain heavy chains, are structurally different from many other forms of antibodies as long as they do not contain light chains. Therefore, these antibodies are also referred to as "heavy chain only antibodies". Heavy chain antibodies are found, for example, in camelids and cartilaginous fish (also called IgNAR).

The variable regions present in naturally occurring heavy chain antibodies are from the heavy chain variable regions ( _{called "VH} domains") present in conventional four-stranded antibodies and in light chain variables present in conventional four-stranded antibodies. To distinguish from the region ( _{called the "VL} domain"), generally in camelid antibodies, "
It is referred to as V _HH domains ", referred to as V-NAR in IgNAR.

Heavy chain antibodies derived from camelids and their variable regions and their production and / or isolation and /
Or, in particular, a general description of the method of use is described in reference International Publication No. 94/04678 below.
No., International Publication No. 97/49805 and International Publication No. 97/49805.

A general description of heavy chain antibodies derived from cartilaginous fish and their variable regions and methods of their production and / or isolation and / or use can be found, among other things, in WO 2005/118629.

Proteins Containing Other Antibodies and Their Antigen Binding Domains The disclosure of this disclosure is, for example,
(I) A "key and keyhole" bispecific protein as described in US Pat. No. 5,731,168;
(Ii) For example, a heterocomplex protein as described in US Pat. No. 4,676,980;
(Iii) Heterocomplex proteins produced using, for example, chemical cross-linking agents as described in US Pat. No. 4,676,980; and (iv) Fab ₃ (eg, as described in EP19930302894).
Other antibodies such as and proteins containing their antigen binding domains are also contemplated.

Mutations to Proteins The disclosure also provides IL-11Rα binding proteins or nucleic acids encoding them that have at least 80% identity to the sequences disclosed herein. In one example, the IL-11Rα binding proteins or nucleic acids of the present disclosure are at least about 85% or 90% or 95% or 97% or 98% or 99% identical to the sequences disclosed herein. The protein specifically binds to IL-11Rα as described herein according to any example.

Alternatively or in addition, the IL-11Rα binding protein is at least about 80% or about 85% or 9 relative to the CDR _{of V H} or _{VL as described herein according to any example.}
0% or 95% or 97% or 98% or 99% identical CDRs (eg, 3 CDRs)
), The protein is IL-11Rα as described herein according to any example.
It is possible to specifically bind to. In this regard, the inventors have produced a large number of antibodies having diverse sequences within their CDRs. Methods for measuring protein binding to IL-11Rα are described herein.

For example, we share at least 40% identity in HCDR1 (and optionally the N-terminal amino acid relative to HCDR1) according to Kabat's numbering scheme.
A group of L-11Rα-binding proteins and another subgroup of proteins that share 80% identity in their HCDR1 have been identified.

We also have a class of IL-11Rα binding proteins that share 77% identity in their HCDR2 according to Kabat's numbering scheme, and at least about 82% identity in their HCDR2 according to Kabat's numbering scheme. We have also identified subclasses of sex-sharing IL-11Rα-binding proteins.

As discussed herein, the five C-terminal residues of heavy chain CDR2 can be mutated to conservative or non-conservative amino acid substitutions (31% of the residues) (Padlan et al., FAS).
EB J. 9: 133-139, 1995) is also known in the art. Thus, the protein can contain CDR2 having at least about 47% identity to the heavy chain CDR2 sequence disclosed herein.

For example, we have identified a group of IL-11Rα-binding proteins that share at least about 44% identity in their HCDR3 according to Kabat's numbering scheme.

For example, we have identified several residues in _VH containing the sequence set forth in SEQ ID NO: 37 that can be replaced without loss of function or that results in improved function. In one example, the IL-11Rα binding protein comprises an amino acid substitution between 1-11 as compared to SEQ ID NO: 37. For example, the IL-11Rα binding protein comprises an amino acid substitution of 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 as compared to SEQ ID NO: 37. For example, the IL-11Rα binding protein contains 3 amino acid substitutions compared to SEQ ID NO: 37. For example, the IL-11Rα binding protein contains 4 amino acid substitutions compared to SEQ ID NO: 37.

In one example, the IL-11Rα binding protein was 1 in CDR3 compared to SEQ ID NO: 37.
Includes amino acid substitutions between ~ 4. For example, the IL-11Rα binding protein contains 1 or 2 or 3 or 4 amino acid substitutions as compared to SEQ ID NO: 37.

In one example, the IL-11Rα binding protein was 1 in CDR2 as compared to SEQ ID NO: 37.
Includes amino acid substitutions between ~ 3. For example, the IL-11Rα binding protein contains an amino acid substitution of 1 or 2 or 3 in CDR3 as compared to SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least tryptophan at position 54 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least threonine at position 56 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least aspartic acid at position 57 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least tryptophan at position 57 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least leucine at position 57 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least proline at position 99 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least glutamic acid at position 100 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least leucine at position 100 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least aspartic acid at position 101 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least leucine at position 104 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequence of the variant comprising at least arginine at position 104 of SEQ ID NO: 37.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequences of the variants being tryptophan at position 54 and aspartic acid at position 56 with respect to SEQ ID NO: 37, respectively. And at position 57, it contains at least leucine.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequences of the variants being tryptophan at position 54 and aspartic acid at position 56 with respect to SEQ ID NO: 37, respectively. And at position 57, it contains at least leucine.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequences of the variants being tryptophan at position 54 and threonine at position 56 with respect to SEQ ID NO: 37, respectively. It contains at least leucine at position 57.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequences of the variants being proline at position 99 with respect to SEQ ID NO: 37, respectively.
It contains at least leucine at position 100, aspartic acid at position 101 and leucine at position 104.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 37, the sequences of the variants being proline at position 99 with respect to SEQ ID NO: 37, respectively.
It contains at least leucine at position 100, aspartic acid at position 101 and arginine at position 104.

For example, we present a group of IL-11Rα-binding proteins that share at least 45% identity in their LCDR1 according to Kabat's numbering scheme, and their LCDRs.
1 identifies another subgroup of proteins that share about 54% identity.

We have also identified a class of IL-11Rα binding proteins that share at least about 55% or 56% identity on their LCDR3 according to Kabat's numbering scheme.

For example, we have identified several residues in _VL containing the sequence set forth in SEQ ID NO: 5, which can be replaced without loss of function or which results in improved function. In one example, the IL-11Rα binding protein comprises an amino acid substitution between 1-11 as compared to SEQ ID NO: 5. For example, the IL-11Rα binding protein comprises an amino acid substitution of 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 as compared to SEQ ID NO: 5. For example, the IL-11Rα binding protein contains 3 amino acid substitutions compared to SEQ ID NO: 5. For example, the IL-11Rα binding protein contains 4 amino acid substitutions compared to SEQ ID NO: 5.
For example, the IL-11Rα binding protein contains 5 amino acid substitutions compared to SEQ ID NO: 5.

In one example, the IL-11Rα binding protein was 1 to 1 in CDR3 as compared to SEQ ID NO: 5.
Includes amino acid substitutions between 4. For example, the IL-11Rα binding protein is SEQ ID NO: 5
Containes 1 or 2 or 3 or 4 amino acid substitutions in CDR3 as compared to.

In one example, the IL-11Rα binding protein was 1 to 1 in CDR1 as compared to SEQ ID NO: 5.
Includes amino acid substitutions between 5. For example, the IL-11Rα binding protein is SEQ ID NO: 5
Containes 1 or 2 or 3 or 4 or 5 amino acid substitutions in CDR3 as compared to.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the variant sequence comprises at least valine at position 29 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least aspartic acid at position 30 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the variant sequence comprises at least lysine at position 31 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least valine at position 33 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the variant sequence comprises at least glutamic acid at position 34 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least alanine at position 91 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least histidine at position 91 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least glutamic acid at position 91 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least aspartic acid at position 93 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least phenylalanine at position 93 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the variant sequence comprises at least serine at position 93 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, and the sequence of the variant comprises at least glutamine at position 94 of SEQ ID NO: 5.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, where the sequences of the variants are valine at position 29 and aspartic acid at position 30, respectively, in relation to SEQ ID NO: 5. , At least lysine at position 31, valine at position 33 and glutamic acid at position 34.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, the sequences of the variants being associated with SEQ ID NO: 5, alanine at position 91 and glutamic acid at position 92, respectively. It contains at least aspartic acid at position 93 and glutamine at position 94.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, the sequences of the variants being histidine, 92, respectively, at position 91 in relation to SEQ ID NO: 5.
It contains at least glutamic acid at the position, phenylalanine at the 93 position and glutamine at the 94 position.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, the sequences of the variants being histidine, 92, respectively, at position 91 in relation to SEQ ID NO: 5.
It contains at least glutamic acid at the position and glutamine at the 94th position.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, the sequences of the variants being histidine, 92, respectively, at position 91 in relation to SEQ ID NO: 5.
It contains at least glutamic acid at the position and glutamine at the 94th position.

In one example, the IL-11Rα binding protein of the present disclosure comprises a variant of the sequence set forth in SEQ ID NO: 5, where the sequences of the variants are glutamic acid, 9 at position 92, respectively, in relation to SEQ ID NO: 5.
It contains at least serine at 3rd position and glutamine at 94th position.

In another example, the nucleic acids of the present disclosure are at least about 80 relative to the sequences shown herein.
% Or 85% or 90% or 95% or 97% or 98% or 99% comprising a sequence encoding an IL-11Rα binding protein that is identical and has the functions as described herein according to any example. .. The disclosure also includes nucleic acids encoding the IL-11Rα-binding proteins of the present disclosure that differ from the sequences exemplified herein as a result of gene coding reduction.

Nucleic acid and polypeptide identity% is GAP (Needleman and Wunsch. Mol. Bio) with a gap formation penalty = 5 and a gap extension penalty = 0.3.
l. 48,443-453,970) Determined by analysis (GCG program).
The query sequence is at least 50 residues long and GAP analysis aligns the two sequences over a region of at least 50 residues. For example, the query sequence is at least 100 residues in length and GAP analysis arranges the two sequences over a region of at least 100 residues. For example, the two arrays are lined up over their entire length.

The present disclosure is also described herein under stringent hybrid formation conditions.
Nucleic acids that hybridize with nucleic acids encoding L-11Rα binding proteins are also contemplated.
"Moderate stringency" is described herein as 2 x SSC buffer, 0.1% (w / v) SDS at a temperature of 45 ° C. to 65 ° C., or hybrid formation performed under equivalent conditions and /.
Or defined as cleaning. "High stringency" is 0.1 x S herein.
SC buffer, 0.1% (w / v) SDS or even lower salt concentration and temperature of at least 65 ° C., or hybrid formation and / or washing performed under equivalent conditions.
References herein for specific levels of stringency are SSCs known to those of skill in the art.
Includes equivalent conditions with other wash / hybrid formation solutions. For example, a method of calculating the temperature at which a double-stranded nucleic acid strand dissociates (also known as melting temperature or Tm) is known in the art. Temperatures that are similar or equivalent to the Tm of nucleic acid (eg, within 5 ° C or within 10 ° C) are considered high stringency. Intermediate stringency should be considered to be within 10 ° C to 20 ° C or 10 ° C to 15 ° C of the calculated Tm of nucleic acid.

The disclosure also contemplates mutant forms of the IL-11Rα binding proteins of the present disclosure that contain one or more conservative amino acid substitutions as compared to the sequences presented herein. In some embodiments, I
L-11Rα binding proteins contain less than 10 conservative amino acid substitutions, eg, 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 or 1. A "conservative amino acid substitution" is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain and / or hydrophobicity and / or hydrophilicity.

Basic side chains (eg, lysine, arginine, histidine), acidic side chains (eg, aspartic acid, glutamic acid), uncharged polar side chains (eg, glycine, asparagine, etc.)
Glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (eg, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine,
A family of amino acid residues having similar side chains, including tryptophan), β-branched side chains (eg, threonine, valine, isoleucine) and aromatic side chains (eg, tyrosine, phenylalanine, tryptophan, histidine) is defined in the art. Has been done. Hydrophobicity indicators include, for example, Kyte and Doolittle, J. et al. Mol. Biol. , 157:
105-132, 1982, the hydrophilicity index is described, for example, in US Pat. No. 4,5541.
It is described in No. 01.

The disclosure also contemplates non-conservative amino acid changes. For example, of particular interest are the substitution of a charged amino acid with another charged amino acid and with a neutral or positively charged amino acid. In some examples, the IL-11Rα binding protein comprises 10 or less, eg, 9 or 8 or 7 or 6 or 5 or 4 or 3 or 2 or 1 non-conservative amino acid substitutions.

In one example, the mutation occurs within the FR of the antigen-binding domain of the IL-11Rα-binding protein of the present disclosure. In another example, mutations occur within the CDRs of the IL-11Rα binding proteins of the present disclosure.

Examples of methods for creating mutant forms of IL-11Rα binding proteins include: DNA (Thie et al., Methods Mol. Biol. 525: 309-322,
2009) or RNA (Kopsidas et al., Immunol. Lett. 107: 16)
3-168, 2006; Kopsidas et al. BMC Biotechnology, 7
: 18,2007; and Mutation Induction of WO 1999/058661);
-Mutagenetic gene cells such as XL-1Red, XL-mutS and XL-mu
Introduction of a nucleic acid encoding a polypeptide into tS-Kanr bacterial cells (Stratagene);
DNA shuffling as disclosed in, for example, Stemmer, Nature, 370: 389-91, 1994; and, for example, Dieffenbach (ed) and Deveksler (ed) (PCR).
Primer: A Laboratory Manual, Cold Spring H
Includes site-specific mutations as described in (arbor Laboratories, NY, 1995).

An exemplary method for measuring the biological activity of the mutant IL-11Rα binding proteins of the present disclosure, eg, antigen binding, will be apparent to a skilled expert and / or described herein. Let's go. For example, methods for measuring antigen binding, competitive inhibition of binding, affinity, association, dissociation and therapeutic efficacy are described herein.

Constant Regions The disclosure includes IL-11Rα binding proteins and / or antibodies described herein that include constant regions of antibodies. This includes antigen-binding fragments of antibodies fused to Fc.

The constant region sequences useful for producing the proteins of the present disclosure can be obtained from a number of different sources. In some examples, the constant region or part of the protein is derived from a human antibody. The constant region or part thereof can be derived from any antibody class including IgM, IgG, IgD, IgA and IgE and any antibody isotype including IgG1, IgG2, IgG3 and IgG4. In one example, the constant region is the constant region of human isotype IgG4 or stabilized IgG4.

In one example, the Fc region of the constant region is, for example, a native or wild-type human Ig.
It has a low ability to induce effector function compared to the Fc region of G1 or IgG3. In one example, the effector function is antibody-dependent cell-mediated cytotoxicity (ADCC) and /
Or antibody-dependent cell-mediated phagocytosis (ADCP) and / or complement-dependent cytotoxicity (ADCP)
CDC). Methods for assessing the level of effector function of proteins containing the Fc region are known in the art and / or described herein.

In one example, the Fc region is the Fc region of IgG4 (ie, derived from the constant region of IgG4), eg, the Fc region of human IgG4. The sequence of the Fc region of suitable IgG4 will be apparent to those of skill in the art and / or will be available in publicly available databases (eg, available from the National Center for Biotechnology Information).

In one example, the constant region is a stabilized IgG4 constant region. The term "stabilized IgG4 constant region" is an IgG modified to reduce Fab arm exchange or the tendency to undergo Fab arm exchange or half-antibody formation or to form half-antibody.
It will be understood to mean the constant region of 4. "Fab arm exchange" refers to a type of protein modification for human IgG4 in which a light chain (half molecule) linked to an IgG4 heavy chain is exchanged for a heavy chain / light chain pair from another IgG4 molecule. Thus, an IgG4 molecule can acquire two distinct Fab arms that recognize two distinct antigens (resulting in a bispecific molecule). Fab arm exchange occurs spontaneously in vivo and can be induced in vitro with purified blood cells or a reducing agent such as reducing glutathione. "Half antibody" is IgG
It occurs when the four antibodies dissociate to form two molecules, each containing a single heavy chain and a single light chain.

In one embodiment, the stabilized IgG4 constant region contains proline at position 241 of the hinge region according to Kabat's scheme (Kabat et al., Sequences of Prot).
eins of Immunological Interest Washing to
n DC United States Department of Health
and Human Services, 1987 and / or 1991). This position is E
Corresponds to the 228th position of the hinge region according to the U numbering method (Kabat et al., Sequen)
ces of Proteins of Immunological Interes
t Washington DC United States Department
of Health and Human Services, 2001 and Edel
man et al., Proc. Natl. Acad. USA, 63, 78-85, 1969). In human IgG4 this residue is generally serine. Following the replacement of serin with proline, I
The hinge region of gG4 contains the sequence CPPC. At this point, one of ordinary skill in the art will notice that the "hinge region" is the proline-rich portion of the heavy chain constant region of the antibody that connects the regions of Fc and Fab, which imparts mobility on the two Fab arms of the antibody. Will. The hinge region contains cysteine residues involved in disulfide bonds between heavy chains. It is generally defined as the extension of human IgG1 from Glu226 to Pro243 according to Kabat's numbering scheme. Hinge regions of other IgG isotypes can be aligned with the IgG1 sequence by placing cysteine residues at the beginning and end to form disulfide (SS) bonds between heavy chains at the same position (eg, International Publication No. 1). (See 2010/080538).

An additional example of stabilized IgG4 antibody is 409 in the heavy chain constant region of human IgG4.
An antibody in which the arginine at the position (according to the EU numbering scheme) is replaced with lysine, threonine, methionine or leucine (eg, as described in WO 2006/0333386). The Fc region of the constant region further or instead contains residues selected from the group consisting of alanine, valine, glycine, isoleucine and leucine at positions corresponding to position 405 (according to EU numbering schemes). Optionally, the hinge area (as described above) is 24
It contains proline (ie, CPPC sequence) at position 1.

In another embodiment, the Fc region is a region that is modified to have reduced effector function, i.e., a "non-immune-stimulating Fc region." For example, the Fc region is 268, 3
The Fc region of IgG1 containing substitutions at one or more positions selected from the group consisting of 09, 330 and 331. In another embodiment, the FC region has the following changes, E233P, L234V,
Changes of 1 or more of L235A and 1 or more and / or less of deletion of G236, A327G, A
It is an Fc region of IgG1 containing one or more of 330S and P331S (Armour et al., E.
ur. J. Immunol. 29: 2613-624, 1999; Shiels et al.,
J. Biol. Chem. 276 (9): 6591-604, 2001). Additional examples of non-immune-stimulating Fc regions are described, for example, by Dollar'Acqua et al., J. Mol. Immunol
.. 177: 1129-1138, 2006; and / or Hezareh J Virol
75: 12161-12168, 2001.

In another example, the Fc region is, for example, at least one C derived from an IgG4 antibody.
Chimeric Fc region comprising at least one _{C H} 3 domain from _H 2 domain and IgG1 antibodies, this time, Fc region 240,262,264,266,297,299
, 307, 309, 323, 399, 409 and 427 (EU numbering) containing substitutions at positions of one or more amino acids selected from the group (eg, WO 2010/08).
As described in No. 5682). Examples of substitutions include 240F, 262L, 264T.
, 266F, 297Q, 299A, 299K, 307P, 309K, 309M, 309P
323F, 399S, and 427F.

Enhancement of Effector Function In one example, the IL-11Rα binding proteins of the present disclosure can induce effector function or high effector function.

In the context of the present disclosure, "effector function" refers to a cell or protein-mediated biological activity that binds to the Fc region of an antibody that causes cell killing (the Fc region of a native sequence or the Fc region of an amino acid sequence variant). Examples of antibody-induced effector function are complement-dependent cytotoxicity; antibody-dependent cell-mediated cytotoxicity (ADCC); antibody-dependent cellular cytotoxicity (ADCP); and B cell cells. Activation is mentioned.

In one example, the IL-11Rα binding protein of the present disclosure is such that it is an ADC, for example.
It binds to IL-11Rα on the surface of cells in such a way that it is possible to induce effector functions such as C or CDC.

For example, the IL-11Rα binding protein remains bound to IL-11Rα on the surface of the cell for a time sufficient to induce effector functions such as ADCC and / or CDC.

In one example, the IL-11Rα binding proteins of the present disclosure are, for example, modified Fc.
It is possible to induce high effector function by region or by including a region capable of binding to immune effector cells. For example, the level of effector function is enhanced compared to the level induced by the Fc region of human IgG1 or IgG3.
The enhancement of effector function induced by the IL-11Rα binding protein of the present disclosure
For example, high therapeutic or prophylactic effects can be achieved not only by blocking the action of IL-11Rα, but also by killing or depleting disease-causing cells, for example, killing autoreactive T cells.

In one example, the Fc region of the IL-11Rα binding protein of the present disclosure is an unmodified Fc.
It is modified to increase the level of effector function that can be guided relative to the region. Such modifications are at the amino acid level and / or the secondary structure level and / or the tertiary structure level and / or extend to glycosylation of the Fc region.

Those skilled in the art will appreciate that greater effector function can be expressed in any of a number of ways, for example, as a higher level effect, as a more sustained effect, or as a faster speed effect.

In one example, the Fc region comprises modification of one or more amino acids that enhances the ability to induce high effector function. In one example, the Fc region binds to one or more FcγRs, such as FcγRIII, with even greater affinity. In one embodiment, the Fc region is Kabat's E.
230, 233, 234, 235, 239, 240, 243 numbered according to U index
, 264, 266, 272, 274, 275, 276, 278, 302, 318, 324
Includes at least one amino acid substitution at a position selected from the group consisting of, 325, 326, 328, 330, 332, and 335. In one example, the Fc region is the EU of Kabat.
Includes the following amino acid substitutions S239D / I332E numbered according to the index. This Fc
The region has about 14-fold higher affinity for FcγRIIIa than the wild-type Fc region.
It has the ability to induce ADCC, which is about 3.3 times higher than the wild-type Fc region. In one example, the Fc region was numbered according to Kabat's EU index and the following amino acid substitutions S239
Includes D / A330L / I332E. This Fc region is FcγR compared to the wild-type Fc region
It has an affinity for IIIa about 138 times higher and is capable of inducing ADCC about 323 times higher than the wild-type Fc region.

Additional amino acid substitutions that enhance the ability of the Fc region to induce effector function are known in the art and / or, for example, U.S. Pat. No. 6,737,056 or U.S. Pat. No. 7,317.
It is described in No. 091.

In one embodiment, the glycosylation of the Fc region is altered to enhance its ability to induce high effector function. In this regard, the native antibody produced by mammalian cells typically comprise a biantennary oligosaccharide branches are connected commonly by the N-linked to Asn297 of the C _{H 2} domain of the Fc region. Oligosaccharides can include various sugars such as mannose, N-acetylglucosamine (GlcNAc), galactose and sialic acid, and fucose linked to GlcNAc in the "stem" of the bifurcated oligosaccharide structure. In some examples
The Fc region according to the present disclosure comprises a sugar structure lacking fucose (directly or indirectly) linked to the Fc region, i.e., the Fc region is "non-fucosylated". Such mutants are AD
It may have an improved ability to induce CC. Methods for producing non-fucosylated antibodies include (eg, Yumane-Ohnuki et al., Biotechnol. Bioengi).
neer. Expressing an antibody or antigen-binding fragment thereof in a cell line that cannot express α-1,6-fucosyltransferase (FUT8) (as described in 87: 614-622, 2004), eg, Mori et al., Biotechnol. Bioengin
ea. , 88: 901-908, 2004) to express an antibody or antigen-binding fragment thereof in cells expressing a small molecule interfering RNA to FUT8 (eg, Kanda et al., J. Biotechnol., 130: 300-310, 2007
(As described in), expression of an antibody or an antigen-binding fragment thereof in cells that cannot express guanosine diphosphate (GDP) -mannose 4,6-dehydrase (GMD) can be mentioned. The present disclosure also includes (eg, Umana et al., Nat. Biotechnology.
For example, β- (1,4) -N (as described in 17: 176-180, 1999).
We also contemplate the use of proteins with reduced levels of fucosylation produced using cell lines modified to express -acetylglucosaminyltransferase III (GnT-III).

Other methods include the use of cell lines that innately produce antibodies capable of inducing Fc-mediated high effector function (eg, duck embryonic stem cells for the production of viral vaccines, etc.). International Publication No. 2008/129058; Birds EBX®
Production of recombinant proteins in cells, WO 2008/142124).

The IL-11Rα-binding proteins of the present disclosure also include those with a bisected oligosaccharide in which the bifurcated oligosaccharide linked to the FC region is bisected by GlcNAc. Such proteins may have reduced fucosylation and / or improved ADCC function. Examples of such proteins are described, for example, in US Pat. No. 6,602,684 and US Patent Application Publication No. 20050123446.

IL-1 with at least one galactose residue in the oligosaccharide linked to the FC region
1Rα binding proteins are also contemplated. Such proteins may have improved CDC function. Such proteins are published International Publication No. 1997/30087 and International Publication No. 19
It is described in 99/22764.

IL-11Rα binding protein is capable of inducing high levels of CDC Fc
It can also include regions. For example, a hybrid of IgG1 and IgG3 produces an antibody with high CDC activity (Natsume et al., Cancer Res. 68: 3863).
-3872, 2008).

Alternatively, the IL-11Rα binding protein can be fused or bound to a protein that binds to immune effector cells (eg, antibody variable region), eg, by binding to CD3 or CD16.

Methods for measuring effector function are known in the art. In one example, the level of ADCC activity is ^{assessed using a 51} Cr release assay, a Europium release assay or a ³⁵ S release assay. In each of these assays, cells expressing IL-11Rα are cultured with one or more of the cited compounds for sufficient time and conditions for the compounds to be taken up by the cells. ^In the case of the 35 S release assay, cells can be cultured for sufficient time to incorporate the amino acids labeled in the newly synthesized protein along with ^{35 S labeled methionine and / or cysteine.} Then in the presence or absence of the IL-11Rα binding protein and in the presence of immune effector cells, such as PBMC and / or N.
The cells are cultured in the presence of K cells. ^{The amount of 51} Cr, europium and / or ³⁵ S in the cell culture medium is then detected and the increase in the presence of the protein compared to the absence of the protein indicates that the binding molecule / agent has effector function. Examples of publications disclosing assays for assessing protein-induced ADCC levels include Hellstrom et al. Proc. Natl. Acad. Sci. USA, 83: 705
9-7063, 1986 and Bruggemann et al., J. Mol. Exp. Med. 166: 1
351-1361, 1987 can be mentioned.

Other assays for assessing protein-induced ADCC levels include the ACTI ™ Non-Radioactive Cell Injury Assay (CellT) for Flow Cytometry.
echology, Inc. CA, USA) or CytoTox96® non-radioactive cytotoxicity assay (Promega, WI, USA).

Alternatively or additionally, the effector function of the IL-11Rα binding protein is assessed, for example, by measuring its affinity for one or more FcγRs as described in US Pat. No. 7,317,991.

A C1q binding assay can also be performed to confirm that the IL-11Rα binding protein can bind C1q and induce CDC. To assess complement activation, a CDC assay can be performed (eg, Gazzano-Santoro et al., J. Immunol.
Methods, 202: 163, 1996).

Additional Modifications The disclosure also contemplates additional modifications to antibodies or IL-11Rα binding proteins containing Fc or constant regions.

For example, an antibody contains one or more amino acid substitutions that increase the half-life of a protein. For example, the antibody comprises an Fc region containing one or more amino acid substitutions that enhance the affinity of the Fc region for the neonatal Fc region (FcRn). For example, the FC region has a low pH, for example pH6.
.. At 0, it has a high affinity for FcRn and facilitates Fc / FcRn binding in endosomes. In one example, the Fc region is approximately p compared to the affinity at approximately pH 7.4.
It has a high affinity for FcRn at H6.0, which promotes the rerelease of Fc into the blood following cell recycling. These amino acid substitutions are useful in extending the half-life of proteins by reducing clearance from the blood.

Examples of amino acid substitutions include T250Q and / or M428 according to EU numbering schemes.
L or T252A, T254S and T266F or M252Y, S254T and T256
E or H433K and N434F can be mentioned. Additional or alternative amino acid substitutions are described, for example, in US Patent Application Publication No. 200701355620 or US Pat. No. 7083784.

Example IL-11Rα-binding protein Table 1 shows an example of IL-11Rα-binding protein containing a variable region produced by the present inventors.

Protein Production In one example, the IL-11Rα binding proteins described herein according to any example are proteins, such as, for example, as described herein and / or as known in the art. It is produced by culturing hybridomas under conditions sufficient to produce.

Recombinant Expression In another example, the IL-11Rα binding protein described herein is recombinant according to any example.

In the case of a recombinant protein, the nucleic acid encoding it is cloned into an expression construct or expression vector, which is then cloned into, for example, Escherichia coli cells, yeast cells, insect cells, or, for example, monkey COS cells, Chinese hamster ovary (CHO) cells. , Human embryonic kidney (HEK)
) Transfect in host cells such as mammalian cells such as myeloma cells that otherwise do not produce cells or proteins. An example cell used to express a protein is CHO
Cells, myeloma cells or HEK cells. Molecular cloning techniques for achieving these objectives are known in the art, eg, Ausubel et al., (Editor), Curren.
t Protocols in Molecular Biology, Greene
Pub. Associates and Wiley-Interscience (1)
988, including all updates to date) or Sambrook et al., Molecule
Cloning: A Laboratory Manual, Cold Spring
It is described in Harbor Laboratory Press (1989). A wide variety of cloning and in vitro amplification methods are suitable for the construction of recombinant nucleic acids. Methods for producing recombinant antibodies are also known in the art, see, for example, US Pat. No. 4,816,567 or US Pat. No. 5,530,101.

Following isolation, the nucleic acid is inserted into a promoter in an expression construct or expression vector for further cloning (amplification of DNA) or expression in a cell-free system or cell and operably linked.

As used herein, the term "promoter" should be construed in the broadest context, including, for example, expression of nucleic acids in response to developmental and / or external stimuli or tissue-specific. TA required for accurate transcription initiation with or without additional regulatory elements that alter (eg, upstream activation sequences, transcription factor binding sites, promoters and silencers)
Includes transcriptional regulatory sequences of genomic genes containing TA boxes or initiation elements. In the current context, the term "promoter" is also used to describe recombinant, synthetic or fused nucleic acids or derivatives that confer, activate or enhance expression of a nucleic acid to which it is operably linked. Will be done. An exemplary promoter can contain an additional copy of one or more specific regulatory elements to further enhance expression and / or to alter spatial and / or temporal expression of the nucleic acid.

As used herein, the term "operably linked" means positioning a promoter relative to a nucleic acid such that expression of the nucleic acid is controlled by the promoter.

Numerous vectors are available for expression in cells. The components of the vector generally include: signal sequences, sequences encoding proteins (eg, derived from the information provided herein), enhancer elements, promoters and one or more of transcription termination sequences.
Not limited to these. Skilled experts will find suitable sequences for protein sequences. Examples of signal sequences include prokaryotic cell secretory signals (eg, pelB, alkaline phosphatase, penicillinase, Ipp, or thermostable enterotoxin II), yeast secretory signals (eg, invertase leaders, α-factor leaders). Or a leader of acid phosphatase) or a mammalian secretory signal (eg, a simple herpes gD signal).

Examples of promoters that are active in mammalian cells include the cytomegalovirus pre-early promoter (CMV-IE), the human elongation factor 1-α promoter (EF1), the small nuclear RNA promoter (U1a and U1b), and α-. Hybrid regulators or immunoglobulin promoters including myosin heavy chain promoter, salvirus 40 promoter (SV40), Rous sarcoma virus promoter (RSV), adenovirus major late promoter, β-actin promoter, CMV enhancer / β-actin promoter or the like. Examples include active fragments.
An example of a useful mammalian host cell line is the SV40-transformed monkey kidney CV1 strain (COS-7).
, ATCC CRL1651), human embryonic kidney strain (293 cells or 293 cells subcloned for growth in suspension culture), immature hamster kidney cells (BHK, ATCC C)
CL10) or Chinese hamster ovary cells (CHO).

For example, a typical promoter suitable for expression in yeast cells, such as yeast cells selected from the group comprising Pichia pastoris, Saccharomyces cerevisiae and fission yeast, is the ADH1 promoter.
GAL1 promoter, GAL4 promoter, CUPl promoter, PHO5 promoter,
Examples include, but are not limited to, the nmt promoter, RPR1 promoter, or TEF1 promoter.

Means for introducing isolated nucleic acids or expression constructs containing them into cells for expression are known to those of skill in the art. The technique used for a given cell depends on known and successful techniques. Means for introducing recombinant DNA into cells include, among other things, microinjection, DEAE / dextran-mediated transfection, such as lipofectamine (Gibco, MD, USA) and /.
Alternatively, liposome-mediated transfection by using selffectin (Gibco, MD, USA), PEG-mediated DNA uptake, electroporation and D.
Fine particle impact (Ag) by using NA-coated tungsten or gold particles
racetus Inc. , WI, USA).

The host cells used to produce the protein can be cultured in a variety of media depending on the cell type used. For example, Ham's F10 (Sigma), basal medium ((MEM)
, (Sigma), RPM1-1640 (Sigma) and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing mammalian cells. Mediums for culturing other cell types discussed herein are known in the art.

Isolation of Proteins Methods for isolating proteins are known in the art and / or described herein.

If the IL-11Rα-binding protein is secreted into the culture medium, the supernatant from such an expression system may first be concentrated using a commercially available protein concentration filter, eg, an Amicon or Millipore Pellicon extrafiltration unit. can. In any of the steps described above, a protease inhibitor such as PMSF can be included to inhibit proteolysis and an antibiotic can be included to prevent the growth of accidental contaminants. Alternatively or further, the supernatant can be filtered and separated from the protein-expressing cells using, for example, continuous centrifugation.

IL-11Rα-binding proteins prepared from cells include, for example, ion exchange, hydroxyapatite chromatography, hydrophobic interaction chromatography, gel electrophoresis, etc.
Purification can be performed using dialysis, affinity chromatography (eg, protein A affinity chromatography or protein G chromatography), or any combination described above. These methods are known in the art and are, for example, WO99 / 57134 or Ed.
Harlow and David Lane (editor), Antibodies: A Lab
oraly Manual, Cold Spring Harbor Labora
It is described in tory, (1988).

Skilled experts will find that the protein is a tag, such as a polyhistidine tag, such as a hexahistidine tag, or an influenza virus hemagglutinin (HA) tag, or a salvirus 5 (V5) tag or FLAG tag or glutathione-S. You will also notice that it can be modified to include a-transferase (GST) tag to facilitate purification or detection. The resulting protein is then purified using methods known in the art, such as affinity purification. For example, a protein-containing sample is contacted with nickel / nitrilotriacetic acid (Ni-NTA), which specifically binds a hexa-His tag immobilized on a solid or semi-solid support, and the sample is washed to unbound protein. The protein containing the hexaHis tag is purified by removing the protein and then eluting the bound protein. Alternatively or additionally, a ligand or antibody that binds to the tag by the affinity purification method is used.

Complex In one example, the IL-11Rα binding protein of the present disclosure is bound to a compound. For example, a compound is a group consisting of radioactive isotopes, detectable labels, therapeutic compounds, colloids, toxins, nucleic acids, peptides, proteins, compounds that increase the half-life of IL-11Rα binding proteins in a subject, and mixtures thereof. Is selected from.

Other compounds can be attached directly or indirectly to the IL-11Rα binding protein (eg, in the case of indirect binding, a linker can be included). Examples of compounds include
Radioisotopes (eg iodine-131, yttrium-90 or indium-11)
1), detectable labels (eg, fluorescent dye molecules or fluorescent nanocrystals or quantum dots), therapeutic compounds (eg, chemotherapeutic agents or anti-inflammatory agents), colloids (eg, gold), toxins (eg, gold)
For example, lysine toxin or tetanus toxin), nucleic acid, peptide (eg, serum albumin-binding peptide), protein (eg, protein or serum albumin containing the antigen-binding domain of an antibody), half-life of IL-11Rα-binding protein in a subject. Examples include compounds that increase the amount of protein (eg, polyethylene glycol or other water-soluble polymers with this activity) and mixtures thereof. Example compounds capable of binding to the IL-11Rα binding proteins of the present disclosure and methods of such binding are known in the art and are described, for example, in WO 2010/059821.

The IL-11Rα binding protein can be attached to nanoparticles (eg, Kogan et al.,
Nanomedicine (Londo). (As outlined in 2: 287-306, 2007). The nanoparticles can be metal nanoparticles.

The IL-11Rα binding protein is an antibody-targeted bacterial minicell (eg, PCT / I).
(As described in B2005 / 000204).

Table 2 lists some exemplary compounds that can bind to the IL-11Rα binding proteins of the present disclosure.

Assaying the activity of IL-11Rα binding proteins Binding to IL-11Rα and its variants Some IL-11Rα binding proteins of the present disclosure are described herein in the extracellular region of hIL-11Rα (eg, herein). Such regions) and specific variant forms of the extracellular region of hIL-11Rα (eg, SEQ ID NO: 3 or SEQ ID NO: 85 with or without certain point mutations) and / or humans and It will be apparent from the disclosure herein to a skilled expert that it binds to both IL-11Rα of cynomolgus monkeys. A method for evaluating binding to a protein is, for example, Scopes (Protein assessment:
Principles and principle, 3rd edition, Springer Ve
It is known in the art as described in rlag, 1994). Such methods generally involve immobilizing an IL-11Rα binding protein and contacting it with a labeled antigen. Following washing to remove non-specific binding proteins, the amount of label, resulting in the amount of bound antigen, is detected. Of course, the IL-11Rα binding protein can be labeled and the antigen can be immobilized. Panning-type assays can also be used.
Alternatively or additionally, a surface plasmon resonance assay can be used.

Proteins to hIL-11Rα or its extracellular space (eg, as contained within SEQ ID NO: 3) or the polypeptide of SEQ ID NO: 3 or SEQ ID NO: 85 or a mutant form thereof using the assay described above. It is also possible to detect the level of binding of.

In one example, the IL-11Rα binding protein of the present disclosure is at least about 1.5-fold or 2-fold or 5-fold or 10-fold or 50-fold or 100-fold or more than it binds to the polypeptide of SEQ ID NO: 85. It binds to the polypeptide of SEQ ID NO: 95 at 150-fold, 160-fold, or 200-fold lower levels.

In one example, the protein of the present disclosure is at least about 1.5-fold, 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, or 1-fold that it binds to the polypeptide of SEQ ID NO: 85.
It binds to the polypeptide of SEQ ID NO: 96 at 50-fold, 160-fold, or 200-fold lower levels.

In one example, the protein of the present disclosure is at least about 1.5-fold, 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, or 1-fold that it binds to the polypeptide of SEQ ID NO: 85.
It binds to the polypeptide of SEQ ID NO: 86 at 50-fold, 160-fold, or 200-fold lower levels.

In one example, the protein of the present disclosure is at least about 1.5-fold, 2-fold, 5-fold, 10-fold, 50-fold, 100-fold, or 1-fold that it binds to the polypeptide of SEQ ID NO: 85.
It binds to the polypeptide of SEQ ID NO: 89 at 50-fold, 160-fold, or 200-fold lower levels.

The level of binding is conveniently determined using a biosensor.

The present disclosure contemplates any combination of the aforementioned properties. In one example, the proteins described herein have all of the binding properties set forth in the five paragraphs above.

Epitope Mapping In another example, the epitopes to which the proteins described herein bind are mapped. Epitope mapping methods will be apparent to skilled and skilled personnel. For example, a series of overlapping peptides spanning an IL-11Rα sequence or region thereof containing a peptide of interest, eg, a peptide containing 10 to 15 amino acids, is created. The IL-11Rα binding protein is then contacted with each peptide to determine which peptide it binds to. This allows the determination of peptides containing epitopes to which the protein binds. A protein can bind a conformational epitope if the protein binds to multiple non-adjacent peptides.

Alternatively or further, for example, alanine scanning mutagenesis or evolutionarily conserved amino acid substitutions mutate amino acid residues within IL-11Rα to determine mutations that reduce or prevent binding of IL-11Rα binding proteins. do. Any mutation that reduces or interferes with the binding of the IL-11Rα binding protein is likely to be in the epitope to which the IL-11Rα binding protein binds.

In this regard, as shown herein, mutations in valine at position 117 of IL-11R in relation to SEQ ID NO: 1 reduced or prevented binding of 8E2 and 8D10. In addition, 8E2
Testing of affinity-maturated variants of IL-11R confirmed that the V117 residue of IL-11R was more important for binding than the other residues analyzed by mutation.

Another method of determining the region containing the epitope to which the IL-11Rα binding protein binds is the form of IL-11Rα to which the IL-11Rα binding protein does not bind (eg, mI).
Substituting the region of hIL-11Rα with the corresponding region of L-11Rα) was involved. I
If the L-11Rα binding protein does not bind to the mutant form of IL-11Rα, then the residues forming part of the protein epitope can be within the substituted region.

A further method of determining the region containing the epitope is an immobilized IL-11R of the present disclosure.
It involves binding IL-11Rα or its region to an α-binding protein and digesting the resulting complex with a protease. Peptides that remain bound to the immobilized IL-11Rα binding protein are then isolated and analyzed using, for example, mass spectroscopy to determine their sequence.

A further method involves converting hydrogen in IL-11Rα or its region to deuterons and binding the resulting protein to the immobilized IL-11Rα binding protein of the present disclosure. The deuteron is then converted back to hydrogen, IL-11Rα or its region is isolated, enzymatically digested and analyzed using mass spectroscopic analysis to identify the deuteron-containing region, which is described herein. It is protected from conversion to hydrogen by the binding of the IL-11Rα binding protein.

Optionally, IL-11Ra or dissociation constant of the immobilized IL-11Ra binding protein for that epitope (Kd), measures the association constant (Ka) and / or affinity constant _{(K D).} The "Kd" or "Ka" or "K _D" an embodiment of the IL-11Ra binding protein, as measured by radioactively labeled or fluorescently labeled IL-11Ra binding assay. In the case of "Kd", this assay equilibrates the IL-11Rα binding protein with the lowest concentration of labeled IL-11Rα in the presence of a titration series of unlabeled IL-11Rα. After washing to remove unbound IL-11Rα, the amount of label is measured, which indicates the protein Kd.

According to another example, Kd, Ka or _{the K D} immobilized IL-11Ra or by its area or immobilized surface plasmon resonance assay with IL-11Ra binding protein, e.g., BIAcore surface plasmon resonance (BIAcore, Inc., Pis
It is measured by using cataway, NJ).

In some embodiments, IL-11Ra binding proteins, because they are likely to compete for the binding of IL-11Ra, similar _{K D} or more to improve the _{K D} (i.e., lower _{K D} values than) the antibody 8E2 Has.

Measuring Competitive Binding Assays for measuring proteins that compete for and inhibit the binding of antibodies 8E2 and / or 8D10 and / or 8E4 will be apparent to skilled experts. One such method is exemplified herein.

For example, the antibody is bound to a detectable label, such as a fluorescent or radioactive label.
The labeled antibody is then mixed with the test IL-11Rα binding protein and IL-11Rα
Or contact with the region (eg, contained within a polypeptide comprising SEQ ID NO: 3) or cells expressing it. The level of the labeled antibody was then measured and IL-11R
The level measured when the antibody labeled in the absence of the α-binding protein is contacted with IL-11Rα or its region is compared. If the level of the antibody labeled in the presence of the test IL-11Rα binding protein is lower than in the absence of the IL-11Rα binding protein, the IL-11Rα binding protein competes for binding of the antibody to IL-11Rα. Is considered to inhibit.

Optionally, the test IL-11Rα binding protein is bound to a different label for the antibody.
This alternating labeling allows detection of the level of binding of the test IL-11Rα binding protein to IL-11Rα or its region or cell.

In another example, the IL-11Rα binding protein is IL-11Rα or a region thereof (eg, SEQ ID NO: 3) prior to contacting the antibody with IL-11Rα, a region or cell.
It is permissible to bind to cells that express (as contained within a polypeptide containing) or express it. A decrease in the amount of bound antibody in the presence of the IL-11Rα binding protein compared to the absence of the IL-11Rα binding protein indicates that the protein competes to inhibit the binding of the antibody to IL-11Rα. .. Using the labeled IL-11Rα binding protein, first I
A reverse assay can also be performed by binding an antibody to L-11Rα. In this case, the reduced amount of labeled IL-11Rα binding protein bound to IL-11Rα in the presence of the antibody compared to the absence of the antibody is such that the IL-11Rα binding protein is associated with the antibody IL-11Rα. Shows that it competes for and inhibits binding.

Any of the assays described above are IL-11Rα and / or mutant forms of SEQ ID NO: 3 and / or SEQ ID NO: 85 and / or, for example, 8E2 and / or 8D10 and / or as described herein. It can be performed in the extracellular region of IL-11Rα to which 8E4 binds.

Measuring Neutralization In some examples of the disclosure, the protein is capable of neutralizing IL-11 signaling.

Various assays are known in the art for assessing the ability of proteins to neutralize receptor-mediated ligand signaling.

In one example, the protein reduces or prevents the binding of IL-11 to IL-11Rα. These assays can be performed as competing assays as described herein using labeled IL-11 and / or labeled IL-11Rα binding proteins.

In a further example, the IL-11Rα binding protein is modified to express IL-11Rα and gp130-expressing cells (eg, BaF3 cells) (both proteins) cultured in the presence of IL-11. Reduces the proliferation of proteins). The cells (eg, about 1 x 10 ⁴ cells) are IL-11 (eg, about 0.3 ng / mL to about 5 ng / mL).
Between mL (eg 0.3 ng / mL or 0.5 ng / m for hIL-11)
0.5 ng / mL or 5 for L or 5 ng / mL or cynoIL-11
ng / mL) or about 1 ng / mL to about 5 ng / mL for mIL-11 (eg, ng / mL)
In the presence of 1 ng / mL or 3 ng / mL or 5 ng / mL)) and test IL-
It is cultured in the presence or absence of 11Rα-binding protein. Methods for assessing cell proliferation are known in the art, including, for example, MTT reduction and / or thymidine uptake. An IL-11Rα-binding protein that reduces the level of proliferation compared to the levels found in the absence of the IL-11Rα-binding protein is considered to neutralize IL-11R signaling. _{IC 50} by examining a plurality of concentrations of IL-11Ra binding protein, i.e., the concentration at which 50% of the maximal inhibition of cell proliferation occurs is determined. 10
_{IC 50 of} μg / ml or less. In one example, the IC ₅₀ is 9 μg / ml or less. For example, the IC ₅₀ is 8 μg / ml or less. For example, the IC ₅₀ is 7 μg / ml or less. For example, the IC ₅₀ is 6 μg / ml or less. For example, the IC ₅₀ is 5 μg / ml or less. For example, the IC ₅₀ is 4 μg / ml or less. For example, the IC ₅₀ weighs 3 μg
It is less than / ml. In one embodiment, the _{IC 50} for each of the foregoing embodiments 10pg
It is / ml or more or 10 ng / ml or more.

Assays similar to those described in the preceding paragraph can be performed on B9 or T10 cells (Dams-Kozlowska et al., BMC Biotechnol, 12).
: 8, 2012; and Yokote et al., J. Mol. AOAC, 83: 1053-1057, 20
00). For assays using T10 cells, proliferation is tetrazolium compound, 4- [3
-(4-Iodophenyl) -2- (4-Nitrophenyl) -2H-5-Tetrazorio]-
It can be measured by detecting the reduction of l, 3-benzenedisulfonate (WST-1) by colorimetrically.

In a further example, the ability of the IL-11Rα binding protein to suppress IL-11-mediated erythropoiesis will be assessed. ^{For example, Lin-} CD34 ⁺ cells (eg, derived from cord blood) are contacted with IL-11 in the presence or absence of IL-11Rα binding protein. For example, the amount of erythropoiesis is determined by detecting the number of cells expressing CD235a using FACS. The IL-11Rα-binding protein that reduces the number of cells expressing CD235a compared to the number in the absence of the IL-11Rα-binding protein is I
It is considered to neutralize L-11-mediated signal transduction.

Moreover, in a further embodiment, IL-11-mediated inhibition of STAT3 phosphorylation I
Assess the capacity of the L-11Rα binding protein. For example, IL-11Rα and gp130
Cells expressing are cultured in the presence of IL-11 and in the presence or absence of IL-11Rα binding protein. The level of phosphorylation of STAT3 is then assessed by Western blotting or FACS with an antibody specific for phosphorylated STAT3. An example assay using FACS is Dams-Kozlowska et al., BMC Biotechn.
It is described in ol, 12: 8, 2012.

In another example, the ability of IL-11Rα-binding proteins to suppress IL-11-mediated proliferation of cancer cells, such as gastric cancer cells or acute myeloid leukemia (AML) cells, is assessed.
In these assays, cancer cells (eg, AGN or MKN45 gastric cancer cells) were treated with IL-1.
Incubate in the presence or absence of IL-11Rα binding protein in the presence of 1. AML
In the case of cells, the cells can also be cultured in the presence of G-CSF. Cell proliferation is then measured, for example, using standard techniques as described above and / or in the case of AML cells, by assessing the formation of L-CFU. An example assay applicable to this disclosure is
Zhang et al., Int. J. Biol. ScL, 8: 383-393, 2012 and Ki
It is included in mura et al., Leukemia, 13: 1018-1027, 1999.

Other methods for assessing the neutralization of IL-11 signaling are contemplated by the present disclosure.

Measuring Effector Function As discussed herein, some IL-11Rα binding proteins of the present disclosure have reduced effector function or have effector function (or high effector function). Methods for assessing ADCC activity are known in the art.

In one example, the level of ADCC activity is ^{assessed using a 51} Cr release assay, a Europium release assay or a ³⁵ S release assay. In each of these assays, I
Cells expressing L-11R are cultured with one or more of the cited compounds for sufficient time and conditions for the compounds to be taken up by the cells. ^In the case of the 35 S release assay, cells expressing IL-11Rα may be cultured for sufficient time to incorporate the amino acids labeled in the newly synthesized protein along with ^{35 S labeled methionine and / or cysteine.} can. The cells are then cultured in the presence or absence of IL-11Rα binding protein and in the presence of immune effector cells such as peripheral blood mononuclear cells (PBMC) and / or NK cells. ^{Then 51} Cr, Europium and / or / or 51 Cr in cell culture medium
^{The amount of 35} S was detected and IL-11Rα compared to the absence of IL-11Rα binding protein.
A small change or no change in the presence of the binding protein indicates that the protein has reduced effector function, and a higher amount than in the absence of the IL-11Rα binding protein (
Or a larger amount than in the presence of IL-11Rα binding protein containing the IgG1 Fc region)
Indicates an effector function or a high effector function. Protein-induced A
Examples of publications disclosing assays for assessing DCC levels include Hells.
trom et al. Proc. Natl. Acad. Sci. USA, 83: 7059-706
3, 1986 and Bruggemann et al., J. Mol. Exp. Med. 166: 1351-1
361 and 1987 are mentioned.

Other assays for assessing protein-induced ADCC levels include the ACTI ™ Non-Radioactive Cell Injury Assay (CellT) for Flow Cytometry.
echology, Inc. CA, USA) or CytoTox96® non-radioactive cytotoxicity assay (Promega, WI, USA).

A C1q binding assay can also be performed to confirm that the IL-11Rα binding protein can bind C1q and induce CDC. To assess complement activation, a CDC assay can be performed (eg, Gazzano-Santoro et al., J. Immunol.
Methods, 202: 163, 1996).

Determining Half-Life Some IL-11Rα-binding proteins included in the present disclosure have an improved half-life, eg, modified to extend their half-life compared to unmodified IL-11Rα-binding proteins. Will be done. Methods for determining IL-11Rα-binding proteins with improved half-lives will be apparent to those of skill in the art. For example, I that binds to the neonatal Fc receptor (FcRn)
The ability of the L-11Rα binding protein is assessed. In this regard, increased binding affinity for FcRn increases the serum half-life of IL-11Rα binding proteins (eg, Kim).
Et al., Euro. J. Immunol. , 24: 2429, 1994).

The half-life of the IL-11Rα-binding protein of the present disclosure is described, for example, by Kim et al., Eur. J
.. Immunol. , 24: 542, can also be measured by pharmacokinetic studies according to the method described in 1994. According to this method, radiolabeled IL-11Rα
Mice are injected intravenously with the binding protein and their plasma concentration is measured periodically, for example, 3 minutes to 72 hours after injection, as a function of time. The resulting clearance curve is biphasic,
That is, it should be α phase and β phase. For measuring the in vivo half-life of proteins,
The β-phase clearance rate is calculated and compared to that of wild-type or unmodified protein.

Assessing Therapeutic Efficacy An assay for assessing therapeutic efficacy in connection with measuring neutralization with IL-11Rα binding protein is described above.

In another example, an in vivo assay is used to assess the effectiveness of a protein that treats a disease.

For example, examine the IL-11Rα binding protein in an animal model of arthritis. An example model is the mouse SKG strain (Sakaguchi et al., Nature, 426: 454-
460), rat type II collagen arthritis model, mouse type II collagen arthritis model, or antigen-induced arthritis model in some species (Bendele, J. Mus)
culoskel Neuron Interact; 1 (4): 377-385, 20
01) can be mentioned. In these assays, arthritis is induced and IL-11R reduces one or more symptoms of arthritis, eg, inflammation markers in joint inflammation and / or synovial fluid.
The ability of sigma-bonded proteins is assessed. IL-11Rα-binding proteins that reduce the symptoms of arthritis are considered useful in treating this disease or IL-11-mediated disease (eg, IL-11-mediated inflammatory disease).

The IL-11Rα binding protein can also or instead be examined in a model of COPD where, for example, non-human mammals (eg, rodents such as mice) are exposed to tobacco smoke. Following exposure, mammals are administered IL-11Rα binding protein and standard techniques are used to assess or estimate the level of lung inflammation and / or the number of neutrophils in the lung. IL-11Rα-binding proteins that reduce lung inflammation and / or the number of neutrophils can be used in lung inflammation or COPD or IL-11-mediated diseases such as IL-11-mediated inflammatory lung disease. It is considered useful for treating IL-11-mediated inflammatory diseases).

The IL-11Rα binding protein can also or instead be examined in Th2-type inflammatory diseases such as, for example, asthma or airway hypersensitivity. Examples of models of allergic asthma include, for example, Wang et al., J. Mol. Immunol. It is an OVA model of a mouse as described in 165: 2222, 2000. Following induction of inflammation, mice are administered IL-11Rα binding protein to assess asthma symptoms such as eosinophil count, mucus secretion and / or goblet cell hyperplasia in bronchoalveolar lavage fluid (BAL). do. Other models of asthma are known in the art, such as sheep models of inflammatory asthma as described in WO 2002/098216, eg mice of allergic asthma induced by host house dust mite proteins. Model (Fattouh et al., Am.J.Respir.Crit
.. Care Med. 172: 314-321, 2005), a mouse model of severe asthma overexpressing IL-5 and eotaxin, or an intraairway infusion of poly-l-lysine, which is hypersensitive to metacholine when delivered with an aerosol. Mice (Homma et al., Am. J.
Physiol. Lung Cell Mol. Physiol. 289: L413-L
418, 2005).

The IL-11Rα binding protein can be further or instead examined in a model of cancer, eg, gastric cancer. For example, mice homologous to the Y757F mutant of gp130 (
gpl30 ^{Y757F / Y757F} ) develops gastric tumors (Jenkins et al., Blood
d, 109: 2380-2388, 2007). Mice (eg, 8 weeks old) IL-1
Treat with 1Rα binding protein and assess the number and weight of gastric polyps. IL-11Rα binding proteins that reduce the size and / or weight of polyps are considered useful in treating cancer. A similar assay can be used to investigate the effect on colon cancer, I
Prior to treatment with L-11Rα binding protein, Greten et al. (Cell, 118)
: 285-296, 2004) essentially as described by gpl30 ^{Y757F
/ Y757F} mice are treated with azoxymethane (AOM) and then with sodium dextran sulfate to induce colon cancer.

The IL-11Rα binding protein is further or instead, for example, Li et al., Oncol.
.. Lett. It can be examined in a model of cancer metastasis or cancer-related bone disease as described in 3: 802-806, 2012.

Diseases Treated The present disclosure contemplates the treatment or prevention of any disease caused or exacerbated by IL-11 in a subject.

In one example, the disease is an autoimmune or inflammatory disease.

In one example, the autoimmune disease is, for example, an autoimmune joint disease such as inflammatory arthritis, rheumatoid arthritis or idiopathic arthritis, eg, juvenile idiopathic arthritis. In one example, the disease is rheumatoid arthritis.

In one example, the autoimmune disease is an autoimmune colorectal disease, such as, for example, an inflammatory bowel disease such as ulcerative colitis or Crohn's disease.

In one example, the autoimmune disease is an autoimmune skin disease, such as psoriasis.

In one example, the inflammatory disease is an inflammatory lung disease, such as a lung disease associated with neutrophil infiltration. For example, the disease is asthma, chronic obstructive pulmonary disease (COPD), rhinitis or allergy. In one example, the disease is asthma.

Other examples of inflammatory diseases include infection-induced inflammation (eg, tuberculosis-induced inflammation), gastric inflammation (eg, associated with gastric cancer), or inflammatory dermatitis (eg, gastric cancer-related).
Atopic dermatitis).

In one example, the disease is a debilitating disease such as cachexia or sarcopenia. In one example, the debilitating illness is cachexia. For example, cachexia can be rheumatoid arthritis, diabetes, heart disease, chronic kidney disease, chronic lung inflammation, intestinal inflammation, inflammatory colon disease, aging, sepsis or A.
It is associated with or caused by a disease selected from the IDS. In one example, cachexia is associated with or is caused by cancer.

In one example, the disease is a bone disease, which results from, for example, inadequate bone formation and / or excessive bone catabolism. Examples of bone disorders include osteoporosis (including postmenopausal osteoporosis), fractures, bone resorption / damage caused by cancer (metastatic bone cancer, myeloma, Paget's disease of bone), and treatment of cancer (eg, treatment of cancer). Bone resorption / damage caused by chemotherapy, hormone removal or hormone inhibition).

In one example, the disease is cancer. Examples of cancers include hematologic cancers, epithelial cancers, gastric cancers, pancreatic cancers, liver cancers, osteosarcomas, endometrial cancers and ovarian cancers.

In one example, the subject is resistant to treatment with another compound that treats the disease, does not respond properly, or is unsuitable. For example, subjects suffering from autoimmune or inflammatory diseases are corticosteroids and / or immunosuppressants and / or cyclophosphamide and / or methotrexate and / or anti-TNF antibodies or soluble TNF receptors and / or Anti-CD20
Resistant to treatment with antibodies and / or anti-IL-6 and / or anti-CD22 antibodies, does not respond properly, or is not suitable.

Composition In some examples, the IL-11Rα-binding protein as described herein is in a conventional non-toxic, pharmaceutically acceptable carrier-containing dosage form or in any other easy-to-use dosage form. Orally, parenterally, by inhalation spray, absorption, and adsorption, topically, intrarectally, intranasally, intratumorally, intravaginally, intraventricularly, via an implantable reservoir. The term "parenteral" as used herein, subcutaneously, intravenously, intramuscularly, intraperitoneally, subarachnoid, intraventricularly,
Includes intrasternal and intracranial injection and infusion techniques.

Suitable forms for administration of IL-11Rα binding protein to a subject (eg, pharmaceutical composition)
The method of preparation is known in the art, for example, Remington's Pharma.
Cecutical Sciences (18th Edition, Mack Publishing C)
o. , Easton, Pa. , 1990) and United States Pharmacopeia: National Drug Collection (Mack)
Publishing Company, Easton, Pa. , 1984).

The pharmaceutical compositions of the present disclosure are particularly useful for parenteral administration, such as intravenous administration or administration into the body or lumen of an organ or joint. Compositions for administration generally include a pharmaceutically acceptable carrier, eg, a solution of IL-11Rα binding protein dissolved in an aqueous carrier. Various aqueous carriers such as buffered saline can be used. The composition is a pharmacy such as a pH regulator and buffer, a toxicity regulator, etc., as required to approach physiological conditions such as, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc. Can contain acceptable auxiliary substances. The concentration of IL-11Rα-binding protein of the present disclosure in these formulations can vary widely and is selected primarily on the basis of the particular method of administration selected and the fluid volume, viscosity, body weight, etc. according to the patient's needs. Will be. Examples of carriers include water, saline, Ringer solution, dextrose solution and 5% human serum albumin. Non-aqueous media such as mixed oils and ethyl oleate can also be used. Liposomes can also be used as carriers. The medium may contain small amounts of additives such as buffers and preservatives that enhance isotonicity and chemical stability.

Once formulated, the IL-11Rα-binding protein of the present disclosure will be administered in an amount that is therapeutically / prophylactically effective in a manner compatible with the dosing formulation. The formulation is readily administered in various dosage forms, such as, for example, the forms of solution for injection described above, but for other pharmaceutically acceptable forms, such as tablets, pills, capsules, or oral administration. Other solids, suppositories, pessaries, intranasal solutions or sprays, aerosols, inhalants, liposome forms and the like are also contemplated. Pharmaceutically "sustained release" capsules or compositions may also be used. Sustained release formulations are generally designed to provide constant drug levels over a long period of time and can be used to deliver the IL-11Rα binding proteins of the present disclosure.

WO 2002/08967 also describes administration of sprayed compositions and compositions comprising antibodies for the treatment of asthma, which are also suitable for administration of the IL-11Rα binding proteins of the present disclosure. doing.

Combination Therapy In one example, the IL-11Rα binding proteins of the present disclosure are used to treat the diseases described herein either as either a combination treatment step or an additional treatment step or as an additional component of a therapeutic formulation. It is administered in combination with another useful compound.

For example, the other compound is an anti-inflammatory compound. Alternatively or further, another compound thereof is an immunosuppressant. Alternatively or further, another compound thereof is, for example, a corticosteroid such as prednisone and / or prednisolone. Instead or even
The other compound is methotrexate. Alternatively or further, another compound thereof is cyclophosphamide. Alternatively or further, another compound thereof is mycophenolate mofetil. Alternatively or in addition, another compound thereof is an anti-CD20 antibody (eg, rituximab or ofatumumab). Alternatively or further, the other compound is anti-CD2
Two antibodies (eg, epratuzumab). Alternatively or in addition, another compound thereof is an anti-TNF antibody (eg, infliximab or adalimumab or golimumab) or a soluble TNF receptor (eg, etanercept). Alternatively or in addition, another compound thereof is a CTLA-4 antagonist (eg, abatacept, CTLA4-Ig). Alternatively or further, another compound thereof is an anti-IL-6 antibody. Alternatively or further, another compound thereof is a BLys antagonist, such as, for example, an anti-BLys antibody (eg, belimumab).

In another embodiment, the other compound is a chemotherapeutic agent or other agent used to treat cancer.

In another example, the proteins described herein are administered before or after radiation therapy for the treatment of cancer.

Dosage and Timing of Administration Suitable doses of the IL-11Rα binding proteins of the present disclosure will vary depending on the particular IL-11Rα binding protein, the disease being treated and / or the subject being treated. For example, it is within the competence of a skilled physician to determine a suitable dose by starting with a suboptimal dose and gradually changing the dose to determine the optimal or useful dose. Is. Alternatively, using the data derived from the cell culture assays or animal studies to determine the dosage suitable for the treatment / prophylaxis, including the time, a suitable dose will ED ₅₀ of little or no active compound is toxic circulation It is within the range of the concentration to be used. The dosage can vary within this range depending on the dosage form adopted and the route of administration utilized. Therapeutically / prophylactically effective doses can be initially estimated from the cell culture assay. Prescribe a dose in animal models, IC 50 as determined in cell culture _(i.e., the concentration or amount of compound which achieves a half-maximal inhibition of symptoms) to achieve a range of plasma concentrations circulating containing. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by fast liquid chromatography.

In some examples, the methods of the present disclosure include administering a prophylactically or therapeutically effective amount of a protein described herein.

The term "therapeutically effective amount" is used when administered to a subject in need of treatment, subject prognosis and /
Or ameliorate the condition and / or reduce or suppress one or more symptoms of the condition described herein to a level below what is recognized or accepted as a clinical diagnosis or clinical feature of the condition. The amount. The amount administered to the subject is a particular feature of the disease being treated,
It will depend on the type and stage of the disease being treated, the method of administration, and the characteristics of the subject such as general condition, other diseases, age, gender, genotype and body weight. One of ordinary skill in the art will be able to determine the appropriate dosage depending on these factors and other factors. Therefore, the term should not be construed to limit this disclosure to a particular amount, eg, the weight or amount of protein, rather the disclosure is sufficient to achieve the results referred to in the subject. IL
Includes any amount of -11Rα binding protein.

As used herein, the term "preventively effective amount" is meant to mean an amount of protein sufficient to prevent, suppress or delay the onset of one or more detectable symptoms of a condition. Should be interpreted. Skilled experts, such amounts are administered, for example, I
You will notice that the L-11Rα binding protein and / or the specific subject and / or the type or severity or level of the disease and / or the predisposition to the disease (genetic or otherwise) will vary. Therefore, the term should not be construed to limit this disclosure to a particular amount, eg, the weight or amount of protein, rather the disclosure is sufficient to achieve the results referred to in the subject. Includes any amount of IL-11Rα binding protein.

For in vivo administration of the IL-11Rα binding proteins described herein, normal doses can vary from about 10 ng / kg above the body weight of the individual to about 100 mg / kg per day. For repeated doses over several days, depending on the severity of the disease or disorder being treated, treatment can be sustained until the desired suppression of symptoms is achieved.

In some examples, the IL-11Rα binding protein is from about 1 mg / kg to about 30 mg / kg.
Between kg, for example, from about 1 mg / kg to about 10 mg / kg, or about 1 mg / kg or about 2
It is administered at the initial (or loading) dose of mg / kg or 5 mg / kg. Then IL-11R
The α-binding protein is between about 0.0 lmg / kg and 2 mg / kg, for example about 0.05.
From mg / kg to about lmg / kg, for example, about 0. From lmg / kg to about lmg / kg, for example, about 0. It can be administered at a lower maintenance dose of lmg / kg or 0.5 mg / kg or lmg / kg. The maintenance dose is every 7-30 days, for example every 10-15 days.
For example, it can be administered every 10 or 11 or 12 or 13 or 14 or 15 days.

In some examples, the IL-11Rα binding protein is from about 0.0 lmg / kg to about 50.
Between mg / kg, eg, between about 0.05 mg / kg and about 30 mg / kg, eg,
About 0. Between lmg / kg and about 20 mg / kg, for example about 0. lmg / kg ~ about l0m
Between g / kg, for example, about 0. It is administered at a dose between lmg / kg and about 2 mg / kg. For example, IL-11Rα binding protein is about 0.0 lmg / kg to about 5 mg / kg.
During, for example, about 0. lmg / kg to about 2 mg / kg, for example about 0.2 mg / kg
Alternatively, it is administered at a dose of 0.3 mg / kg or 0.5 mg / kg or lmg / kg or 1.5 mg / kg (eg, without a high loading dose or a lower maintenance dose). In some examples, multiple doses are available, eg, every 7-30 days, eg, every 10-22 days, eg, every 10-15 days, eg, 10 or 11 or 12 or 13 or 14 Or 1
It is administered every 5 or 16 or 17 or 18 or 19 or 20 or 21 or 22 days. For example, the IL-11Rα binding protein is administered every 7 days, every 14 days, or every 21 days.

In some examples, at the start of treatment, mammals are administered IL-11Rα binding protein for up to 7 consecutive days, 6 consecutive days, 5 consecutive days, or 4 consecutive days. ..

For mammals that are not responding properly to treatment, multiple doses can be administered in a week. Alternatively or in addition, increasing doses may be administered.

In another example, for mammals experiencing adverse reactions, the initial (or loading) dose may be divided over a week or multiple consecutive days.

Administration of the IL-11Rα binding protein according to the methods of the present disclosure is continuous, depending on, for example, the physiological condition of the recipient, whether the purpose of administration is therapeutic or prophylactic, and other factors known to the skilled practitioner. Can be objective or intermittent. Administration of the IL-11Rα binding protein may be essentially continuous over a preselected period of time, or may be a series of spaced dosings, eg, during or after the onset of the disease. ..

IL-11Rα Detection Assays The following assays can be performed with the IL-11Rα binding proteins of the present disclosure, eg, IL-11Rα binding proteins bound to detectable labels as discussed herein. Detection of IL-11Rα or cells expressing it by the assays described herein is useful for diagnosing disease or prognosis.

The immunoassay is an exemplary assay format for diagnosing disease in a subject or for detecting IL-11Rα and cells expressing it in a sample. The present disclosure includes Western blots, enzyme-linked immunosorbent assay (ELISA), and fluorescence-linked immunosorbent assay (FL).
For ISA), competitive assays, radioimmunoassays, lateral flow immunoassays, flow-through immunoassays, electrochemical luminescence assays, turbidimetric assay-based assays, turbidimetrically based assays, and fluorescence activated cell selection (FACS). Any form of an immunoassay, including an assay based on the assay, is contemplated.

A suitable form of immunoassay is, for example, ELISA or FLISA.

In one form, such an assay involves immobilization of the IL-11Rα binding proteins of the present disclosure on a solid matrix, such as polystyrene or polycarbonate microwells or dipsticks, membranes or glass supports (eg, glass slides). Is involved. The test sample is then brought into direct contact with the IL-11Rα binding protein to bind or capture IL-11Rα or cells expressing it in the sample. IL-11 with different epitopes following washing to remove any unbound protein in the sample
An IL-11Rα-binding protein that binds to Rα or binds to a different antigen on the cell is brought into direct contact with the captured IL-11Rα or cell. This detector protein is generally E
In the case of LISA, for example, an enzyme (eg, horseradish peroxidase (HRP),
Alkaline phosphatase (AP), or β-galactosidase), or in the case of FLISA, labeled with a detectable reporter molecule such as a fluorescent dye molecule. Alternatively, a second labeled protein that binds to the detector protein can be used. Following washing to remove any unbound protein, in the case of ELISA, for example, hydrogen peroxide, TMB or toluidine or 5-bromo-4-chloro-3-indole-β-D-galactopyranoside (x). Detectable reporter molecules by the addition of substrates such as −gal). Naturally, the immobilized (capture) protein and the detector protein can be used in the reverse manner.

The level of antigen in the sample is then determined using a calibration curve made with a known amount of marker or by comparison with a control sample.

The assays described above are readily modified to use chemiluminescence or electrochemical luminescence as the basis for detection.

Other detection methods based on immunoadsorption assays are useful in the practice of the present disclosure, as will be apparent to skilled experts. For example, a radioactive label for detection or a gold label for detection (eg,
Colloidal gold) or, for example, an immunoadsorption method based on the above description using liposomes encapsulating NAD + for detection or using an acridinium-bound immunoadsorption assay.

In some examples of the disclosure, the level of IL-11Rα or cells expressing it is a surface plasmon resonance detector (eg, BIAcore ™, GE Healthcare).
e, Piscataway, N. et al. J), eg, a flow-through device as described in US Pat. No. 7,205,159, a micro or nanoimmunoassay device (eg, as described in US Patent Application Publication No. 20130124619), a lateral flow device. (For example, U.S. Patent Application Publication No. 2004028761 or U.S. Patent Application Publication No. 200402
As described in 65926), or immunoturbidimetric assay (eg, US Pat. No. 5)
Determined using (as described in 571728 or US Pat. No. 6,248,597).

Samples and Control Samples Some of the examples described herein are IL.
It requires some quantification to determine the level of -11Rα or cells expressing it.
Such quantification can be determined by including suitable control samples in the assays of the present disclosure.

In one example, a suitable control sample is a sample derived from a healthy subject or a normal subject.

In this context, the term "healthy subject" should be construed to mean an individual known not to suffer from a disease associated with IL-11Rα, such as an inflammatory disease.

The term "normal subject" should be construed to mean an individual having normal levels of IL-11Rα or cells expressing it in a sample compared to a population of individuals.

The disclosure also contemplates a control sample as a dataset obtained from a normal and / or healthy subject or a population of normal and / or healthy subjects.

In one example, the methods of the present disclosure further include, for example, determining the level of IL-11Rα in a control sample using the methods described herein.

In one example, a sample from the subject and a control sample are assayed at about or substantially the same time.

In one example, a sample derived from a subject and a control sample are assayed using the same methods of the present disclosure as described herein in any one or more samples to allow comparison of results.

Kit This disclosure further states:
(I) The IL-11Rα-binding protein of the present disclosure or an expression construct encoding the same;
(Ii) the cells of the present disclosure; or (iii) a kit containing one or more of the pharmaceutical compositions of the present disclosure.

In the case of a kit for detecting IL-11Rα, the kit can further include, for example, a detection means linked to the IL-11Rα binding protein of the present disclosure.

For kits for therapeutic / prophylactic use, the kit can further include a pharmaceutically acceptable carrier.

Optionally, the kits of the present disclosure are packaged with instructions for use in the methods described herein according to any example.

The present disclosure includes the following non-limiting examples.

Non-limiting Examples Materials and Methods Phagemid Display Antibodies specific for human IL-11Rα were isolated from the human Fab-phagemid antibody library. Immobilized hIL-11Rα-Fc in the presence of wild-type hIL-11 or hIL-11 mutant proteins (R & D Systems Catalog No. 1977-MR)
The phage that binds to was eluted. A large number of positive clones (confirmed by Phagemid ELISA) were reconfigured with human IgG4 antibody.

IL-11 Responsive Cell Proliferation Assay The ability of antibodies to block the biological activity of IL-11 was examined using BaF3 cell lines that are reactive to hIL-11, cinoIL-11 and mIL-11. BaF reactive to mIL-11
The three cell lines are described in WO 2009/052588.

In BaF3 cell lines reactive with hIL-11 and cynoIL-11, wild-type human and cynomolgus monkey IL-11Rα and human gp130 and cynomolgus monkey g, respectively.
Stable transfection was performed with the construct encoding p130. hIL-11 or cynoIL-
Cells were selected by proliferation in medium containing 11 and cloned cell lines were derived by limiting dilution cloning. A large number of stably transfected clones were analyzed for their dose-responsive growth (using a thymidine uptake assay) when cultured in the presence of hIL-11 or cynoIL-11. One hIL-11 reactive clone and cy
One noIL-11 reactive clone was selected for antibody analysis.

IL-11 (hIL-11: 0.) With a total volume of 200 μL / well and a concentration lower than the maximum value.
3 ng / mL or 0.5 ng / mL or 5 ng / mL; mIL-11: 1 ng / mL, 3
ng / mL or 5 ng / mL; cynoIL-11: 0.5 ng / mL or 5 ng / mL
) And increasing concentrations of the purified monoclonal antibody or hIL-11 mutant protein (containing SEQ ID NO: 110 and having an N-terminal hexaHis tag) RPMI / 10%
IL-11-reactive BaF3 cells were seeded ^{at approximately 1 × 10 4} cells / well in a 96-well plate at FCS / Glutamax / PenStrep. Prior to the addition of cytokines, cells were cultured for 30 minutes in the presence of antibody or initially hIL-11 mutant protein. The cells were approximately 48 to 50 hours at 37 ° C., was applied last 6 hours of ^culture, the 3 H- thymidine. Cells were harvested on a fiberglass filter and the level of radioactive thymidine incorporated into the DNA was measured by liquid scintillation counting. The assay was performed in pairs and then the mean at each assay point was plotted.

Affinity maturation of antibody 8E2 Affinity maturation of antibody 8E2 was performed using the following method. The sequence encoding the _{V H} and _{V L} of 8E2 inserted into a construct phagemid, to encode germlined the Fab, CDR
A germline stop template was created by replacing 18 codons (6 amino acid residues) in all CDRs except -L2 with TAA stop codons. Sidhu et al., (Metho)
The library was constructed using a method essentially as described by ds in Enzymeology: 238: 333-336, 2000). Kunkel mutagenesis method (K
unkel et al., Methods in Enzymology: 154: 367-38
Using each stop template as a template for 2,1987), the mutagenic oligonucleotide was designed to simultaneously repair the stop codon and introduce the mutation at the planned site. The mutagenesis reactant was introduced into E. coli by electroporation and phage production was initiated by the addition of helper phage. After overnight growth at 30 ° C., phages were harvested by precipitation with PEG / NaCl.

The library reduced the concentration of biotinylated polypeptide containing SEQ ID NO: 3 and circulated through several selections. The target concentration was reduced 10-fold each time.

Binding of Antibodies to Domain-Exchanged IL-11R Variant polypeptides Various soluble forms of IL-11R containing the regions of hIL-11R and mIL-11R were made, which are shown in SEQ ID NOs: 3 and 86-90. The binding of antibodies 8E2, 8D10 and 8E4 to these polypeptides was measured using Western blot or Biacore analysis.

For Biacore analysis, anti-human IgG was immobilized on the sensor surface at about 10,000-12,000 RU and 0.2 μg / mL-0.5 μg / for 120 seconds per cycle.
Each antibody was captured between mL. The IL-11 receptor was injected into the capture antibody at various concentrations ranging from 1 μM to 2.5 nM, including injection of a buffer blank. Meetings were monitored for 3-5 minutes and dissociation was monitored for 3-10 minutes. Approximate affinity was determined by fitting the coupling curve of each interaction to a 1: 1 dynamic model.

Antibody binding of soluble hIL-11R to a point mutant The amino acid derived from mIL-11 was added to hIL-11 (SEQ ID NO: 85) (eg, for the location of the mutation relative to SEQ ID NO: 1 and to the SEQ ID NO: of each polypeptide. Various point mutants of the soluble form of IL-11R introduced into the soluble form of (see Table 5 for reference) were created and these polypeptides or SEQ ID NOs: 3 were used by Biacore analysis or FACS.
Alternatively, the binding of the antibody to the polypeptide of SEQ ID NO: 85 was measured.

Antibodies specific for anti-human IgG Fc were chemically immobilized on CM5 chips up to about 9000 RU. Antibodies were captured at approximately 0.3-1 μg / mL for 120 seconds at 2 spots in each flow cell. Adjacent spots consisting only of anti-human IgG were used as a reference. The IL-11 receptor was injected into the capture antibody and reference spot at 40, 10, 5 and 2.5 nM in pairs. Blank injection of buffer solution only was also performed in pairs. The injection was performed for 3 minutes and dissociation was monitored for an additional 5 minutes.

The binding curve was dereferenced prior to fitting to the 1: 1 dynamic model and the buffer was blanked.

Antibody-mediated inhibition of IL-11 signaling in cancer cells DLD-1 cells (colon-rectal cancer cell line) and MKN-28 cells (gastric cancer cell line) were stimulated with increasing concentrations of hIL-11 for 15 minutes. Alternatively, cells were incubated in the presence of increasing concentrations of 8E2 anti-IL-11R or BM4 isotype control antibody prior to stimulation with hIL-11 (50 ng / mL). Cells were immobilized, permeabilized and stained with PE-conjugated anti-phospho STAT3 antibody. Cells were analyzed by flow cytometry. The assay was performed in pairs.

Antibody isolation and property analysis IL-11 of BaF3 cells transfected with three antibodies 8E2, 8D10 and 8E4
It was isolated from the Fab-Phagemid antibody library based on its ability to inhibit dependent growth. 8E4 also inhibited mouse IL-11-dependent proliferation of BaF3 cells.

8E2, 8D10 and 8E4 bound to cells transfected with hIL-11Rα or cynoIL-11Rα. 8E4 bound to cells transfected with mIL-11Rα, but 8
E2 and 8D10 did not bind.

Of the three antibodies, 8E2 had the best thermal stability when evaluated by differential scanning calorimetry (69.8 compared to 63.2 ° C to 71.4 ° C for 8D10 and 8E4).
It has a Tm between ° C. and 76.6 ° C.).

8E2 was selected for affinity maturation. C mutated using heavy and light chain libraries
Clone with DR was generated (FIGS. 1, 2 and 3). The binding of 62 of these affinity variants to hIL-11R was assessed by Biacore and BaF3 cells hIL-11.
The relative ability to inhibit growth induced by is measured. The results are shown in Table 3.

Affinity maturation of 10 based on improved ability to inhibit hIL-11-induced proliferation in BaF3 cells compared to 8E2, 8D10 and 8E4 and improved affinity for human IL-11Rα compared to 8E2. Antibodies (TS-306, TS-2, TS-4, T
S-7, TS-14, TS-51, TS-101, TS-108, TS-134 and TS
-136) was selected. The sequence of CDR was also considered in selecting these affinity matured antibodies. Several clones with CDR sequences close to or identical to the relevant consensus sequence were selected.

These antibodies were examined for IL-11-induced growth inhibition of human, cynomolgus monkey and / or mouse IL-11R-transfected BaF3 cells of human, cynomolgus monkey or mouse. Binding of human and cynomolgus monkeys to cells transfected with IL-11R and measurement of average fluorescence intensity by flow cytometry were also performed. Compared to the 8E2 parental clone, each of the selected clones more strongly inhibited hIL-11 and cynoIL-11-induced proliferation and bound to human and cynomolgus monkey IL-11R with greater affinity.

Comparison of antagonism between hIL-11 mutant protein and antibody Using the above assay using BaF3 cell line transfected with human IL-11R and nucleic acid encoding human gp130 and 0.3 ng / ml human IL-11. The antagonistic activity of some antibodies was compared with that of the hIL-11 mutant protein (containing SEQ ID NO: 110 and having an N-terminal hexaHis tag). The results are presented in Table 4.

The data presented in Table 4 show that all examined antibodies more effectively inhibit IL-11 signaling than hIL-11 mutant proteins. Because of a large difference in molecular weight between the mutein and antibodies, IC ₅₀ values are expressed in nM.

Epitope mapping Competitive ELISA and Biacore data show that 8E2, 8E4 and 8D10 are hIL-
It is shown that they compete with each other for binding to 11α and that they can recognize the same region of hIL-11Rα.

Biacore data for domain exchange (mouse / human) shows that binding of 8E2 and 8D10 requires at least amino acids 111-215 (Fn type 3 domain 1) of hIL-11Rα (SEQ ID NO: 1), and mice in this region. Replacing the sequence of with a human sequence is 8
It was shown to reduce the affinity of E4 binding (Table 5).

Table 5 results presented in the "strong bond" to see about 10nM or less of affinities (K _D)
Point to. Reference to a "weak coupling" refers to about 50nM or more of affinities _{(K D).}

By replacing the native human amino acid with the corresponding mouse amino acid residue, 28 constructs with a single amino acid substitution were made in the region covering both the Ig-like domain of hIL-11Rα and the fibronectin type 3 domain 1. .. Truncated hIL-11
Five variants of R (SEQ ID NO: 85) (P65S, K66R, L101S, V117E, A
178S) was expressed and purified (numbering for the amino acid position of SEQ ID NO: 1). Cells were transfected with the corresponding constructs, which were then stained with 8E2, 8E4 and 8D10. Flow cytometry showed that 8E2 and 8E10 binding was reduced in V117E-transfected cells.

Flow cytometric data were confirmed by Biacore. Biacore
All sensorgram 1: was well adapted to the first binding model, to provide the derived K _D values in Table 6.

At the concentrations used in this assay, the V117E mutant did not bind to 8E2 and 8D10.
K _D of this interaction could not be determined. This residue contributes to the binding interaction of these two antibodies.

Mutations in K66R are WT D1 / 2 (SEQ ID NO: 85) for antibodies 8E2 and 8D10.
The fact that resulted in a decrease K _D of just over twice when compared, show some involvement of this residue in the antibody binding.

Mutants V117E and K66R also bound antibody 8E4 with significantly lower affinity than WT D1 / 2 (SEQ ID NO: 85). These residues can contribute to the binding interaction of antibody 8E4 with hIL-11Rα.

ANOVA and Tukey's multiple comparison tests showed significant (p <0.0) against WT D1 / 2 (SEQ ID NO: 85) for all antibodies examined for both V95E and K44R affinities.
5) It was shown to be different.

The fact that all of the mutant forms of IL-11R examined in this example were able to bind to IL-11 means that the mutation did not induce a substantial change in conformation at the receptor. Is shown.

Comparative Data Non-neutralizing anti-IL-11R antibody (4D12; antibody marketed from Santa Cruz) was shown to bind to human IL-11Rα by ELISA. 4D12 has been shown to bind to BaF3 cells transfected with human IL-11Rα and mouse IL-11.
It was shown to bind Rα to 293 cells transfected.

4D12 did not neutralize human or mouse IL-11-induced cell proliferation in BaF3 cells incubated with 0.5 ng / ml hIL-11 or 3 ng / ml mIL-11R.

8D10 or 8E for binding of 4D12 to IL-11Rα using competing ELISA
It was shown that it does not conflict with 2.

Anti-IL-11R antibody inhibits IL-11 signaling in cancer cells IL-11 phosphorylates STAT-3 in DLD-1 colon cancer cells and MKN-28 gastric cancer cells, as shown in FIG. To induce. FIG. 4 also shows that antibody 8E2 inhibits STAT-3 phosphorylation in these cells, whereas isotype control antibody does not.

The present invention includes the following embodiments.
[1] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα to neutralize IL-11 signal transduction and the antigen. The IL-11Rα binding protein, wherein the binding domain is capable of binding to hIL-11R and cynoIL-11Rα.
[2] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα, neutralizes IL-11 signal transduction, and causes the protein. Is an IL-11Rα-binding protein that inhibits IL-11-mediated proliferation of BaF3 cells expressing IL-11Rα and gp130 at IC _{50 of 10 μg / ml or less.}
[3] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα, neutralizes the signal transduction of IL-11, and causes the IL. The IL-11Rα binding protein, wherein the level of binding of the -11Rα binding protein to the polypeptide of SEQ ID NO: 86 or 89 is lower than the level of binding of the IL-11Rα binding protein to the polypeptide of SEQ ID NO: 3 and / or 85. ..
[4] The IL-11Rα-binding protein according to [3] above, wherein the protein does not detectably bind to the polypeptide of SEQ ID NO: 86 or 89.
[5] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα, neutralizes IL-11 signal transduction, and the antigen. The IL-11Rα binding protein, wherein the binding domain binds to an epitope containing a residue in the first fibronectin III domain of IL-11Rα.
[6] The IL-11Rα-binding protein according to the above [5], wherein the epitope contains an immunoglobulin-like domain of IL-11Rα and a residue in the first fibronectin III domain.
[7] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds to or specifically binds to IL-11Rα, neutralizes IL-11 signaling, and causes the protein. With antibody 8E2 (including a heavy chain containing the sequence set forth in SEQ ID NO: 83 and a light chain containing the sequence set forth in SEQ ID NO: 84) and / or a heavy chain containing the sequence set forth in SEQ ID NO: 92 and SEQ ID NO: 91. SEQ ID NO: 3 and / or antibody 8E4 and / or antibody 8D10 (containing a heavy chain containing the sequence set forth in SEQ ID NO: 94 and a light chain containing the sequence set forth in SEQ ID NO: 93) containing the light chain containing the sequence shown. Alternatively, the IL-11Rα binding protein that competitively inhibits binding to 85 polypeptides.
[8] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα, neutralizes the signal transduction of IL-11, and causes the IL. The IL-11Rα-binding protein, wherein the level of binding of the -11Rα-binding protein to the polypeptide of SEQ ID NO: 95 is lower than the level of binding of the IL-11Rα-binding protein to the polypeptide of SEQ ID NO: 85.
[9] Antibody 8E2 (including a heavy chain containing the sequence set forth in SEQ ID NO: 83 and a light chain containing the sequence set forth in SEQ ID NO: 84) and / or a heavy chain containing the sequence set forth in SEQ ID NO: 92 and SEQ ID NO: SEQ ID NO: 3 of antibody 8E4 and / or antibody 8D10 (containing a heavy chain containing the sequence set forth in SEQ ID NO: 94 and a light chain containing the sequence set forth in SEQ ID NO: 93) and / or antibody 8E4 containing the sequence set forth in 91. And / or the IL-11Rα-binding protein according to [8] above, which competitively inhibits binding to a polypeptide of 85.
[10] The antigen-binding domain
(I) The polypeptide of SEQ ID NO: 97 and / or
(Ii) The polypeptide of SEQ ID NO: 98 and / or
(Iii) Polypeptide of SEQ ID NO: 99
The IL-11Rα-binding protein according to the above [8] or [9], which cross-reacts with.
[11] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα to neutralize IL-11 signal transduction and the antigen. The binding domain is
(I) Between amino acids 50-66 of SEQ ID NO: 37 and Complementary Determination Region (CDR) 1 containing a sequence that is at least about 40% identical to the sequence shown between amino acids 31-35 of SEQ ID NO: 37. CDR2 containing a sequence that is at least about 76% identical to the sequence represented by, and CDR3 containing a sequence that is at least about 55% identical to the sequence shown between amino acids 99-107 of SEQ ID NO: 37. Including V _H ;
_{(Ii) A VH} comprising a sequence that is at least about 95% or 96% or 97% or 98% or 99% identical to the sequence set forth in SEQ ID NO: 37 ;
(Iii) CDR1 containing a sequence that is at least about 45% identical to the sequence shown between amino acids 24-34 of SEQ ID NO: 5 and CDR2 containing the sequence shown between amino acids 50-56 of SEQ ID NO: 5. When, _V and a CDR3 comprising the sequence at least about 44% identical to the sequence given between amino acids 89-97 of SEQ ID NO: 5 L;
_{(Iv) A VL} containing a sequence that is at least about 94% identical to the sequence set forth in SEQ ID NO: 5 .
(V) CDR1 containing the sequence shown between amino acids 31-35 of SEQ ID NO: 74, CDR2 containing the sequence shown between amino acids 50-66 of SEQ ID NO: 74, and amino acids 99-115 of SEQ ID NO: 74. _VH containing CDR3 containing the sequences shown between ;
_{(Vi) VH} containing the sequence set forth in SEQ ID NO: 74 ;
(Vii) CDR1 containing the sequence shown between amino acids 23-36 of SEQ ID NO: 73, CDR2 containing the sequence shown between amino acids 52-58 of SEQ ID NO: 73, and amino acids 91-101 of SEQ ID NO: 73. _VL containing CDR3 containing the sequences shown between ;
_{(Viii) VL} containing the sequence represented by SEQ ID NO: 73 ;
(Ix) CDR1 containing the sequence shown between amino acids 31 to 35 of SEQ ID NO: 76, CDR2 containing the sequence shown between amino acids 50 to 66 of SEQ ID NO: 76, and amino acids 99 to 107 of SEQ ID NO: 76. _VH containing CDR3 containing the sequences shown between ;
_{(X) VH} containing the sequence shown in SEQ ID NO: 76 ;
(Xi) CDR1 containing the sequence shown between amino acids 24-34 of SEQ ID NO: 75, CDR2 containing the sequence shown between amino acids 50-57 of SEQ ID NO: 75, and amino acids 89-97 of SEQ ID NO: 75. _VL containing CDR3 containing the sequences shown between ;
_{(Xii) VL} containing the sequence represented by SEQ ID NO: 75 ;
_{(Xiii) V H represented} by (i) and _{VL represented} by (iii) ;
_{(Xiv) V H} indicated by (i) and _{V L} indicated by (iv) ;
_{(Xv) V H represented} by (ii) and _{VL represented} by (iii) ;
_{(Xvi) V H} indicated by (ii) and _{V L} indicated by (iv) ;
_{(Xvii) V H represented} by (v) and _{VL represented} by (vii) ;
_{(Xviii) V H represented} by (v) and _{VL represented} by (viii) ;
_V represented by a _{V H} represented by (xix) (vi) (vii ) L;
_{V H represented} by (xx) (vi) and _{VL represented} by (viii) ;
_{(Xxi) V H represented} by (ix) and _{V L represented} by (xi) ;
_{(Xxi) V H represented} by (ix) and _{VL represented} by (xii) ;
_{(Xxiii) V H represented} by (x) and _{VL represented} by (xi) ; or
_{(Xxiv) V H represented} by (x) and _{VL represented} by (xii) ;
The IL-11Rα binding protein comprising at least one of the above.
[12] The antigen-binding domain is
(I) _{V L} comprises the sequence given in _{V H} and SEQ ID NO: 35 comprising the sequence set forth in SEQ ID NO: 71; or
(Ii) _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 36 comprising the sequence set forth in SEQ ID NO: 72; according to [112] including IL-11Ra binding protein.
[13] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα to neutralize IL-11 signal transduction and the antigen. The binding domain is
(I) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (ii) SEQ ID NO: 37 L;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 38 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (iv) SEQ ID NO: 38 L;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 39 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (vi) SEQ ID NO: 39 L;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 40 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 40 L;
(Ix) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 41 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (x) SEQ ID NO: 41 L;
(Xi) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 42 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xii) SEQ ID NO: 42 L;
(Xiii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 43 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xiv) SEQ ID NO: 43 L;
(Xv) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 44 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xvi) SEQ ID NO: 44 L;
(Xvii) including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 5 CDR1,2 and 3 comprising the sequences shown in SEQ ID NO: 45 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xviii) SEQ ID NO: 45 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xix) SEQ ID NO: 46 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xx) SEQ ID NO: 46 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxi) SEQ ID NO: 47 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxii) SEQ ID NO: 47 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxiii) SEQ ID NO: 48 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxiv) SEQ ID NO: 48 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxv) SEQ ID NO: 49 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxvi) SEQ ID NO: 49 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxvii) SEQ ID NO: 50 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xxviii) SEQ ID NO: 50 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxix) SEQ ID NO: 51 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxx) SEQ ID NO: 51 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxxi) SEQ ID NO: 52 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxii) SEQ ID NO: 52 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxxiii) SEQ ID NO: 53 V _{L;
(Xxxx) V H} containing the sequence represented by SEQ ID NO: 53 and _VL containing the sequence represented by SEQ ID NO: 5 .
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxxv) SEQ ID NO: 54 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xxxvi) SEQ ID NO: 54 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxxvii) SEQ ID NO: 55 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence set forth in (xxxviii) SEQ ID NO: 55 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xxxix) SEQ ID NO: 56 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xl) SEQ ID NO: 56 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xli) SEQ ID NO: 57 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlii) SEQ ID NO: 57 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xliii) SEQ ID NO: 58 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xliv) SEQ ID NO: 58 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xlv) SEQ ID NO: 59 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlvi) SEQ ID NO: 59 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xlvii) SEQ ID NO: 60 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (xlviii) SEQ ID NO: 60 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (xlix) SEQ ID NO: 61 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (l) SEQ ID NO: 61 L;
(Li) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 62 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lii) SEQ ID NO: 62 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (liii) SEQ ID NO: 63 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (liv) SEQ ID NO: 63 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lv) SEQ ID NO: 64 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lvi) SEQ ID NO: 64 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lvii) SEQ ID NO: 65 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lviii) SEQ ID NO: 65 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lix) SEQ ID NO: 66 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lx) SEQ ID NO: 66 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lxi) SEQ ID NO: 67 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXII) SEQ ID NO: 67 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (LXIII) SEQ ID NO: 68 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXIV) SEQ ID NO: 68 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (LXV) SEQ ID NO: 69 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXVI) SEQ ID NO: 69 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (LXVII) SEQ ID NO: 70 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (LXVIII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 5 containing a CDR1,2 and 3 of the sequence shown in (lxix) SEQ ID NO: 70 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (lxx) SEQ ID NO: 70 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 6 CDR1,2 and 3 comprising the sequence represented by (Ixxi) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 6 comprising the sequence represented by (LXXII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 7 containing CDR1,2 and 3 of the sequence shown in (LXXIII) SEQ ID NO: 37 V _{L;
(Lxxiv) V H} containing the sequence set forth in SEQ ID NO: 37 and _VL containing the sequence set forth in SEQ ID NO: 7 .
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 8 CDR1,2 and 3 comprising the sequence represented by (LXXV) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 8 comprising the sequence given in (LXXVI) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 9 CDR1,2 and 3 comprising the sequence represented by (LXXVII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 9 comprises a sequence represented by (LXXVIII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 10 CDR1,2 and 3 comprising the sequence represented by (LXXIX) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 10 comprises the sequence represented by (LXXX) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 11 CDR1,2 and 3 comprising the sequence represented by (LXXXI) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 11 comprises the sequence given in (LXXXII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 12 including CDR1,2 and 3 of the sequence shown in (LXXXIII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 12 comprises the sequence represented by (LXXXIV) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 13 CDR1,2 and 3 comprising the sequence represented by (LXXXV) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 13 comprises the sequence represented by (lxxxvi) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 14 including CDR1,2 and 3 of the sequence shown in (LXXXVII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 14 comprises the sequence given in (LXXXVIII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 15 CDR1,2 and 3 comprising the sequence represented by (LXXXIX) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence represented by (xc) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 16 including CDR1,2 and 3 of the sequence shown in (xci) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xcii) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 17 CDR1,2 and 3 comprising the sequence represented by (xciii) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 17 comprises the sequence given in (XCIV) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 18 CDR1,2 and 3 comprising the sequence represented by (xcv) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence represented by (XCVI) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 19 CDR1,2 and 3 comprising the sequence represented by (XCVII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 19 comprises the sequence represented by (XCVIII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (including N-terminal amino acids relative to CDR1 optionally) _{V H} and SEQ ID NO: 20 including CDR1,2 and 3 of the sequence shown in (XCIX) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 20 comprises the sequence represented by (c) SEQ ID NO: 37 L;
(Ci) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 21 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 21 comprises the sequence represented by (cii) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 22 CDR1,2 and 3 comprising the sequence represented by (ciii) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 22 comprises the sequence represented by (civ) SEQ ID NO: 37 L;
(Cv) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 23 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 23 comprises the sequence represented by (cvi) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 24 including CDR1,2 and 3 of the sequence shown in (cvii) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 24 comprises the sequence represented by (cviii) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (including amino acids N-terminal to the optionally CDRl) _{V H} and SEQ ID NO: 25 including CDR1,2 and 3 of the sequence shown in (cix) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 25 comprises the sequence represented by (cx) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 26 CDR1,2 and 3 comprising the sequence represented by (cxi) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 26 comprises the sequence given in (CXII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 27 including CDR1,2 and 3 of the sequence shown in (cxiii) SEQ ID NO: 37 V _{L;
(Cxiv) V H} containing the sequence set forth in SEQ ID NO: 37 and _VL containing the sequence set forth in SEQ ID NO: 27 ;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 28 CDR1,2 and 3 comprising the sequence represented by (CXV) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 28 comprises the sequence given in (CXVI) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 29 CDR1,2 and 3 comprising the sequence represented by (CXVII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence represented by (cxviii) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 30 CDR1,2 and 3 comprising the sequence represented by (cxix) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 30 comprises the sequence given in (cxx) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 31 CDR1,2 and 3 comprising the sequence represented by (cxxi) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 31 comprises the sequence represented by (CXXII) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to CDR1 optionally) _{V H} and SEQ ID NO: 32 including the CDR1,2 and 3 of the sequence shown in (CXXIII) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 32 comprises the sequence represented by (CXXIV) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 33 CDR1,2 and 3 comprising the sequence represented by (cxxv) SEQ ID NO: 37 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 33 comprises the sequence represented by (CXXVI) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid with respect to an arbitrary CDRl) _{V H} and SEQ ID NO: 34 CDR1,2 and 3 comprising the sequence represented by (CXXVII) SEQ ID NO: 37 V _L; or
(Cxxviii) _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 34 comprises the sequence given in SEQ ID NO: 37; including, the IL-11Ra binding protein.
[14] An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds or specifically binds to IL-11Rα to neutralize IL-11 signal transduction and the antigen. The binding domain is
(I) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 49 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (ii) SEQ ID NO: 49 L;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 53 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (iv) SEQ ID NO: 53 L;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 57 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (vi) SEQ ID NO: 57 L;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 58 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 58 L;
(Ix) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 8 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 8 comprising the sequence represented by (x) SEQ ID NO: 37 L;
(Xi) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 15 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence given in (xii) SEQ ID NO: 37 L;
(Xiii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 16 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xiv) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (xv) SEQ ID NO: 37 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 18 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence given in (xvi) SEQ ID NO: 37 L;
(Xvii) (including also the N-terminal amino acids relative optionally CDRl) comprising CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 29 V _L; or
(Xviii) _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence given in SEQ ID NO: 37; including, the IL-11Ra binding protein.
[15] at least comprises a heavy chain variable region _{(V H)} and light chain variable region _{(V L),} said bonded _{V H} and _{V L} to form a Fv comprising an antigen binding domain, the _{V H} and _{V L} The IL-11Rα binding protein according to any one of the above [1] to [14], wherein is in a single polypeptide chain or the V _H and _{VL are in separate polypeptide chains.}
[16] If the V _H and _VL are in a single polypeptide chain, then the protein is
(I) Single chain Fv fragment (scFv);
(Ii) Dimer scFv (di-scFv);
(Iii) One of (i) or (ii) linked to the constant region of the antibody, Fc or heavy chain constant domain ( _CH ) 2 and / or _{CH 3, or}
(Iv) One of (i) or (ii) linked to a protein that binds to immune effector cells;
If the V _H and _VL are in separate polypeptide chains, then the protein is
(I) Bispecific antibody;
(Ii) Trispecific antibody;
(Iii) Quadruspecific antibody;
(Iv) Fab;
(V) F (ab') ₂ ;
(Vi) Fv
(Vi) One of (i)-(vi) linked to the constant region of the antibody, Fc or heavy chain constant domain ( _CH ) 2 and / or _{CH 3.}
(Viii) One of (i)-(vi) linked to a protein that binds to an immune effector cell; or
(Ix) The IL-11Rα-binding protein according to [15] above, which is an antibody.
[17] An antibody that binds to IL-11Rα and neutralizes the signal transduction of IL-11.
(I) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 49 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (ii) SEQ ID NO: 49 L;
And (iii) a CDR1,2 and 3 of the sequence shown in SEQ ID NO: 53 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising the sequence represented by (iv) SEQ ID NO: 53 L;
(V) sequences (including amino acids N-terminal to the optionally CDRl) of CDR1,2 and 3 comprising the sequence shown in ID NO: 57 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (vi) SEQ ID NO: 57 L;
(Vii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 58 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 5 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 5 comprising a sequence shown in (viii) SEQ ID NO: 58 L;
(Ix) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 (optionally including amino acids N-terminal to the CDRl) sequence shown in _{V H} and SEQ ID NO: 8 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 8 comprising the sequence represented by (x) SEQ ID NO: 37 L;
(Xi) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 15 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 15 comprises the sequence given in (xii) SEQ ID NO: 37 L;
(Xiii) including CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in (N including terminal amino acid for any in CDRl) _{V H} and SEQ ID NO: 16 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 16 comprises the sequence given in (xiv) SEQ ID NO: 37 L;
Including CDR1,2 and 3 of the sequence shown in (xv) SEQ ID NO: 37 (including the N-terminal to optionally CDR1 amino acids) including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 18 V _L;
V comprises the sequence represented by _{V H} and SEQ ID NO: 18 comprises the sequence given in (xvi) SEQ ID NO: 37 L;
(Xvii) (including also the N-terminal amino acids relative optionally CDRl) comprising CDR1,2 and 3 of the sequence shown in SEQ ID NO: 37 including CDR1,2 and 3 of the sequence shown in _{V H} and SEQ ID NO: 29 V _L; or
(Xviii) _{V L} comprising the sequence represented by _{V H} and SEQ ID NO: 29 comprises the sequence given in SEQ ID NO: 37; including the antibody.
[18] The IL-11Rα-binding protein according to any one of the above [1] to [16] or the antibody according to the above [17], which is bound to another compound.
[19] A nucleic acid encoding the IL-11Rα-binding protein according to any one of the above [1] to [16] or the antibody or a polypeptide thereof according to the above [17].
[20] An expression construct containing the nucleic acid according to the above [19].
[21] An isolated or recombinant cell expressing the IL-11Rα-binding protein according to any one of the above [1] to [16] or the antibody according to the above [17].
[22] A composition comprising the IL-11Rα-binding protein according to any one of the above [1] to [16] or [18] or the antibody according to the above [17] or [18] and a pharmaceutically acceptable carrier. thing.
[23] A method for treating or preventing a disease mediated by IL-11 in a subject, which is the IL-11Rα-binding protein according to any one of the above [1] to [16] or [18], or the above [17]. ] Or [18] or the composition according to [22] above.
[24] A method of contraception in a subject, which is the IL-11Rα-binding protein according to any one of the above [1] to [16] or [18], the antibody according to the above [17] or [18], or the above [[24]. 22] The method, which comprises administering the composition according to 22].
[25] The IL-11Rα-binding protein according to any one of the above [1] to [16] or [18], the antibody according to the above [17] or [18], or the composition according to the above [22]. Use in medicine.
[26] The IL-11Rα-binding protein according to any one of the above [1] to [16] or [18] or the above [17] or [18] in the production of a drug for treating a disease mediated by IL-11. ] Use of the antibody described in.
[27] The IL-11Rα-binding protein according to any one of the above [1] to [16] or [18] for use in the treatment of IL-11-mediated diseases, or the above [17] or [18]. The antibody or composition according to [22] above.
[28] IL-11-mediated disease localization method and / or detection method and / or diagnostic method and / or prognostic method, if present, such as IL-11-mediated disease associated with cells expressing IL-11Rα. The IL-11Rα-binding protein or antibody according to [18] above, which is bound to a cell expressing -11Rα, is detected in vivo, and the IL-11Rα-binding protein or antibody is detected. The method described above, which is bound to a possible tag.
[29] The method according to [28] above, further comprising administering to the subject the IL-11Rα binding protein or antibody.
[30] A method for detecting IL-11Rα or a cell expressing the IL-11Rα in a sample, wherein the sample is prepared as described in any of the above [1] to [16] or [18] so as to form a complex. The detection of the complex comprises contacting the binding protein or the antibody according to the above [17] or [18] and detecting the complex, and the detection of the complex comprises IL-11Rα or a cell expressing the same in a sample. Shown, said method.
[31] A method for diagnosing a disease mediated by IL-11Rα or a method for diagnosing a prognosis, which comprises performing the method according to the above [30] to detect IL-11Rα or cells expressing the same. The method, wherein detection of IL-11Rα or cells expressing it is a diagnosis or prognosis of the disease.
[32] Any of the above [23], [28] or [31], wherein the IL-11-mediated disease is an autoimmune disease, an inflammatory disease, a debilitating disease, a bone disease or cancer. IL-11Rα binding protein or antibody or composition for use according to the method described above or according to [26] above or according to [27] above.

Claims (16)

An IL-11Rα-binding protein containing an antigen-binding domain of an antibody, wherein the antigen-binding domain binds to or specifically binds to IL-11Rα and IL-11 of a BaF3 cell expressing IL-11Rα and gp130. Inhibiting _{intervening proliferation with an IC 50} of 10 μg / ml or less
(I) The level at which the IL-11Rα-binding protein binds to the polypeptide of SEQ ID NO: 95 is at least 1.5 times lower than the level at which the IL-11Rα-binding protein binds to the polypeptide of SEQ ID NO: 85. ,
(Ii) The antigen-binding domain is
An antibody comprising a heavy chain comprising the sequence set forth in SEQ ID NO: 83 and a light chain comprising the sequence set forth in SEQ ID NO: 84, and / or a heavy chain comprising the sequence set forth in SEQ ID NO: 92 and the sequence set forth in SEQ ID NO: 91. Poly of SEQ ID NO: 3 and / or SEQ ID NO: 85 of an antibody comprising a light chain comprising Competitively inhibits binding to peptides,
(Iii) The antigen-binding domain is
(A) Polypeptide of SEQ ID NO: 97,
(B) a polypeptide of SEQ ID NO: 98,及Beauty
( C) Cross-reactivity with the polypeptide of SEQ ID NO: 99,
The IL-11Rα binding protein. The IL-11Rα-binding protein according to claim 1, wherein the protein does not detectably bind to the polypeptide of SEQ ID NO: 86 or 89. The protein
(I) it binds to the K66-containing epitope of human IL-11Rα defined in SEQ ID NO: 96 and / or (ii) binds to the V117-containing epitope of human IL-11Rα defined in SEQ ID NO: 95.
The IL-11Rα-binding protein according to claim 1 or 2. The protein is
(I) Single chain Fv fragment (scFv);
(Ii) Dimer scFv (di-scFv);
(Iii) Binds to the constant region of the antibody, one of _{(i) or (ii) linked to Fc or heavy chain constant domains (CH} ) 2 and / or _CH 3, and (iv) immune effector cells. If selected from one of (i) or (ii) linked to the protein; or if V _H and _VL are in separate polypeptide chains, the protein is (i) a bispecific antibody. ;
(Ii) Trispecific antibody;
(Iii) Quadruspecific antibody;
(Iv) Fab;
(V) F (ab') ₂ ;
(Vi) Fv
(Vii) Constant region of antibody, Fc or heavy chain constant domain ( _CH ) 2 and / or _CH 3
One of (i) to (vi) linked to;
(Viii) The IL-. 11Rα binding protein. The IL-11Rα-binding protein according to claim 4, which is an antibody. The IL-11Rα-binding protein according to any one of claims 1 to 5, which is bound to another compound. A nucleic acid encoding the IL-11Rα-binding protein according to any one of claims 1 to 6. An expression construct comprising the nucleic acid according to claim 7. An isolated cell or a recombinant cell expressing the IL-11Rα-binding protein according to any one of claims 1 to 6. A composition comprising the IL-11Rα-binding protein according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier. The composition according to claim 10, for contraception in the subject. The composition according to claim 10, for treating a disease mediated by IL-11. The composition according to claim 12, wherein the IL-11-mediated disease is an autoimmune disease, an inflammatory disease, a debilitating disease, a bone disease or cancer. Use of the IL-11Rα-binding protein according to any one of claims 1 to 6 in the manufacture of a drug for treating an IL-11-mediated disease. The use according to claim 14, wherein the IL-11-mediated disease is an autoimmune disease, an inflammatory disease, a debilitating disease, a bone disease or cancer. A method for detecting IL-11Rα or a cell expressing the IL-11Rα in a sample, wherein the sample is contacted with the IL-11Rα-binding protein according to any one of claims 1 to 6 so as to form a complex. The method of comprising detecting the complex, wherein detection of the complex indicates IL-11Rα or a cell expressing it in a sample.

Images